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General introduction 
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LEUKEMIA 
 
Blood cell formation takes place in the bone marrow (hematopoiesis). Leukemia is 
cancer of the blood characterized by an abnormal growth of immature white 
blood cells in the bone marrow. Based on two characteristics, i.e. growth rate and 
immunophenotype, leukemia can be divided into several subtypes. Fast-growing, 
or acute leukemia, is the most common form of leukemia in children, whereas 
slow-growing, or chronic leukemia, is typically diagnosed in adults. Depending on 
the type of white blood cell that was subjected to malignant transformation, we 
distinguish between lymphocytic and myeloid leukemia. Lymphocytic leukemia 
arises in a type of white blood cell from which the lymphocytes are formed, while 
myeloid leukemia arises in white blood cells that develop into neutrophils, 
eosinophils, basophils, or macrophages. Due to the uncontrolled proliferation of 
the non-functional immature leukemic white blood cells (or blasts), the bone 
marrow becomes overgrown and the formation of healthy blood cells is strongly 
inhibited. In turn, the lack of healthy blood cells cause a substantial part of the 
symptoms that are associated with leukemia, including anemia, frequent 
infections and fevers, and bleedings or bruising. The non-functional leukemic 
blasts are released into the peripheral blood, from where they rapidly invade 
other organs such as  the spleen, the liver, and occasionally the central nervous 
system. When left untreated, leukemia is typically fatal within weeks or months.  
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INFANT ACUTE LYMPHOBLASTIC LEUKEMIA 
 
Acute lymphoblastic leukemia (ALL) in infants (i.e. children below the age of 1 
year) is rare, accounting for about 4% of all pediatric ALL cases. Compared with 
older children with ALL, infant ALL possesses unique clinical and biological 
features. The majority (~80%) of the infants diagnosed with ALL carry leukemia-
specific chromosomal translocations involving the Mixed Lineage Leukemia (MLL) 
gene. 1, 2 As a result of such translocations, the N-terminal portion of the MLL gene 
becomes fused to the C-terminal region of one of its many translocation partner 
genes (Figure 1). 3 The hereby generated chimeric fusion genes are translated into 
MLL fusion proteins with pronounced transforming capacity. To date over 70 
partners have been identified. 4 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. MLL translocation. Schematic representation of chromosomal translocation 
t(4;11)(q21;q23), fusing the N-terminal region of the MLL gene on chromosome 11 to the 
C-terminal region of the AF4 gene on chromosome 4, and vice versa.  
double strand  
break 
chromosomal 
translocation 
normal 
chromosomes 
t(4;11)(q21;q23) 11 4 
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The most recurrent MLL translocations found among infant ALL patients are 
t(4;11), t(11;19), and t(9;11) 5, 6, giving rise to the fusion proteins MLL-AF4, MLL-
ENL, and MLL-AF9, respectively (Figure 2). Infant ALL patients without a 
rearrangement of the MLL gene, are generally referred to as wild-type MLL infant 
ALL patients or MLL germline infant ALL patients. 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Frequencies of MLL rearrangements and wild-type MLL in infant ALL. Frequency 
of wild-type MLL and MLL rearrangement in infant ALL (left) and frequencies of fusion 
partner in MLL-rearranged infant ALL (right) according to the Interfant-99 study. 6  
 
 
While in the last decades event-free survival (EFS) chances for pediatric ALL 
patients have increased dramatically, nowadays exceeding 80%,7 obtaining 
successful treatment results in infant ALL remains a major challenge. Although 
morphological complete remission is achieved in approximately 95% of the infant 
ALL patients, 8, 9 overall outcome in infant ALL is very poor due to an exceptionally 
Infant ALL  
by MLL status 
MLL-rearranged infant ALL  
by fusion partner 
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high relapse rate. To date, EFS rates for MLL-rearranged infant ALL approach 
50%.6 Apart from the presence of an MLL translocation (Figure 3), age <6 months, 
very high white blood cell counts at diagnosis, and a poor response to prednisone 
are the most important factors predicting a poor outcome in infant ALL. 6 
Furthermore, minimal residual disease is an independent prognostic factor in 
infant ALL. Moreover, MDRD can be used for treatment intervention in infant 
ALL.10 Neonatal leukemia (age <1 month) is very rare and generally assumed to be 
fatal. Except for case reports, there is no published data available concerning 
these neonates.  
  
Figure 3. Clinical outcome of infant ALL. Event-free survival of infant ALL patients 
according to the status of MLL gene and type of MLL translocation. 
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TOWARDS TARGETED THERAPY IN INFANT ALL 
 
Several studies demonstrated that MLL-rearranged ALL is characterized by a 
unique gene expression profile.11, 12 Recently our laboratory published high-
resolution gene expression profiling data showing that, apart from a fundamental 
signature shared by all MLL-rearranged infant ALL samples, each type of MLL 
translocation is associated with a translocation-specific gene expression signature 
as well. Furthermore, it was demonstrated that wild-type MLL infant ALL specifies 
a gene expression pattern that is different from both MLL-rearranged infant ALL 
and pediatric (non-infant) precursor BCP-ALL.13 Although the large majority of 
patients achieves complete remission, approximately 63% relapses in the first 
year after achieving complete remission. More effective therapeutic strategies are 
therefore needed to improve prognosis. The unique gene expression profiles 
associated with MLL-rearranged infant ALL hold the potential to reveal novel 
genetic characteristics that may serve as therapeutic targets. 
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OUTLINE OF THIS THESIS 
 
Chapter 2 is a review describing leukemia in neonates (infants <1 month), 
including neonatal acute myeloid leukemia (AML) and ALL. It covers biological and 
clinical aspects of this subgroup of infant leukemia patients and discusses future 
perspectives.  
Neonatal –or congenital– ALL is rare and assumed inevitably fatal, but no series 
have been published on neonatal ALL except for case reports. Chapter 3 reports 
the clinical features and outcome of neonatal ALL uniformly treated with curative 
intent according to the Interfant-99 protocol.  
Infant ALL patients that do not harbor a rearrangement of the MLL gene (wild-
type MLL infant ALL patients), carry a gene expression pattern that is different 
from both MLL-rearranged infant ALL and pediatric precursor BCP-ALL. These 
gene expression profiles are described in chapter 4 and are the foundation of 
research described in the following chapters. 
Chapter 5 addresses the thus far underreported group of wild-type MLL infant ALL 
patients. Although this group of patients generally does better than MLL-
rearranged infant ALL patients in terms of survival, their prognosis is still worse 
compared with non-infant pediatric BCP-ALL patients. In order to find new 
openings for treatment optimization, in this chapter we clinically and molecularly 
characterize this wild-type MLL infant ALL patient group.  
In order to facilitate the discovery of therapeutic targets in MLL-rearranged infant 
ALL, in chapter 6 we report on gene expression profiling after repression of the 
MLL fusion protein. Herewith we identify genes readily responsive to the loss of 
the MLL fusion with the aim of discovering new therapeutic targets in MLL-
rearranged infant ALL.  
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One of the genes responsive to the loss of the MLL fusion, and a gene recently 
identified to be transcriptionally driven by MLL fusion proteins is cyclin-dependent 
kinase 6 (CDK6). In chapter 7 we validate CDK6 as a direct target of the MLL-AF4 
fusion protein and assess its role in the proliferative advantage of MLL-rearranged 
leukemia cells. We initiate investigation of the role of CDK6-inhibitor PD0332991 
as a new treatment agent in MLL-rearranged ALL.  
Differential gene expression analysis between infant ALL patients and pediatric 
(non-infant) BCP-ALL patients reveals EID1 as specifically expressed in infant ALL 
which is discussed in chapter 8. To assess the potential of this gene as therapeutic 
target, we use lentiviral knockdown experiments to determine the consequences 
of loss of EID1 on the growth and survival of MLL-rearranged leukemia cells. 
Chapter 9 summarizes this thesis and comprises a general discussion and this 
thesis concludes with a Dutch summary in layman’s terms in chapter 10.  
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SUMMARY 
 
Leukemia in neonates (infants <1 month) is rare, whereby neonatal acute myeloid 
leukemia (AML) is more frequent than neonatal acute lymphoblastic leukemia 
(ALL). High mortality rates are observed, though AML has a better prognosis than 
ALL. Neonatal leukemia is typically presented with hepatosplenomegaly, leukemia 
cutis and/or hyperleucocytosis. Congenital infections should be ruled out before 
diagnosis. Rearrangement of the MLL gene is the most frequently occurring 
genetic aberration. Treatment includes intensive multi-agent chemotherapy, 
usually with age-related dose adjustments next to supportive care. Treatment 
intensification for ALL could be indicated in the future as the dismal prognosis is 
subject to high relapse rates in ALL. 
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INTRODUCTION 
 
Neonatal – or congenital – leukemia is diagnosed in the first 30 days after birth. 
Estimated incidence of neonatal leukemia ranges from 1 to 5 per million live 
births. 1,2 Less than 1% of all childhood leukemia is diagnosed in neonates. 1 Two 
publications reviewing 117 patients and 145 patients respectively described a 
higher reported frequency of acute myeloid leukemia (AML) (56–64%) than acute 
lymphoblastic leukemia (ALL) (21–38%), plus a few cases of biphenotypic 
leukemia. 3,4   
Aside from trisomy 21, the most frequently occurring chromosomal aberration in 
both neonatal AML and ALL is a translocation involving the mixed lineage 
leukemia (MLL) gene, located on chromosomal band 11q23. Hereby the MLL gene 
breaks and fuses to one of its many translocation partners, forming a new fusion 
product. In normal embryogenesis MLL regulates gene expression in an epigenetic 
manner and is required for adequate numbers of hematopoietic progenitors and 
their proper differentiation.5 In MLL-rearranged leukemia this program is 
deregulated, leading to an aberrant gene expression with upregulation of multiple 
oncogenes. 6 In earlier reports a frequency of MLL rearrangements in neonatal 
leukemia has been described of 30–65%, 3,4  but a more recent report in neonatal 
ALL describes a frequency of MLL rearrangements of up to 93%.7 Very likely this 
difference is due to refinement of the technique in discovering MLL 
rearrangements over the last decades, like the introduction  of the split-signal 
FISH methodology facilitating the identification of known and new translocations 
involving MLL.14 Further, acute megakaryotic leukemia (AMKL) (FAB M7) in non-
Down patients is strongly associated with t(1;22)(p13;q13), forming the fusion 
gene RBM15-MKL1. This rearrangement is present in about 70% of all infant AMKL 
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patients 8,9 and was reported in eight out of 13 non-Down AMKL patients 
reviewed by Isaacs.4  
 
 
ETIOLOGY 
 
The etiology of infant (<1 year of age) leukemia rather than neonatal leukemia has 
been studied. As the definition of congenital leukemia is arbitrary and due to the 
high incidence of MLL rearrangements in both congenital and infant leukemia, the 
etiology of these two groups will largely overlap and will here be discussed as one 
group. 
The etiology of MLL-rearranged infant leukemia has been studied in depth over 
the last decades. The observation of infant twins with concordant leukemia who 
each share clonal MLL rearrangements in their leukemic cells provides 
unequivocal evidence that the leukemogenic event originates in utero.10 In the 
same context it was demonstrated that MLL-AF4 genomic fusion sequences are 
already present in the neonatal blood spots of Guthrie cards of infants later 
diagnosed with ALL, providing more profound evidence for prenatal initiation of 
the disease.11 Associations between developing infant leukemia and maternal 
exposure to multiple toxins have been extensively explored, and demonstrated 
increased risk after maternal marijuana use and alcohol consumption, but not for 
instance cigarette smoking. 12,13 The observation that the topoisomerase-II 
inhibitor etoposide causes therapy-related MLL-rearranged AML14 led to 
epidemiological and experimental studies of related dietary compounds called 
(bio)flavonoids. Flavonoids, present in citrus fruit, wine, tea and dark chocolate, 
2 
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have been demonstrated in vitro to induce double-strand breaks of the MLL gene. 
A maternal diet high in flavonoids is therefore suspected to increase the risk of 
MLL-rearranged infant leukemia. Definite evidence for this hypothesis has not 
been provided, possibly due to the complexity of dietary research and the low 
incidence of MLL-rearranged infant leukemia. 15-17  
 
 
SIGNS AND SYMPTOMS 
 
Clinical signs of neonatal leukemia vary a great deal among patients. 
 
Characteristic clinical manifestations 
Hepatosplenomegaly, a very frequently occurring symptom, can be found in 
around 80% of the patients. 3.18 Enlargement of the liver is found more often than 
an enlarged spleen. Enlarged lymph nodes are found in only one out of four 
patients. 3 
Leukemia cutis, which is described in around 60% of all patients, 3,4,18 are specific 
cutaneous leukemic infiltrates and usually appear as firm blue, red, or purple 
nodules in a generalized distribution. 19 Leukemia cutis is reported to be the initial 
presenting sign in about half of the neonatal cases. 4,20 It is a cause of the so-called 
‘blueberry muffin baby’. 
The third clinical feature, hyperleucocytosis, is present in the majority of the 
patients. Forty-seven out of 55 (85%) ALL patients and 37 out of 72 (49%) of the 
AML patients had a white blood cell (WBC) count >50 × 109/l from the neonatal 
leukemia patient group reviewed by Isaacs.4 By contrast, infant AMKL patients 
with t(1;22) were described with a decreased leukocyte number, anemia and 
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thrombocytopenia.21 A severe complication of hyperleucocytosis is the leucostasis 
syndrome, in which white cell plugs are formed in the microvasculature, leading 
to cardiac failure and respiratory and neurological problems. Neurological 
symptoms in the neonate as part of the leucostasis syndrome can be in the form 
of somnolence and coma, papilloedema, retinal vein distension and retinal 
haemorrhage.22,23 A respiratory leucostasis manifests itself usually in the form of 
unspecific symptoms such as tachypnoea, dyspnoea, hypoxia, pulmonary 
infiltrates or respiratory failure. 
 
Secondary clinical manifestations 
Extramedullary infiltration of the leukemia and overgrowth of the bone marrow 
leading to anaemia, thrombocytopenia and/or neutropenia may cause various 
secondary clinical manifestations, e.g. increased bleeding tendency, infections and 
failure to thrive. 
Diverse neurological findings such as cranial nerve palsies, seizures, and 
papilloedema are likely caused by infiltration into the central nervous system, 
which is present in more than a third of the patients. Meningeal leukemic 
infiltration is indicated by a bulging fontanel. Neurological findings may 
alternatively be explained by intracranial bleeding due to the thrombocytopenia, 
possibly also leading to a bulging fontanel, and secondary to infarction in the 
presence of leucostasis. Respiratory signs and symptoms may be caused by 
thrombocytopenia due to pulmonary hemorrhage, but can also be explained by 
leukemic infiltration leading to atelectasis or pneumonia due to neutropenia. 
Besides pneumonia, diverse infectious problems including sepsis occur in these 
neonates. Cardiac failure and non-immune hydrops in the newborn have been 
described due to severe anaemia. 24 Anaemia and thrombocytopenia can further 
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induce diverse signs such as pallor, failure to thrive, lethargy, melena, and 
bleeding tendencies. 
 
Signs in utero 
In-utero hepatosplenomegaly, hydrops and polyhydramnios can be detected by 
ultrasound. Fetoscopy and umbilical blood sampling can then establish the 
diagnosis of leukemia. When the leukemia leads to stillbirth, the placenta is 
enlarged and leukemic cells can be found in the extramedullary organs at autopsy. 
Isaacs4 described five stillbirths among 145 diagnoses of neonatal leukemia, but 
the incidence should likely be estimated higher due to underreporting of stillbirth. 
 
 
CYTOGENETICS 
 
ALL 
Morphologically three out of four patients with neonatal ALL have an immature B-
cell phenotype without CD10 expression and with CD19 positivity.3,17 T-Cell acute 
leukemia was described in only one case report. 25 Typical for neonatal (and 
infant) ALL is the coexpression of myeloid-associated antigens (e.g. CD33), 
suggesting origin in a stem cell not fully committed to the lymphoid 
differentiation. 4,26 A phenotypic switch from lymphoid to myeloid lineage (and 
vice versa) at relapse has been described repeatedly. 27-30 Ten out of 145 reviewed 
neonatal leukemia patients were described as biphenotypic.4 In the great majority 
of these ALL patients t(4;11)(q21;q23) or t(11;19)(q23;p13) can be detected in the 
leukemic blasts. 
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AML 
Around half of the reported neonatal AML patients have a monoblastic leukemia 
(FAB M5) which is therefore the most common form of myeloid leukemia in 
neonates. A myelomonocytic form (FAB M4) is present in around one out of five 
neonates presenting with AML.4 Monoblastic and myelomonocytic leukemias are 
typified by positivity for CD13, CD14, CD15 and CD33. The most common 
chromosomal aberrations present in neonatal AML are t(11;19)(q23;p13) and 
t(9;11)(p21;q23). In the great majority of the AMKL (FAB M7) non-Down neonates 
t(1;22)(p13;q13) is present. 
 
 
DIFFERENTIAL DIAGNOSIS 
 
A true leukemia in neonates has to be distinguished both from other conditions 
such as transient myeloproliferative disorder (TMD); congenital infections, 
hypoxia, and haemolytic disease causing a leukaemoid reaction; and other 
congenital neoplasms such as neuroblastoma. 
Although rare, several case reports have been published describing TMD in non-
Down neonates. 31-37 A true differentiation from TMD can only be made in 
retrospect as, by definition, TMD remits spontaneously, generally in the first 
months of life. TMD usually shows characteristics of megakaryocytic 
differentiation under the light microscope and by flow cytometry. TMD is 
frequently presented by pronounced organomegaly. In TMD patients (including 
patients with trisomy 21) 20–30% develop into full-blown leukemia within three 
2 
28             
years and this is typically of the acute megakaryocytic phenotype (M7),38 with a 
specific genetic abnormality (GATA1 mutation).  
A leukaemoid reaction is seen in the presence of congenital infections due to 
cytomegalovirus, syphilis, toxoplasmosis, rubella, listeria monocytogenes, herpes, 
and sepsis39  but also after haemolytic disease and (birth-related) hypoxia. A 
leukaemoid reaction presents itself – like leukemia – with hyperleucocytosis and 
circulating blasts. Also hepatosplenomegaly and skin nodules (blueberry muffin 
baby) due to extramedullary haematopoiesis in the neonate is frequent with a 
leukaemoid reaction. However, the peripheral blood does not show the 
monoclonal cell population as is seen in a true leukemia. Further, in a leukaemoid 
reaction the bone marrow aspirate usually shows an increase of immature 
myeloid cells at different maturation stages and not the monoclonal leukemic 
population. Congenital infections usually come with intrauterine growth 
retardation and/or microcephaly and should be ruled out through serological 
tests. 39 
Other congenital neoplasms such as disseminated neuroblastoma and Langerhans 
histiocytosis can resemble congenital leukemia. Disseminated neuroblastoma can 
also present itself with hepatosplenomegaly and a blueberry muffin appearance. 
The bone marrow aspirate, however, will show no hyperleucocytosis and cell 
counts in peripheral blood are usually within normal ranges. A blueberry muffin 
appearance has a number of other differential diagnoses such as 
rhabdomyosarcoma and also Langerhans histiocytosis. Certain congenital 
infections and haemolytic disease can cause the dermal erythropoiesis underlying 
this particular appearance of the skin. A definite diagnosis can be made by 
performing a skin biopsy. 
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DIAGNOSIS 
 
As soon as leukemia in the neonate is suspected, immediate referral to a 
paediatric oncologist/haematologist is required. Differential diagnoses such as 
congenital infections and haemolytic disease should be ruled out. A complete 
blood cell count including WBC differential count is required. Definite diagnosis 
can be made based on peripheral blood smear and bone marrow aspirate. 
Additionally laboratory assessment is needed to perform morphology, 
immunophenotyping and genotyping for full diagnosis and stratification of the 
leukemia (Box 1). 
 
 
Box 1. Key diagnostic tests for diagnosing leukemia 
 
 
TREATMENT AND PROGNOSIS 
 
When the diagnosis leukemia is established, an intensive multi-agent 
chemotherapeutic regimen should be started. There is no specific treatment 
protocol for the treatment of either neonatal ALL or neonatal AML. Neonatal ALL 
patients are usually treated as infant ALL patients with a chemotherapeutic 
regimen based on ALL principles combined with elements of AML treatment. 
Complete blood cell count 
Peripheral blood smear 
Bone marrow aspirate with morphology, immunophenotyping and genotyping 
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Treatment protocols include steroids, vincristine, l-asparaginase, 6-
mercaptopurine and methotrexate together with anthracyclines and cytarabine. 
Neonatal AML patients are treated similarly to older AML patients with a 
chemotherapeutic regimen mainly based on cytarabine and anthracyclines. An 
overall survival of <10% is estimated for neonatal ALL from case reports published 
from 1970 to 2003. 3.4 In the more recent Interfant-99 study, 30 neonatal ALL 
patients were treated with a hybrid regimen combining ALL treatment with 
elements designed for treatment of AML, resulting in 17% long-term survival. 7 
Relapse in neonatal ALL is particularly high; although in the Interfant-99 study 87% 
of neonates achieved a morphological complete remission, 73% of the patients 
relapsed. 7  
There is no report of neonatal AML patients treated on a uniform protocol but the 
survival is estimated at about 25%.3.4 Relapse rate in AML was estimated at about 
50%.3 These numbers may be better nowadays as these case reports date back as 
far as the 1970s and the outcome of infant AML has improved considerably with 
intensive chemotherapy including repeated cycles of high-dose cytarabine and 
anthracyclines. 40,41 After age-related dosage adjustments, toxicities are 
considered manageable in neonates for AML and ALL. 7,41  
Next to chemotherapy, haematopoietic stem cell transplantation (HSCT) might be 
an additional treatment option. In paediatric AML it was recently shown that 
patients without MLL rearrangements did not benefit from transplantation. 42 
Concerning the role of HSCT in the management of MLL-rearranged infant AML, 
contradictory results have been published; it was suggested that improved 
survival rates were achieved allocated to allogeneic stem cell transplantation in 
the AML-BFM 98 study, 42 whereas Balgobind et al. 43 in a much larger cohort 
showed that patients with MLL-rearranged AML did not benefit from allogenic 
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HSCT. In infant ALL, HSCT was reported to be a valuable option only in a small, 
group; namely MLL-rearranged ALL patients aged <6 months, either with poor 
response to steroids at day 8 or with leucocytes >300 × 109/l. 44 In infant ALL 
overall no added value of HSCT compared with chemotherapy alone has been 
shown. 45-47 
 
 
SUPPORTIVE CARE 
 
During the initial period after diagnosis of leukemia, conservative measures are 
indicated such as correction of the electrolyte balance, hydration control, 
treatment of hyperuricaemia and coagulation imbalances in order to prevent 
serious complications. A more ambiguous topic in the initial supportive care of 
leukemia is rapid cytoreduction in order to prevent leucostasis syndrome. 
Whereas many practitioners order leukapheresis or exchange transfusion when 
WBC reaches 300 × 109/l, the actual therapeutic benefit of leukapheresis and 
exchange transfusion is unknown. 48-51 Besides WBC the clinical condition of the 
patient is important role in the decision-making for supportive care of the 
neonate with leukemia. 
 
 
FUTURE PERSPECTIVES 
 
The low survival rates for both neonatal ALL and AML warrant a decisive 
approach. Understandably there is a hesitation to treat these vulnerable patients, 
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but above all it is important to achieve and maintain complete remission for these 
neonates. New treatment strategies are urgently needed in order to increase 
current survival rates of neonatal leukemia. Data from the Interfant-99 study 
implied not that induction failure is causing the dismal prognosis of neonatal ALL 
but rather that the relapse rate is very high.7 This advocates an early 
intensification of treatment. One possible strategy for intensification is 
reconsidering the dose reductions that are now common practice in the 
treatment of neonates due to fear of severe toxicity. Possibly these dose 
reductions contribute to the higher relapse rate in these young children, as the 
strongest predictor of relapse in patients with ALL is the administered treatment 
itself.52 The limited number of pharmacokinetic studies in this population 
represent a challenge. Both the Interfant-99 study (infant ALL)7 and the AML-BFM-
98/-200441 applied age-related dose reductions and reported no excessive toxicity 
in neonates, which may allow dose intensification. 
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ABSTRACT 
 
Acute lymphoblastic leukemia (ALL) diagnosed in the first month of life (congenital 
ALL) is very rare. Although congenital ALL is often assumed to be fatal, no studies 
have been published on outcome except for case reports. The present study 
reports the outcome of thirty patients with congenital ALL treated with the 
uniform Interfant-99 protocol, a hybrid regimen combining ALL-treatment with 
elements designed for treatment of acute myeloid leukemia. Congenital ALL was 
characterized by a higher WBC-count and a strong trend for higher incidence of 
MLL-rearrangements and CD10-negative B-lineage ALL compared to older infants. 
Induction failure rate was 13% and not significantly different from that in older 
infants (7%, p=0.14) but relapse rate was significantly higher in congenital ALL 
patients (2-year cumulative incidence (SE) was 60.0 (9.3) vs 34.2 (2.3), p<0.001). 
Two-year EFS and survival of congenital ALL patients treated with this protocol 
was 20% (SE 9.1). Early death in CR and treatment delays due to toxicity were not 
different. The survival of 17% after last follow-up, combined with a toxicity profile 
comparable to that in older infants, justifies treating congenital ALL with curative 
intent.  
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INTRODUCTION 
 
Acute lymphoblastic leukemia (ALL) in infants (up to 1 year of age) is known to be 
biologically different from ALL in older children diagnosed with ALL. ALL in infants 
is more often associated with a higher tumor load at diagnosis1,2, a rearrangement 
in the mixed lineage leukemia (MLL) gene and very immature B-cell phenotype 
(pro-B ALL) without CD10-expression.1-3 Infant ALL cells are more resistant to 
several standard chemotherapeutic agents3,4 and the disease is also characterized 
by a poorer prognosis compared to older children.5-14  
Congenital ALL is diagnosed at birth or within the first month of life and is very 
rare. Although it is assumed to be inevitably fatal and toxicity of the 
chemotherapeutic agents in these very young infants is unclear, to the best of our 
knowledge no series have been published on congenital ALL except for case 
reports. Bresters et al15 reviewed 24 patients with congenital ALL diagnosed over 
25 years of time that were described in case reports: all patients died.  
We recently reported the results of a large international collaborative trial, 
Interfant-99, in infants younger than 1 year with ALL.14 Here we detail the 
outcome and characteristics of thirty patients with congenital ALL who received 
uniform therapy with curative intent. 
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PATIENTS AND METHODS 
 
Patients 
The Interfant-99 trial design, the inclusion criteria and recruitment methods have 
been published earlier.14 Individual study groups obtained ethics approval from 
their own institutions. Of the 518 infants diagnosed with ALL, which account for 
approximately 3% of the ALL population, 35 patients were younger than 1 month 
(≤ 30 days), confirming the rarity of congenital ALL (about two children per every 
thousand with ALL). The present study reports on thirty cases were treated with 
Interfant-99 (Figure 1).  
 
 
 
Figure 1. Trial profile 
 
 
518 assessed 
for eligibility
483 aged  
1-12 moths
31 did not enter 
protocol:                   
14 did not meet            
inclusion criteria                                             
3 clinical decisions
452 eligible
452 analysed
35 aged 
0-1 month
30 eligible
30 analysed
5 did not enter 
protocol:
1 clinical decision                  
1 parent withdrew
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Procedures 
Enrolled patients were stratified into standard-risk and high-risk groups on the 
basis of their response to one week of daily systemic prednisone (at a dose of 60 
mg/m2) and one intrathecal dose of methotrexate. Patients were classified as 
standard risk if their peripheral blood blast count was less than 1000 cells per µl at 
day 8 and high risk if the blast count was equal to or greater than 1000 per µl.4,7 
Patients were tested for MLL gene rearrangement with split-signal fluorescent in-
situ hybridisation (FISH), polymerase chain reaction (PCR), or both. Absence of 
MLL rearrangement was defined as a negative split signal for FISH. 
The Interfant-99 treatment was a hybrid regimen combining standard ALL 
treatment with elements designed for treatment of acute myeloid leukemia. The 
protocol consisted of multiagent phases of induction and consolidation 
chemotherapy, followed by maintenance treatment with antimetabolites.16 Doses 
were adjusted according to patients’ ages at the start of each treatment phase: 
children younger than 6 months were given two-thirds of the full dose and 
children of 6 to 12 months received three-fourths of the full dose. Total treatment 
duration was 104 weeks. 
The induction phase consisted of a standard four-drug induction: dexamethasone, 
vincristine, daunorubicin, L-asparaginase (E. Coli) with the addition of low-dose 
cytarabine.16 The MARAM phase was a consolidation course17 that included high-
dose cytarabine and high-dose methotrexate. OCTADD was a reinduction block 
derived from the consolidation phase of the Berlin-Frankfurt-Münster (BFM) trials 
for treatment of acute myeloid leukemia18, except that prednisone was replaced 
by dexamethasone. Standard-risk patients were given a maintenance phase of 
oral 6-mercaptopurine and methotrexate, combined with pulses of 
dexamethasone and vincristine and intrathecal methotrexate with steroid in the 
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first three cycles. High-risk patients were given standard maintenance therapy 
intensified with pulses of cytarabine and etoposide in the first three cycles. 
Patients were randomly assigned to receiving an extra late intensification 
(VIMARAM) phase (similar to the MARAM maintenance block but with the 
addition of vincristine).17 In case of availability of a suitable donor, high-risk 
patients were eligible for allogenic bone marrow transplantation. Only one 
congenital ALL patient underwent a bone marrow transplantation instead of 
maintenance therapy. For more details on the treatment protocol see Pieters et 
al, 2007.14 
 
Statistical Analysis 
The Interfant-99 trial database was used for analysis. The Fisher exact test was 
applied to investigate the association between age group (congenital ALL-patients 
versus older infants) and both patients’ characteristics and rate of induction 
failures. The Wilcoxon test was used to compare durations of treatment phases 
between age groups. Endpoints were early death (during induction); resistance to 
induction (i.e., no complete remission (CR) at the end of the induction phase); 
relapse; death in CR; and second malignancy. Outcome measures were event-free 
survival (EFS), defined as the time from diagnosis to any one of the endpoints and 
survival, defined as time to death from any cause. Time was censored at the latest 
follow-up available, if no events were recorded. Follow-up was updated at 
December 2007. EFS and survival curves were computed with the Kaplan-Meier 
estimator and their standard error (SE) with the Greenwood formula. The log-rank 
test was used for univariate comparisons. A one-step Cox model was applied to 
estimate the hazard of relapse for congenital ALL as compared to older infants, 
adjusting for relevant factors. The probabilities of relapse and death in CR were 
3 
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estimated by applying the cumulative incidence estimator which accounts for 
competing risks, and were compared according to Gray.19 All tests were two-
sided. SPSS 16.0 statistical software (SPSS Inc., Chicago, IL, USA), SAS 8.2 package 
(SAS Institute, Cary, NC, USA) and R statistical software (http://www.R-
project.org) were used for data analysis. 
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RESULTS 
 
Patient characteristics 
35 Congenital ALL patients were eligible to enter the Interfant-99 protocol. Five 
patients did not enter due to various reasons (see figure 1), whom all died 
respectively at the day of diagnosis, two days after diagnosis, one month after 
diagnosis (two patients), and one patient who was treated died five months after 
diagnosis (two weeks after relapse). Table 1 shows the distribution of relevant 
characteristics in thirty patients with congenital ALL and in the remaining 452 
infants treated with Interfant-99. The percentage of patients with a poor response 
to prednisone was not significantly different between the congenital ALL group 
(39%) and the older infants aged 1-12 months (30%) (p=0.29). Also sex and CNS-
involvement did not differ between these two groups (p=0.71 and p=0.48, 
respectively). Congenital ALL cases more often presented with a high white blood 
cell (WBC) count (p=0.01): only 23% had a WBC count at diagnosis < 100 x109/l 
compared to 46% in the group aged 1-12 months. There was a trend towards a 
higher incidence of a CD10-negative, B-lineage immunophenotype in the 
congenital ALL group (76%) compared to the older patients (62%) (p=0.09) and for 
a higher incidence (p=0.09) of MLL-rearrangement in congenital ALL (93%) versus 
older patients (78%). The distribution of the different MLL fusion partners did not 
differ (p=0.53). In both age groups, t(4;11) was the most common type of 
translocation (congenital ALL 48% vs. 53% in older patients). A t(11;19) was found 
in 32% of congenital ALL patients, while this was seen in 19% of  older infants.  
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Enrolled 
patients 
ZX  Standard-
risk patients 
High-risk 
patients 
Age at diagnosis, months  0-1 1-12  0-1 1-12 0-1 1-12 
        
Total patients 30 452  17 307 12 139 
        
Female sex 17 
(57%) 
234 
(52%) 
0.71 10 
(59%) 
161 
(52%) 
6 
(50%) 
71 
(49%) 
        
WBC count (cells per L)      0.01  
    Less than 100x109 7 
(23%) 
204 
(46%) 
 7  
(41%) 
167 
(55%) 
0 35 
(25%) 
    100-300x109 16 
(53%) 
123 
(27%) 
 9  
(53%) 
91 
(30%) 
6 
(50%) 
32 
(23%) 
    > 300x109 7 
(23%) 
121 
(27%) 
 1  
(6%) 
48 
(16%) 
6 
(50%) 
72 
(52%) 
    Not known 0 4  0 1 9 0 
        
Immunophenotype                   0.09   
    B-lineage: CD10 positive  22 
(76%) 
251 
(62%) 
 14 
(88%) 
168 
(61%) 
7 
(58%) 
80 
(63%) 
    B-lineage: CD10 negative 6 
(21%) 
133 
(33%) 
 2  
(13%) 
103 
(37%) 
4 
(33%) 
29 
(23%) 
    B-lineage: CD10 unknown 1 37  1 25 0 12 
    Other 0 21 
(5%) 
 0 5 
(2%) 
0 16 
(11%) 
    AUL 1 
(3%) 
2 
(0%) 
 0 1 
(0%) 
1 
(8%) 
1 
(1%) 
    Not known 0 8  0 5 0 1 
        
11q23 abnormalities      0.09†  
    Not (fully) known 3 83  0 51 3 20 
    MLL germline 2 
(7%) 
80 
(22%) 
 1  
(6%) 
59 
(24%) 
1 
(11%) 
21 
(18%) 
    MLL rearrangement 25 
(93%) 
289 
(78%) 
 16 
(94%) 
187 
(76%) 
8 
(89%) 
98 
(82%) 
       t(4;11) 12 
(48%) 
154 
(53%) 
 8  
(50%) 
101 
(54%) 
3 
(38%) 
50 
(51%) 
       t(9;11) 1 34  1  25 0 8 
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(4%) (12%) (6%) (13%) (8%) 
       t(11;19) 8 
(32%) 
56 
(19%) 
 5  
(31%) 
34 
(18%) 
3 
(38%) 
22 
(22%) 
      Other fusion partner‡ 2 
(8%) 
23 
(8%) 
 2 
 (13%) 
12 
(6%) 
0 11 
(11%) 
      Fusion partner unknown 2 
(8%) 
22 
(8%) 
 0 15 
(8%) 
2 
(25%) 
7 
(7%) 
        
CNS involvement 0.48   
    Yes 3 
(10%) 
41 
(11%) 
 1  
(8%) 
25 
(9%) 
1 
(13%) 
14 
(12%) 
    No 18 
(90%) 
347 
(89%) 
 11 
(92%) 
244 
(91%) 
7 
(88%) 
102 
(88%) 
   Not evaluable or not     
   Known 
9 64  5 38 4 31 
        
In vivo prednisone response      0.29  
    Good response 17 
(61%) 
301 
(70%) 
 16 300 1 
(8%) 
1 
(1%) 
    Poor response 11 
(39%) 
127 
(30%) 
 0 0 11 
(92%) 
127 
(99%) 
    Not evaluable 0 6  0 2 0 4 
    Not known 2 18  1 5 0 7 
 
Table 1. Patient characteristics by age group and risk group. All data are number (%). 
Percentages calculated as proportion of the known and evaluable data. AUL = acute 
undifferentiated leukemia. MLL = mixed lineage leukemia. CNS =  central nervous system. 
 Comparison (Fisher exact test) between congenital ALL patients and ALL patients aged 1-
12 months. † p-value for association between age group and presence of MLL 
rearrangement. For MLL rearranged patients, distribution of translocation did not differ 
significantly (p=0.53) between age groups. ‡ The fusion partner of the MLL gene is 
defined, but differs from that in t(4;11), t(9;11) or t(11;19).  
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Outcome 
Outcomes are described for 482 enrolled patients overall (thirty with congenital 
ALL, see Table 2), with a median follow-up time from diagnosis of 58 months 
(range 1-102). Nine patients were diagnosed at the age of 0-7 days and 21 
patients at the age of 8-30 days. One congenital ALL patient (diagnosed at the age 
of 24 days) and two older patients died during the first week of prednisone 
treatment (and could therefore not be further stratified in the standard- or high-
risk group). Two out of thirty congenital ALL patients (7%, diagnosed both at the 
age of 0-7 days) died during the induction phase whereas sixteen of 452 (4%) 
older patients died during induction. One congenital ALL patient did not achieve 
CR at the end of induction and died thereafter (age at diagnosis 0 days), while 
eleven patients were resistant among the older infants (eight died). The induction 
failure rate in congenital cases (13%) was not significantly different from that in 
older patients (7%, p=0.14). 
Nineteen out of 26 (73%) congenital ALL patients had a relapse after achieving CR, 
while relapses in the infants of 1-12 months were 176/423 (42%) (p<0.001). All 
relapses in congenital ALL patients presented in the bone marrow and none were 
detected in the CNS. Ten relapses occurred within 6 months from CR, six between 
7 and 12 months, and the remaining three after one year (of whom only one after 
the end of therapy, at 2.6 years). All relapsed patients died. The cumulative 
incidence (SE) of relapse in the congenital ALL patients was 60.0 (9.3) at two 
years, while the corresponding figure for older infants with ALL was 34.2 (2.3) 
(p<0.001). Results of the multivariable Cox model indicate that congenital ALL 
cases had a significantly higher risk of relapse than older infants (hazard ratio 2.4, 
95% CI 1.5-3.9, p<0.001), even after adjusting for known prognostic factors (WBC  
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Enrolled 
patients 
       p¨ Standard-
risk patients 
High-risk 
patients 
Age at diagnosis, months  0-1 1-12  0-1 1-12 0-1 1-12 
Total patients 30 452  17 309 12 139 
       
 
No CR 4 
(13%) 
29 
(7%) 
0.14§ 2 
(12%) 
10 
(3%) 
1 
(8%) 
17 
(12%) 
     Deaths in pre-phase 1 
(3%) 
2 
(3%) 
 0 0 0 0 
     Deaths in induction 2 
(7%) 
16 
(4%) 
 1  
(6%) 
8 
(3%) 
1 
(8%) 
8 
(6%) 
     Resistants 1 
(3%) 
11 
(2%) 
 1 
 (6%) 
2 
(1%) 
0 9 
(6%) 
        
CR 26 
(87%) 
423 
(93%) 
 15 
(88%) 
299 
(97%) 
11 
(92%) 
122 
(88%) 
    Relapses 19 
(73%) 
176 
(42%) 
<0.001 10 
(67%) 
102 
(33%) 
9 
(75%) 
72 
(51%) 
       Bone marrow 18 
(95%) 
124 
(70%) 
 10 
(100%) 
67 
(66%) 
8 
(89%) 
56 
(76%) 
       Bone marrow+ testis 1  
(5%) 
1 
(1%) 
 10 
(100%) 
67 
(66%) 
8 
(89%) 
56 
(76%) 
       Other 0 50 
(13%) 
 0 34 
(15%) 
0 16 
(10%) 
    SMN 0 1 
(0%) 
 0 1 
(0%) 
0 0 
    Alive in CR 5 
(17%) 
223 
(54%) 
 3 
(18%) 
180 
(63%) 
2 
(17%) 
43 
(36%) 
    Deaths in CR 2 
(8%) 
23 
(9%) 
0.7 2 
(40%) 
16 
(5%) 
0 7 
(6%) 
 
Table 2. Outcome by age group and risk group. All data are number (%). SMN = secondary 
malignant neoplasm, CR = complete remission. * Unless mentioned otherwise, comparison 
of cumulative incidence of events in corresponding row(s), in congenital ALL versus ALL 
patients aged 1-12 months, † Comparison of complete remission rate in congenital ALL-
patients vs. ALL-patients aged 1-12 months. 
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count at diagnosis, MLL gene rearrangement and response to prednisone) and 
other characteristics (sex, immunophenotype). 
Two out of 26 (8%) congenital ALL patients in CR died from toxicity, one from a 
brain abscess and one due to septic complications (2 and 5 months from 
diagnosis, respectively). 23 deaths (9%) occurred in older ALL infants. The 
cumulative incidence (SE) of death in CR at two years was 6.7 (4.7) and 5.1 (1.0) in 
congenital ALL and older ALL infants, respectively (p=0.70).  
Five patients (17%) with congenital ALL were still in CR at last follow-up, after 29 
up to 103 months from diagnosis. No second malignancies were diagnosed among 
the congenital ALL-patients. 
 
EFS and survival for congenital ALL were significantly lower than for older infants 
(Figure 2). Two-year EFS was 20.0% (SE 9.1, CI 2.2-37.8) and 54.2% (SE 2.4, 95%CI 
49.5-58.9) and overall 2-year survival was 20.0% (SE 9.1, CI 2.2-37.8) and 66.4% 
(SE 2.4, 95%CI 62.1-70.7) for congenital ALL and older infants with ALL, 
respectively.  
 
                                                           Neonatal ALL                 55 
 
 
Figure 2. Outcome by age group in the Interfant-99 protocol. Log-rank test for difference 
in EFS and survival between congenital ALL patients and ALL patients 1 to 12 months of 
age. Continuous lines represent congenital ALL patients; dashed lines, ALL patients 1 to 12 
months of age; thick lines (both groups), EFS; thin lines (both groups), survival. 
 
 
As expected a treatment delay, as an indirect measure for toxicity, was observed 
in all phases of chemotherapy in congenital ALL patients as well as in older infants 
(see table 3). Nineteen congenital ALL patients and 335 infants aged 1-12 months 
of whom data were available had a median induction phase delay of 1 versus 0.3 
weeks respectively. The consecutive phases, consolidation and reinduction were 
started with a median delay in congenital ALL patients of 2.1 weeks (1.8 in older 
infants), 1.6 weeks (2.1 in older infants) and 2.8 weeks (2.7 weeks in older 
infants). None of these differences in treatment delay between the two groups 
was statistically significant. 
 
log-rank <=30 days vs. 1-12 months
EFS: p-value<0.0001
SURV: p-value<0.0001
At risk
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 Congenital ALL Infant ALL   
Phase (planned duration) Patients 
with 
available 
data 
Actual 
duration 
(median) 
Patients 
with 
available 
data 
Actual 
duration 
(median) 
P* 
Induction (6) 19 7 335 6.3 0.22 
Consolidation (6) 14 8.1 288 7.8 0.5 
Reinduction (8) 11 9.6 209 10.1 0.26 
Intensification (6) 4 8.8 69 8.7 0.84 
Maintenance 1B (42) 4 42.7 98 41.9 0.55 
Maintenance 1A (42) 2 44.4 14 43.1 - 
 
Table 3. Treatment phase duration by age group. Patients in numbers. Durations in 
weeks. Infant ALL=aged 1-12 months. * Comparison of phase duration in congenital ALL-
patients versus ALL-patients aged 1-12 months. 
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DISCUSSION 
 
The limited, single case report based, literature to date suggested that congenital 
ALL was invariably fatal. The present study is the first that reports on a series of 
thirty patients with congenital ALL treated uniformly with curative intent. The 
Interfant database includes all diagnosed infants with ALL, even if they were not 
treated or not treated according to protocol. The present analysis demonstrates 
that the outcome, though worse than in older infants, is not inevitably fatal. 17% 
of the congenital ALL patients were still alive at last follow-up.  
Resistance to prednisone prephase did not differ between the neonates and older 
infants. Neither was induction failure or mortality in CR significantly higher in the 
congenital ALL cases compared to older infants. Due to the small sample size, lack 
of significance in this study does not prove equivalence, therefore results should 
be interpreted with caution. However, patients with congenital ALL did have a 
significantly higher relapse rate. Congenital ALL was characterized by a 
significantly higher white blood cell count, a trend towards a higher incidence of 
MLL gene rearrangements and a CD10-negative B-lineage immunophenotype than 
ALL in older infants. These biological characteristics have all been associated with 
a dismal outcome, as also a very young age per se has been established as risk 
factor for an inferior outcome.14 Nevertheless, a multivariate analysis showed that 
congenital ALL cases had a higher relapse rate also after adjustment of other risk 
factors than age. Possibly, due to fear for severe side-effects in these young 
patients, the reduced doses administered to these patients contribute to the 
higher relapse rate.  
As there is evidence for a prenatal initiation of acute leukemia in young patients20, 
we realize the definition of congenital ALL defined as diagnosed within the first 1st 
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month of life is arbitrary. The definition is based on previous literature (e.g. 
Bresters et al15), though the type of MLL-rearrangement shifts as infants are 
diagnosed later. 91% of infants younger than 6 months had MLL-rearrangements, 
compared with 66% of infants aged 6-12 months. Two-thirds of patients with 
t(4;11) or t(11;19) were younger than 6 months at diagnosis compared to one-
third of patients with t(9;11).14 A longer latency from initiation to diagnosis, and 
by this possibly a less aggressive form of leukemia, could be in part an explanation 
for the better outcome of the older infants with MLL-rearranged ALL.  
Improvement of outcome for the congenital ALL patients is still urgently needed. 
New treatment strategies are under current investigation in order to improve 
outcome of infants with ALL. Unpublished observations of the Interfant-99 trial 
suggest that infants with MLL-rearrangements, younger age and a very high WBC 
might benefit from stem cell transplantation. In the current Interfant-06 study 
different early intensification strategies are studied in order to prevent early bone 
marrow relapses. New therapeutic targets have to be identified by unraveling the 
biology of MLL-rearranged ALL. Phase I/II trials with FLT3-inhibitors21 are currently 
being initiated in infant MLL-rearranged ALL. 
In conclusion, the current study shows a survival of 17% for congenital ALL and a 
toxicity profile comparable to that in older infants. This proves that congenital ALL 
is not invariably fatal and justifies treatment with curative intent. For now, the 
treatment to be used should be the same as for older infants but their poor 
outcome also necessitates the testing of newer approaches, such as new 
strategies to prevent early relapses as tested in the ongoing Interfant-06 and new 
targeted treatments as FLT3-inhibitors.  
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ABSTRACT 
 
Acute lymphoblastic leukemia (ALL) in infants (< 1 year) is characterized by a poor 
prognosis and a high incidence of MLL translocations. Several studies 
demonstrated the unique gene expression profile associated with MLL-rearranged 
ALL, but generally small cohorts were analyzed as uniform patient groups 
regardless of the type of MLL translocation, whereas the analysis of translocation 
negative infant ALL remained unacknowledged. Here we generated and analyzed 
primary infant ALL expression profiles (n=73) typified by translocations t(4;11), 
t(11;19), and t(9;11), or the absence of MLL translocations. Our data show that 
MLL germline infant ALL specifies a gene expression pattern that is different from 
both MLL-rearranged infant ALL and pediatric precursor BCP-ALL. Moreover, we 
demonstrate that, apart from a fundamental signature shared by all MLL-
rearranged infant ALL samples, each type of MLL translocation is associated with a 
translocation-specific gene expression signature. Finally, we show the existence of 
2 distinct subgroups among t(4;11)–positive infant ALL cases characterized by the 
absence or presence of HOXA expression, and that patients lacking HOXA 
expression are at extreme high risk of disease relapse. These gene expression 
profiles should provide important novel insights in the complex biology of MLL-
rearranged infant ALL and boost our progress in finding novel therapeutic 
solutions. 
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INTRODUCTION 
 
In recent years, genome-wide assessment of gene activity has proven to be of 
great value in tumor classification as well as in identifying unique gene expression 
signatures associated with drug response, prognosis, metastasis, angiogenesis, 
and tumorigenesis. In pediatric acute lymphoblastic leukemia (ALL), 
oligonucleotide microarray analyses have been shown to accurately predict 6 
major prognostic and genetically distinct patient groups, including specific 
precursor B-cell lineage subtypes characterized by E2A- PBX1, BCR-ABL, TEL-AML1, 
and MLL translocations, or hyperdiploidy (> 50 chromosomes), and T-cell lineage 
ALL (T-ALL).1-3 In addition, our laboratory recently identified a novel subgroup 
among children with genetically yet unclassified precursor B- ALL.3 In other 
studies, we demonstrated how gene expression profiling can identify unique gene 
expression signatures associated with resistance to prednisone, vincristine, L-
asparaginase, and daunorubicin in pediatric ALL.4, 5 Moreover, these gene 
expression signatures appeared to be highly predictive for clinical outcome for the 
patients under investigation as well as in a completely independent patient 
cohort.4 
Among the different genetic subgroups of pediatric ALL, MLL-rearranged ALL 
represents the most unfavorable type of leukemia and is most frequently 
diagnosed in infants (i.e., children younger than 1 year). In infant ALL, 
approximately 80% of the cases are typified by leukemia-specific chromosomal 
translocations involving the Mixed Lineage Leukemia (MLL) gene,6 fusing the N-
terminal portion of MLL to the C-terminal region of one of its many translocation 
partner genes. By far the most frequent MLL translocations found among infant 
ALL patients are t(4;11), t(11;19), and t(9;11),7  giving rise to the fusion proteins 
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MLL-AF4, MLL-ENL, and MLL-AF9, respectively. These chimeric MLL fusion 
proteins exhibit pronounced transforming capacities8 and independently 
contribute to an unfavorable prognosis.7 To date, event-free survival rates for 
MLL-rearranged infant ALL range between 20% and 50%, depending on the 
treatment protocol.7 Approximately 20% of the infant ALL patients carry germline 
(or wild-type) MLL genes, and nowadays have a far better prognosis with event-
free survival chances of 75% to 95%.7, 9 
Multiple microarray studies demonstrated that MLL translocations specify a 
distinct gene expression profile that is clearly distinguishable from other ALL 
subtypes and from acute myeloid leukemia (AML).1-3, 10, 11 Moreover, Zangrando et 
al recently reported a gene expression signature commonly shared by MLL- 
rearranged ALL and AML patients, identifying deregulated genes specifically 
associated with the MLL translocation, irrespective of the type of leukemia.14 In 
most of these studies, however, rather small numbers of MLL-rearranged ALL 
samples were analyzed as a uniform patient group, regardless of the type of MLL 
translocation. Nevertheless, MLL-rearranged ALL may well represent 
heterogeneous biologic entities characterized by a fundamental gene expression 
profile shared by all patients despite the MLL fusion partner, whereas underlying 
expression signatures may discriminate between the different types of MLL 
translocations. To test this, we generated and analyzed gene expression profiles in 
a relatively large cohort of MLL-rearranged infant ALL samples, and indeed reveal 
the existence of specific gene expression signatures associated with the different 
MLL translocations frequently found in infant ALL. Furthermore, we sought to 
determine whether infant ALL patients carrying germline (or wild-type) MLL genes 
display gene expression profiles that resemble those of childhood ALL patients 
older than one year of age (non-infants), or whether these patients form yet 
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another genetically distinct ALL subgroup, and concluded the latter. Finally, we 
show that, among t(4;11)-positive infant ALL cases, 2 distinct subgroups can be 
identified based on the absence or presence of HOXA9, HOX10, HOXA7, HOXA5, 
and HOXA3 expression, and show dramatic differences in  relapse-free survival. 
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METHODS 
 
Patient samples 
Bone marrow or peripheral blood samples from untreated infants (younger than 1 
year) diagnosed with ALL were collected at the Erasmus MC–Sophia Children’s 
Hospital and other institutes participating in the recently published international 
collaborative INTERFANT-99 treatment protocol.7 Samples from pediatric ALL 
patients older than 1 year (i.e., non-infants) were selected from our cell bank. 
Absence of MLL rearrangement was defined as a negative split signal for FISH. For 
all primary patient samples used in this study, approval was obtained from the 
Erasmus MC Institutional Review Board, and authorization was acquired from the 
parents or legal guardians of the children via informed consent in accordance with 
the Declaration of Helsinki. Patient characteristics are listed in Supplemental 
material Chapter 4 Table 1. 
 
Sample preparation 
All samples were processed within 24 hours after sampling as described 
recently.12 Briefly, mononuclear cells were isolated by density gradient 
centrifugation using Lymphoprep (Nycomed Pharma), and non-leukemic cells 
were removed using immunomagnetic beads.13 All leukemia samples used in this 
study contained more than 90% leukemic cells, as determined morphologically on 
May-Grünwald-Giemsa (Merck)–stained cytospins. 
 
Gene expression profiles 
Total RNA was extracted using TRIzol reagent (Invitrogen) according to the 
manufacturer’s instructions, and quantified on a Nanodrop ND-1000 
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spectrophotometer (Isogen). The integrity of the extracted RNA was assessed on 
an Agilent 2100 Bioanalyzer (Agilent). High-quality RNA was reverse transcribed 
using T7-linked oligo-dT primers, and the obtained cDNA was used as a template 
to synthesize biotinylated cRNA. Labeled cRNA was then fragmented and 
hybridized to HU133plus2.0 GeneChips (Affymetrix) according to the 
manufacturer’s guidelines. The infant ALL gene expression data presented in this 
study have been deposited in the National Center for Biotechnology Information 
Gene Expression Omnibus14 and is accessible via GEO Series accession number 
GSE19475. The gene expression data for the pediatric precursor BCP-ALL samples 
were deposited as GSE13351 as part of a recently published study.3 
 
Quantitative real-time PCR analyses 
Total RNA was extracted from a minimum of 5 X 106 leukemic cells using TRIzol 
reagent (Invitrogen) according to the manufacturer’s instructions. The quality of 
the extracted RNA was assessed on 1% agarose gels. Extracted RNA was reverse 
transcribed as described before,15 and the obtained cDNA was used to quantify 
mRNA expression of HOXA9, HOXA7, HOXA5, HOXA10, and HOXA3 relative to the 
housekeeping gene B2M using quantitative real-time polymerase chain reaction 
(PCR). For this, PCR products were amplified using the DyNAmo SYBR Green qPCR 
kit (Finnzymes) according to the manufacturer’s recommendations, using SYBR 
Green as a fluorophore to detect transcripts on an ABI Prism 7900 sequence 
detection system (Applied Biosystems). 
 
Statistical analyses 
Raw array data were collectively normalized using variance-stabilizing 
normalization,16 and differential gene expression was statistically evaluated using 
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linear models for microarray analyses.17 Differences in gene expression were 
deemed significant at P values (adjusted for multiple testing according to the step-
up procedure of Benjamini) of less than .01 (i.e.,  false  discovery  rate  [FDR] < 
0.01).  All  statistical  analyses  were performed in the statistical environment R 
using Bioconductor packages. Heatmaps were generated in GenePattern,18 and 
graphical representations of principal component analyses (PCA) were produced 
using the GeneMath XT 1.6.1 software (Applied Maths). 
As a measure of internal validation for the subtype-specific gene expression 
signatures, the global test19 was applied to evaluate whether gene lists were 
significantly associated with a certain patient group. In all instances, the global 
test indicated that the expression of all selected probe sets was significantly 
associated with the corresponding patient group. To produce informative 
representations of discriminative probe sets, we chose to visualize the top 50 
most significantly overexpressed probe sets for each subgroup in each 
comparison. 
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RESULTS 
 
MLL-rearranged infant ALL versus pediatric precursor BCP-ALL: dataset validation 
Nowadays, proper validation of gene expression profiling data is achieved either 
by a double-loop cross-validation procedure in which the sample population is 
divided into a training and a test set,3 or by confirming differential gene 
expression in a truly independent patient cohort (e.g., Holleman et al4). However, 
infant ALL is a rare malignancy, and collecting an adequate number of samples to 
apply such validations remains difficult, even in our INTERFANT-99 patient cohort 
that currently represents the largest collection of infant ALL samples. Therefore, 
to avoid reduction of the sample size and maintain sufficient statistical power, we 
here adopted 2 recently published expression signatures that separate MLL-
rearranged ALL from other ALL subtypes, based on which we used our samples as 
an independent patient cohort to validate the integrity of our dataset. The first 
signature was reported by Armstrong et al,10 and represents 100 probe sets most 
significantly discerning between MLL-rearranged ALL (n = 17) and conventional 
precursor BCP-ALL samples. The second was published by Yeoh et al,2 and 
composes 40 genes that distinguished pediatric MLL-rearranged  ALL  (n = 20)  
from  all  other  known  genetic subtypes of childhood ALL, including E2A-PBX1, 
BCR-ABL, and TEL-AML1 positive or hyperdiploid (> 50 chromosomes) BCP-ALL, 
and T-ALL. As both of these studies were performed on Affymetrix HU95A 
microarrays (containing 12 600 probe sets), we assessed the corresponding probe 
sets on the HU133plus2.0 arrays (containing 54 675 probe sets) and determined 
their discriminative capacity on our samples. For the MLL-rearranged ALL 
signature by Armstrong et al,10 97 probe sets (HU133plus2.0) could be identified 
to correspond with the 100 probe sets (HU95A) in the original signature. For the 
                                                                                            Gene expression profiling                   73  
signature reported by Yeoh et al,2 all corresponding probe sets were found. Both 
signatures clearly separated our MLL-rearranged infant ALL patients (n = 59), 
consisting of t(4;11) (n = 29),  t(11;19)  (n = 22),  and  t(9;11)-positive  (n = 8)  
cases, from our pediatric precursor BCP-ALL (n = 16) samples (Figure 1). 
To exclude influences from subtype-specific gene expression signatures 
underlying pediatric ALL, we intentionally selected BCP-ALL samples from children 
older than one year of age that could not be assigned to any of the major genetic 
ALL subtypes. Of the 97 probe sets corresponding to the MLL-rearranged ALL 
signature by Armstrong et al,10  80 probe sets (82%) were significantly 
differentially  expressed  (FDR < 0.01)  between  our  MLL-rearranged infant ALL 
and BCP-ALL samples. For the signature by Yeoh et al,2 32 of the 40 probe sets 
(80%) were expressed differentially (FDR < 0.01).  Probe  set  identifications  and  
descriptions,  gene names, log-fold changes, and P values are listed in 
Supplemental material Chapter 4 Tables 2 and 3, respectively. 
Given the superior number of probe sets on the HU133plus2.0 GeneChips used in 
the present study over the formerly used first-generation HU95A microarrays, we 
further explored whether this advantage results in a more pronounced class 
distinction than reported earlier. Comparing our gene expression profiles of MLL- 
rearranged infant ALL (n = 59) with those from pediatric BCP-ALL patients  (n = 
16),  we  found  14 246  of  the  54 675  probe  sets (26%) to be differentially 
expressed (FDR < 0.01), of which 6990 were up-regulated in MLL-rearranged 
infant ALL. Figure 2A shows a heatmap visualization of 100 probe sets most 
significantly up  (n = 50)  and  down-regulated  (n = 50)  in  MLL-rearranged infant 
ALL compared with pediatric precursor BCP-ALL. Probe set identifications and 
descriptions, gene names, log-fold changes, and P values are listed in 
Supplemental material Chapter 4 Table 4.  
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Figure 1. MLL-rearranged infant ALL versus pediatric precursor BCP-ALL (HU95A): dataset 
validation. Heatmaps separating our MLL-rearranged infant ALL (n = 59) from pediatric 
precursor BCP-ALL (n = 16) samples based on the MLL-rearranged ALL specific gene 
expression signatures (obtained on HU95A microarrays) published by Armstrong et al10 (A) 
and Yeoh et al2 (C). Columns represent patient samples, and rows represent the gene 
names corresponding to the probe sets. Normalized gene expression is depicted in red 
(high expression) or blue (low expression). (B,D) PCA for both signatures, respectively. Red 
dots indicate MLL-rearranged infant ALL samples (including t(4;11) (n = 29), t(11;19) (n = 
22), and t(9;11)-positive (n = 8) cases), and blue dots represent pediatric precursor BCP-
ALL cases (n = 16). Patient characteristics and detailed gene descriptions are listed in 
Supplemental Material Chapter 4 Tables 1, 2, and 3. 
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PCA revealed that using high-resolution HU133plus2.0 microarrays, by estimate 
covering the entire human genome, additional genes can be found that more 
clearly distinguish between MLL-rearranged ALL and conventional BCP-ALL than 
the signatures reported before (Figure 2B). For examples, probe sets 
corresponding to RLP38 (ribosomal protein L38), KCNK12 (potassium channel 
subfamily K member 12), and MDS027 (also known as HSPC300; hematopoietic 
stem/progenitor cell protein 300) are not present on HU95 microarrays but did 
appear among the 50 most significantly up-regulated genes in MLL-rearranged 
infant ALL samples in our HU133plus2.0- based data (Figure 2A). Of particular 
interest is the high-level expression of HSPC300, which was recently hypothesized 
to be associated with the metastatic potential of lung squamous cell carcinoma.25 
As such, high level HSPC300 expression may well contribute to the aggressive 
nature of MLL-rearranged ALL and exemplifies how our HU133plus2.0-based gene 
expression profiles may further extend our insights in the biology of this 
malignancy. 
Given the vast amount of probe sets significantly up- or down-regulated in MLL-
rearranged infant ALL, we used high-level HSPC300 expression merely as an 
example of presumably many genes that have not been associated with MLL-
rearranged ALL before. 
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Figure 2. MLL-rearranged infant ALL versus pediatric precursor BCP-ALL. A. Heatmap 
showing the separation of MLL-rearranged infant ALL (n = 59) from pediatric precursor 
BCP-ALL (n = 16) samples based on the 100 probe sets most significantly discriminative 
between both patient groups as attained in our analyses using HU133plus2.0 GeneChips. 
Columns represent patient samples, and rows represent the gene names corresponding to 
the probe sets. Normalized gene expression is depicted in red (high expression) or blue 
(low expression). The top 50 probe sets are relatively overexpressed and the bottom 50 
probe sets relatively underexpressed in MLL-rearranged infant ALL (which include t(4;11) 
(n = 29), t(11;19) (n = 22), and t(9;11)-positive (n = 8) cases). B. Graphic representation of 
PCA based on this gene expression signature, separating the MLL-rearranged infant ALL 
(red dots) from pediatric precursor BCP-ALL (blue dots) samples. 
 
 
MLL germline infant ALL represents a unique subtype of childhood ALL 
Next we asked whether infant ALL patients bearing germline MLL genes simply 
represent pediatric ALL patients of very young age (i.e., < 1 year) or whether these 
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patients compose an isolated ALL subgroup different from other known ALL 
subtypes. Therefore, we compared gene expression profiles of MLL germline 
infant ALL samples  (n = 14)  to  those  of  the  MLL-rearranged  infant ALL (n = 59)  
and  the  pediatric  precursor  BCP-ALL samples  (n = 16),  lacking known genetic 
abnormalities. Initially, we performed a PCA, using all 54 675 probe sets present 
on the HU133plus2.0 GeneChip, without any selection. This unsupervised analysis 
roughly separated the germline MLL infant ALL samples from both the MLL-
rearranged infant ALL and pediatric precursor BCP-ALL samples (Figure 3). 
Remarkably, the MLL germline infant ALL samples as a group clustered tightly to, 
but separately from, the MLL-rearranged infant ALL samples, and clearly away 
from the pediatric precursor BCP-ALL samples. Thus, apart from the presence of  
MLL  translocations,  young  age  (< 1 year),  characteristically shared by all infants 
either carrying rearranged or germline MLL genes, also influenced this clustering 
(Figure 3). 
 
 
Figure 3. Unsupervised clustering analysis of MLL-rearranged infant ALL, MLL germline 
infant ALL, and pediatric precursor BCP-ALL. Completely unsupervised clustering analysis 
(PCA) of MLL-rearranged infant ALL (n = 59; red dots), MLL germline (wild-type MLL) infant 
ALL (n = 14; green dots), and pediatric precursor BCP-ALL (n = 16; blue dots) samples, 
using all 54 675 probe sets present on the HU133plus2.0 GeneChip. 
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Subsequently, to explore whether specific expression profiles could define these 3 
patient groups more accurately, the 50 most significantly up-regulated probe sets 
for each group (compared with the other 2 groups combined) were selected. 
Differential expression of these most discriminative probe sets is visualized in a 
heatmap (Figure 4A). Probe set identifications and descriptions, gene names, log-
fold changes, and P values are listed in supplemental Table 5. As expected and 
consistent with our unsupervised analysis (Figure 3), PCA showed that these 150 
probe sets (almost) completely separated the MLL germline infant ALL samples 
from both the MLL-rearranged infant ALL and the pediatric precursor BCP-ALL 
samples (Figure 4B). 
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Figure 4. Supervised clustering analysis of MLL-rearranged infant ALL, MLL germline 
infant ALL, and pediatric precursor BCP-ALL. A. Heatmap visualizing differential gene 
expression separating MLL germline infant ALL (n = 14), from MLL-rearranged infant ALL (n 
= 59) and pediatric precursor BCP-ALL (n = 16) samples, based on the 50 most significantly 
up-regulated probe sets for each patient group (compared with the other patient groups 
combined). Columns represent patient samples, and rows represent the gene names 
corresponding to the probe sets. Normalized gene expression is depicted in red (high 
expression) or blue (low expression). B. Graphical representation of the supervised 
clustering of the samples based on this expression signature. Red dots indicate MLL-
rearranged infant ALL; green dots, MLL germline infant ALL; and blue dots, the pediatric 
precursor BCP-ALL samples. 
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MLL translocation–specific GEP’s among MLL-rearranged infant ALL patients 
Accumulating evidence suggests that MLL translocations cause deregulated gene 
expression as a result of translocation-specific histone modifications, which may 
in part be influenced by the translocation partner gene.31, 32 Therefore, we asked 
whether distinct gene expression profiles could be identified associated with the 
type of MLL translocation. For this we separated our MLL- rearranged infant ALL 
samples according to the type of translocation, i.e., t(4;11) (n = 29), t(11;19) (n = 
22), or t(9;11) (n = 8), and determined the differentially expressed probe sets for 
each subgroup (compared with the other 2 subgroups combined). In total, 1229 
probe sets were significantly differentially expressed between the 3 MLL-
rearranged subgroups (FDR < 0.01). Figure 5A shows a heatmap visualizing the 50 
most significantly up-regulated probe sets for each of the MLL-rearranged 
subgroups. Probe set identifications and descriptions, gene names, log-fold 
changes, and P values are listed in Supplemental material Chapter 4 Table 6. PCA 
showed that based on these 150 probe sets, t(4;11), t(11;19) and t(9;11)-positive 
infant ALL cases cluster completely separate form one another (Figure 5B). 
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Figure 5. Gene expression–based separation of MLL-rearranged infant ALL subtypes. A. 
Heatmap demonstrating differential gene expression between t(4;11), t(11;19), and 
t(9;11)-positive MLL-r infant ALL samples, based on the 50 most significantly up-regulated 
probe sets for each patient group (compared with the other patient groups combined). 
Columns represent patient samples, and rows represent the gene names corresponding to 
the probe sets. Normalized gene expression is depicted in red (high expression) or blue 
(low expression). B. PCA plot clustering the t(4;11) (red dots), t(11;19) (orange dots), and 
t(9;11) (yellow dots) according to these 150 selected probe sets. 
Subdivision of t(4;11)-positive infant ALL based on the presence or absence of 
HOXA expression 
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Finally, we asked whether gene expression profiles existed that subdivided MLL-
rearranged infant ALL samples even among patients characterized by the same 
type of MLL translocation. Translocation t(4;11), giving rise to the MLL-AF4 fusion 
protein, is by far the most common MLL translocation among infant ALL patients 
(found in 50% of all cases).7 As such, t(4;11)-positive infant ALL represents the 
largest subgroup of MLL-rearranged infant ALL cases in this study. Therefore, we 
particularly chose our t(4;11)-positive gene expression profiles to explore 
differential gene expression among t(4;11)-positive infant ALL cases. For this, the 
SD of the expression of each probe set was calculated among all t(4;11)-positive  
cases  (n = 29),  to  identify  probe  sets  with  the largest variation, possibly 
indicating differential expression among these patients. Surprisingly, 6 probe sets 
corresponding to HOXA9, HOXA7, HOXA10, HOXA5, and HOXA3, appeared to 
display pronounced standard deviations, and consistently separated 2 sub- groups 
of t(4;11)-positive infant ALL samples uniformly characterized either by the 
presence (n = 13) or absence (n = 16) of HOXA expression (Figure 6 top panel). To 
validate these findings, quantitative  reverse-transcribed  PCR  was  applied  to  
quantify HOXA9, HOXA7, HOXA10, HOXA5, and HOXA3 expression relative to the 
housekeeping gene B2M in primary t(4;11)-positive infant ALL samples 
characterized by either high (n = 5) or low (n = 5) HOXA expression (Figure 7). 
Adopting this separation, we compared the gene expression profiles and 
identified an additional 31 probe sets to be differently expressed between these 
subgroups (Figure 6 bottom panel). Several  of  these  probe sets represented 
other homeobox genes, such as HOXA4, HOXB9, and IRXA1 (or IRX1) or denoted 
additional probe sets for HOXA10 and  HOXA7.  Probe  set  identifications  and  
descriptions,  gene names, log-fold changes, and P values are listed in 
Supplemental material Chapter 4 Table 7. 
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Figure 6. HOXA-based subclustering of t(4;11)-positive infant ALL samples. Heatmap 
visualizing 2 clusters among t(4;11)-positive infant ALL samples (n = 29) based on the 
present or absent of HOXA9, HOXA10, HOXA7, HOXA5, and HOXA3 expression (upper 
panel). Apart from the 6 probe sets initially separating both patient groups, and additional 
31 probe sets (lower panel) appeared to be significantly (FDR < 0.01) differentially 
expressed between HOXA-negative (n = 16) and HOXA-positive (n = 13) 
t(4;11)-positive infant ALL.  
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Figure 7. HOXA-based subclustering of t(4;11)-positive infant ALL samples. HOXA9, 
HOXA10, HOXA7, HOXA5, and HOXA3 expression as determined by quantitative reverse-
transcribed PCR analyses in t(4;11)-positive infant ALL samples characterized by high (n = 
5) or low (n = 5) HOXA expression according to the microarray data.  
 
 
Interestingly, the relapse-free survival varied significantly between both 
subgroups (P = .034), with t(4;11)-positive infant ALL patients negative for HOXA 
expression being at extreme high risk of  disease  relapse  (Figure  8). The  1-year  
cumulative  relapse incidence for HOXA-positive patients was 18.2% (± 12.3%) and 
for HOXA-negative patients 58.3% (± 15.4%). In a Cox model on the hazard of 
relapse, HOXA-negative t(4;11)-positive infant ALL patients had a significantly (P = 
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.036) 4.17-fold increased hazard ratio (95% confidence interval, 1.10-15.81) 
compared with HOXA- positive patients. However, as indicated by the relatively 
large 95% confidence interval, these findings should be interpreted with caution 
because of the small sample size. Nonetheless, a possible explanation for the 
pronounced difference in relapse-free survival between both t(4;11)-positive 
patient groups may lie in the genes that discriminate between them. For example, 
high-level PRDX4 (Peroxiredoxin 4) expression, such as that found in HOXA-
negative t(4;11)-negative infant ALL samples (Figure 6), has been associated with 
metastasizing colon cancer.21 In case PRDX4 also contributes to tumor progression 
and metastasis in MLL-rearranged ALL, up-regulated PRDX4 expression may 
contribute to the worse outcome of HOXA-negative t(4;11)-negative infant ALL 
patients compared with patients who do show HOXA expression. 
 
 
Figure 8. HOXA-based subclustering of t(4;11)-positive infant ALL samples. Relapse-free 
survival curves for HOXA-negative (n = 12) and HOXA-positive (n = 11) t(4;11)-positive 
infant ALL patients, demonstrating a significantly higher relapse incidence in t(4;11)-
positive infant ALL patients lacking HOXA expression (P = .034). Because of a lack of data 
availability or exclusion of patients who died before entering the INTERFANT-99 treatment 
protocol, relapse-free survival could only be plotted for 23 of the 29 t(4;11)-positive infant 
ALL cases. 
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DISCUSSION 
 
MLL-rearranged ALL samples display unique and ample deregulated expression 
profiles that are clearly distinguishable from profiles found in other specific ALL 
subtypes.1-3, 10, 11 However, the number of MLL- rearranged infant ALL cases in 
these studies were small, inevitably leading to the analyses of these samples as a 
single patient group regardless of the type of MLL translocation. The most 
common MLL translocations among infant ALL patients are translocation t(4;11), 
t(11;19), and t(9;11), and the possible existence of specific gene expression 
profiles underlying these different MLL translocations re- mains unacknowledged. 
In addition, the aforementioned profiling studies made tremendous progress in 
classifying unique types of genetically distinct ALL subgroups, but infant ALL cases 
carrying germline MLL genes were never studied in these analyses. Therefore, the 
present study was designed to explore the possible existence of MLL translocation 
specific gene expression profiles, and evaluates how MLL germline infant ALL 
genetically relates to MLL-rearranged infant ALL and ALL in children older than 1 
year. 
Establishing the integrity of our data, we took 2 previously published gene 
expression profiles associated with MLL-rear- ranged ALL and applied these 
signatures to our MLL-rearranged infant ALL samples compared with pediatric 
precursor BCP-ALL samples. For both published signatures, approximately 80% of 
the probe sets in both of the signatures appeared significantly differentially 
expressed in our MLL-rearranged infant ALL samples, demonstrating that our 
dataset is consistent with other datasets reported earlier. The approximately 20% 
of the probe sets in both signatures that did not show differential expression in 
our samples may be explained by slight differences or biases in the composition of 
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the patient cohorts in which these signatures were originally identified. For 
example, the signature reported by Armstrong et al,10 was based predominantly 
on t(4;11) and t(11;19)-positive cases, whereas no t(9;11)-positive cases were 
included. Moreover, this patient cohort also included MLL-rearranged ALL 
samples from children older than one year of age, as well as a few adult patients. 
Likewise, in the study of Yeoh et al,2 the inclusion criteria of MLL-rearranged ALL 
samples were solely based on the presence of an MLL translocation regardless of 
age. Our MLL-rearranged ALL cohort consists entirely of infants younger than 
one year in which all 3 common MLL translocations found among infant ALL 
patients are represented.  
Given the superior number of probe sets on the HU133plus2.0 GeneChips (used 
in the present study) over the first generation HU95A chips used in earlier 
studies,2,12 we also compared MLL- rearranged infant ALL with MLL translocation-
negative non-infant pediatric precursor BCP-ALL samples, based on our data. 
This comparison demonstrated that high-resolution HU133plus2.0 data are 
capable of separating these patient groups even more convincingly than already 
shown earlier and revealed differential expression of genes that have not been 
associated with MLL-rearranged ALL before, which may therefore provide further 
insights into this aggressive type of leukemia, on top of recent progress in 
understanding mechanism by which MLL fusions alter gene expression. The most 
important breakthrough in our comprehension of MLL translocation induced 
transformation has been the notion that, because of the loss of MLL-specific 
histone methyltransferase activity necessary for H3K4 methylation, MLL fusions 
recruit alternative histone methyltransferases (e.g., DOT1L) that subsequently 
establish H3K79 methylation. In turn, H3K79 methylation results in accessible 
chromatin at inappropriate loci, allowing the abnormal and presumably 
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pathogenic activation (expression) of associated genes.22, 23 From this respect, MLL 
fusion proteins are often regarded as activating oncogenic molecules. In line with 
this assumption, we here show that approximately 7000 probe sets are 
significantly up-regulated in MLL-rearranged infant ALL compared with non-infant 
pediatric precursor BCP-ALL samples. On the other hand, we found an equal 
amount of probe sets to be significantly down-regulated in MLL-rearranged infant 
ALL, indicating that the considerably deregulated gene expression patterns in this 
disease are not necessarily characterized by an overrepresentation of activated 
genes but show that down-regulated gene expression is at least as common. In 
concordance with this, we recently found MLL-rearranged infant ALL samples to 
display vast amounts of genome-wide gene promoter methylation that appeared 
to be associated with the transcriptional silencing of the affected genes.24 Thus, 
whereas the mechanisms by which MLL fusions activate gene expression are 
currently being elucidated, the mechanisms by which MLL fusions deactivate gene 
expression remain to be studied. 
As infant ALL samples carrying germline MLL genes have not yet been properly 
analyzed as a single patient group, we compared gene expression profiles of these 
patients against MLL-rearranged infant ALL and non-infant pediatric precursor 
BCP-ALL profiles. A completely unsupervised clustering analysis revealed that MLL 
germline infant ALL resembles neither MLL-rearranged infant ALL nor pediatric 
precursor BCP-ALL lacking known genetic abnormalities. Based on this 
unsupervised analysis using all probe sets present on the HU133plus2.0 GeneChip, 
the MLL germline infant ALL samples seem more closely related to MLL-
rearranged infant ALL samples (of the same age) than to the precursor ALL 
samples, also carrying germline MLL genes, derived from children older than one 
year. This finding possibly reflects the influences of very young age, at which ALL 
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(in the absence of MLL rearrangements) apparently develops after alternative 
mechanisms, giving rise to a characteristic gene expression profile. In other words, 
MLL germ- line infant ALL may represent a unique biologic entity. Alternatively, 
these patients could also display a gene expression profile. that is more similar 
than one of the established ALL subtypes not included in the present study. 
Since the observation that MLL-rearranged ALL displays a highly characteristic 
gene expression profile,10 scientists have been searching for the mechanisms 
driving deregulated transcription induced by the MLL fusion. As the MLL gene 
itself has specific histone methyltransferase activity,25, 26 which is lost during 
fusion of MLL to one of its translocation partner genes, MLL translocations 
probably result in altered chromatin structures resulting from aberrant histone 
modifications. This may, to a large extent, explain the characteristic gene 
expression patterns uniformly associated with MLL-rearranged leukemia. 
However, influence of the translocation partner gene should not be ignored. A 
growing body of evidence implies that many of the MLL fusion partners are part of 
transcriptional regulation networks that also function through chromatin 
remodeling,27 and not necessarily lead to similar changes. For instance, although 
the recruitment of the histone methyltransferase DOT1L has been well 
established for MLL-AF4 fusions, it is certainly not unthinkable that other MLL 
fusion partners recruit histone methyltransferases other than DOT1L, leading to 
alternative chromatin modifications. In any case, apart from basal deregulation of 
gene expression driven by the interruption of the MLL gene that is shared by all 
MLL-rearranged leukemias, the fusion partner seems to determine additional 
changes in gene expression characteristic for the type of MLL translocation. As 
shown in the present study, MLL-rearranged infant ALL samples carrying 
translocations t(4;11), t(11;19), or t(9;11) indeed display translocation specific 
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gene expression signatures that clearly separate these samples into 3 distinct 
patient groups. In line with these findings, we recently found that these different 
MLL translocations also specify distinct genome-wide promoter methylation 
patterns.24 Hypothetically, these data may collectively imply that MLL- rearranged 
leukemias transform by dramatically changing epigenetic landscapes induced and 
guided by the type of MLL fusion protein, which initially triggers abnormal 
chromatin remodeling and subsequently alters genome-wide DNA methylation 
patterns and transcription, all in favor of the development of leukemia. 
Finally, we asked  whether distinct  gene expression  profiles could also be hidden 
among infant ALL patients carrying the same type of MLL translocation. 
Interestingly, we found the presence of 2 separate clusters among our t(4;11)-
positive ALL samples, distinguishable by either the presence or absence of HOXA9, 
HOXA7, HOXA10, HOXA5, and HOXA3 expression. Moreover, the separation of 
both t(4;11)-positive infant ALL subgroups was not based on moderate variations 
in HOXA expression but rather divided patients either firmly expressing or 
completely lacking HOXA gene expression. These findings confirm a similar 
observation recently reported by Trentin et al,28 who showed that, based on the 
localization of the MLL breakpoints and the absence or presence of AF4-MLL (the 
reciprocal fusion transcript of MLL- AF4), and the presence or absence of HOXA 
expression, t(4;11)- positive ALL samples can be subdivided into 2 separate 
genetic subgroups. However, in contrast to the data from Trentin et al,28 who 
identified hundreds of genes to be associated with either high or low HOXA 
expression, we only found 27 probe sets to significantly discriminate between 
t(4;11)-positive infant ALL patients expressing either high or low HOXA levels. 
Nevertheless, these findings are particularly remarkable, as HOXA overexpression 
is thought to be a hallmark of MLL-rearranged leukemias,10, 29 and HOXA9 
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expression has recently been postulated to be required for leukemia survival in 
MLL-rearranged leukemia cell lines and primary MLL-rearranged AML samples.30  
Surprisingly, our data revealed that the absence of HOXA expression appears to 
be of significant clinical importance, as these patients are at extreme high risk of 
disease relapse, even within a patient group already characterized by a poor 
prognosis. Collectively, these observations challenge the dogma that HOXA9 is 
consistently highly expressed in all MLL-rearranged leukemias, and demonstrate 
that HOXA9 is not per se required for the maintenance of MLL-rearranged infant 
ALL, as t(4;11)-positive infant ALL patients lacking HOXA9 expression seem to be 
burdened by a more aggressive leukemia with a high risk of early relapse. Thus, in 
contrast to recent suggestions that suppression of HOXA9 may represent an 
attractive therapeutic approach in AML, targeting HOXA9 in t(4;11)- positive 
infant ALL appears not to be an option. Finally, these data clearly indicate that 
variations in gene expression patterns among MLL-rearranged infant ALL cases are 
not limited to the type of MLL translocation alone but continue to extend beyond 
translocation-specific subgroups, at least in case of translocation t(4;11). 
Taken together, the present study demonstrates that the distinct gene expression 
profiles associated with MLL-rearranged infant ALL are more heterogeneous and 
complicated than ostensibly shown earlier and, to a certain extent, are dependent 
on the MLL translocation partner genes. In addition, based on our gene expression 
profiles, infant ALL patients lacking MLL translocations differ both from MLL-
rearranged infant ALL and non-infant pediatric precursor BCP-ALL patients. The 
expression signatures reported here potentially constitute new and additional 
insights in the genetic makeup of both MLL-rearranged and MLL germline infant 
ALL. The work at hand now is to unravel the biologic meaning of these signatures 
and implement these novel pieces of the puzzle into currently ongoing studies on 
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the complex biology of this malignancy. Eventually, these profiles should reveal 
novel therapeutic targets, uncover yet unidentified regulators of leukemogenesis 
and leukemia maintenance, and perhaps may become useful in future gene 
expression-based classification of pediatric ALL. 
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ABSTRACT 
 
Approximately 20% of all infant ALL cases carry wild-type (or germline) MLL genes. 
Wild-type MLL infant ALL patients are generally regarded as young pediatric 
precursor BCP-ALL patients, but extensive characterization of this specific patient 
group largely remains unacknowledged. We studied a relatively large cohort of 78 
wild-type MLL infant ALL samples, using clinical parameters, array-comparative 
genomic hybridization analysis, gene expression profiling, multiplex ligation-
dependent probe amplification, and conventional sequencing. Wild-type MLL 
infant ALL patients are generally characterized by a lower incidence of favourable 
prognostic factors than pediatric (non-infant) BCP-ALL patients, and patients at 
high risk of therapy failure typically display an immature pro-B immunophenotype 
or respond poorly to prednisone. Using gene expression profiling, we found MEIS1 
expression to additionally be highly predictive for clinical outcome in wild-type 
MLL infant ALL with a favourable prognosis in the wild-type MLL infants with low 
MEIS1 expression (DFS 88%% versus 50%, p=0.01). Wild-type MLL infant ALL 
represents a highly heterogeneous patient group, which cannot be unified by one 
or a few known recurrent genomic aberrations. High-level MEIS1 expression and 
an immature pro-B immunophenotype in high-risk wild-type MLL infant ALL 
patients shows parallel with the unfavourable prognosis of MLL-rearranged infant 
ALL patients.  
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INTRODUCTION 
 
Acute lymphoblastic leukemia (ALL) in infants (<1 year of age) is a rare but highly 
aggressive type of leukemia, typically characterised by the presence of MLL-
rearrangements, occurring in ~80% of these patients.1 The prognosis for MLL-
rearranged infant ALL patients is highly unfavourable.2 In contrast, infant ALL 
patients carrying wild-type (or germline) MLL genes fare significantly better, with 
reported event free survival (EFS) chances of 74%-95%.1, 2 
For infant ALL in general, the strongest predictors of a poor outcome are the 
presence of MLL rearrangements and age <6 months, followed by high white 
blood cell (WBC) counts (>300x109/L) and poor in vivo prednisone responses.1, 3 
Infant ALL patients not carrying leukemia-specific rearrangements of the MLL 
gene are thought to resemble B-cell precursor ALL in older children (>1 year of 
age). However, we recently showed that wild-type MLL infant ALL specifies a gene 
expression pattern that is different from both MLL-rearranged infant ALL as well 
as from pediatric non-infant precursor BCP-ALL.4 In an unsupervised clustering 
analysis, wild-type MLL infant ALL samples even appeared more closely related to 
MLL-rearranged infant ALL than to pediatric precursor BCP-ALL cases. Thus, 
regardless of the MLL status, young age (<1 year) apparently specifies gene 
expression similarities that are likely to be important to the biology of these 
leukemias.  
Pediatric (non-infant) precursor BCP-ALL can generally be subdivided based on 
gross chromosomal aberrations, including the chromosomal translocations 
t(12;21) (ETV6-RUNX1), t(9;22) (BCR-ABL1), t(1;19) (E2A-PBX1), translocations of 
the MLL gene, or hyperdiploidy (>50 chromosomes). All of these subtypes display 
distinct clinical outcomes and gene expression profiles.3, 5, 6 De Lorenzo et al 7 
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recently published cytogenetic data of wild-type MLL infant ALL patients from the 
Interfant-99 trial and Children’s Oncology Group (COG-P9407), and demonstrated 
that infants without MLL translocations share the same cytogenetic abnormalities 
as older children with ALL, albeit with a different distribution: a lower incidence of 
the favourable abnormalities ETV6-RUNX1 and high hyperdiploidy, and a higher 
incidence of unfavourable abnormalities, including BCR-ABL1.  
Other recent advances in pediatric BCP-ALL revealed several additional and often 
prognostically relevant DNA copy-number alterations and mutations, including 
IKZF1 and PAX5 deletions,8 deletions in the 9p21.1 locus including the cell cycle 
regulators CDKN2A and CDKN2B,9 ETV6 alterations,10 JAK2R683 mutations,8, 11 
PAR1 deletions, and CRLF2 rearrangements.12 By contrast, MLL rearranged infant 
ALL carry few somatic changes (copy number abnormalities, loss of 
heterozygosity, or single nucleotide variants)13, 14, indicating that only a very small 
number of mutations are necessary to generate infant MLL-leukemia. Yet, no 
specific data exists on the distribution of such copy-number variations, or 
mutations in infant ALL patients carrying wild-type MLL genes. 
In the present study we extensively characterize a relatively large cohort of wild-
type MLL infant ALL patients, all treated according to INTERFANT treatment 
protocols (i.e. Interfant-99 or Interfant-06). The results are compared to similar 
data obtained in MLL-rearranged infant ALL patients (enrolled in INTERFANT 
studies) and pediatric (non-infant) precursor BCP-ALL patients uniformly treated 
according to the Dutch Childhood Oncology Group (DCOG) ALL-10 protocol. 
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MATERIALS AND METHODS 
 
Note: A more elaborate and detailed description of all experimental procedures 
and data analysis methods can be found in the Supplemental Material Chapter 5. 
 
Patient samples and sample preparation 
Bone marrow and peripheral blood samples from infants (<1 year of age) with 
newly diagnosed ALL were collected at institutes participating in the international 
collaborative Interfant-994 and Interfant-06 studies. Pediatric (non-infant) patient 
data was obtained from the Dutch Childhood Oncology Group (DCOG) treated 
according to the ALL-10 protocol. Leukemic samples preparation was essentially 
carried out as described before.4 
 
Gene expression profiling data 
The gene expression profiling (Affymetrix platform) data used in the present study 
has previously been published, 4 and has been deposited in the National Center 
for Biotechnology Information Gene Expression Omnibus15 and is accessible via 
GEO Series accession number GSE19475. Additional unpublished gene expression 
data can be found under GEO accession number GSE58565.  
 
In vivo and in vitro prednisone response  
In vivo prednisone responses were determined after seven days of prednisone 
monotherapy (including a single intrathecal dose of methotrexate), prior to the 
initiation of combination chemotherapy. Patients were defined as good 
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responders when <1000 leukemic blasts/μL were detectable in the peripheral 
blood. Patients still burdened with ≥1000 leukemic blasts/μL after prednisone 
monotherapy were defined as poor responders. In vitro response to prednisolone 
(the active metabolite of prednisone) was determined by 4-day MTT assay as 
previously described.16 
 
Oligo array-CGH 
Oligo array-CGH (array competitive genomic hybridization) analysis was 
performed using the human genome CGH Microarray 105k-A (Agilent 
Technologies, Palo Alto, CA) according to the manufacturer’s protocol using a dye-
swap experimental design to minimize false positive results, as previously 
described.17 
 
Multiplex ligation-dependent probe amplification (MLPA) analysis and JAK2 
mutations 
MLPA was performed using the SALSA MLPA P335 ALL-IKZF1 probemix kit (MRC-
Holland, Amsterdam, The Netherlands) according to the manufacturer’s protocol. 
Mutations in JAK2 exon 16 were analyzed by polymerase chain reaction 
amplification and subsequent sequencing as described previously.11 
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RESULTS 
 
Wild-type MLL infant ALL patients are characterized by favorable clinical 
parameters 
Clinical parameters known to predict outcome in MLL-rearranged infant ALL were 
compared between infant ALL patients carrying wild-type MLL genes (n=78) and 
MLL-rearranged infant ALL cases (n=70), as well as between wild-type MLL infant 
ALL patients and pediatric (non-infant) ALL patients (n=484). The adverse 
prognostic factors analyzed included age <6 months, white blood cell (WBC) 
counts >300 x 109 leukemic cells/L, a pro-B (CD10-) immunophenotype, and a 
poor in vivo prednisone window response (Table 1). Compared with MLL-
rearranged infant ALL cases, infant ALL patients carrying wild-type MLL genes 
were significantly more often diagnosed at age >6 months, presented with more 
favourable WBC counts, more mature (pre-B or common) immunophenotypes, 
and generally responded well to a 7-day window of prednisone monotherapy 
(Table 1). However, despite the fact that wild-type MLL infant ALL patients were 
characterized by favourable prognostic factors, these factors were less frequently 
present compared to pediatric (non-infant) ALL patients. For instance, only 2% of 
the pediatric ALL patients presented with a highly immature pro-B 
immunophenotype, compared to 11% of the wild-type MLL infant ALL patients 
(p<0.0001).  
 
 
 
 
  
                                                                      Wild-type infant ALL         107 
 
 Wild-type MLL 
infant ALL  
(n=78) 
MLL-
rearranged 
infant ALL 
(n=70) 
p Pediatric  
(non-infant) 
ALL 
(n=484) 
P 
Sex   0.62  0.09 
Male 36 (46%) 29 (41%)  274 (57%)  
Female 42 (54%) 41 (59%)  210 (43%)  
      
Age at diagnosis   <0.001  NA 
< 6 months 18 (23%) 41 (59%)  NA  
> 6 months 60 (77%) 29 (41%)  NA  
      
WBC (cells/L)   <0.001  <0.001 
< 100 x 109 52 (69%) 16 (24%)  389 (89%)  
100-300 x 109 19 (25%) 24 (36%)  38 (9%)  
> 300 x 109 6 (8%) 27 (40%)  11 (3%)  
not known 1 3  46  
      
Immunophenotype   <0.001  <0.001 
pro-B cell 8 (11%) 52 (78%)  9 (2%)  
common B-cell 25 (33%) 3 (4%)  257 (54%)  
pre-B cell 29 (39%) 10 (15%)  132 (28%)  
T-lineage 9 (12%) 0  80 (17%)  
Other* 4 (5%) 2 (3%)  1 (0%)  
not known 3 3  5  
      
Prednisone 
response 
  0.009  0.21 
good response 62 (85%) 39 (65%)  385 (90%)  
poor response 11 (15%) 21 (35%)  41 (10%)  
not known 5 9  58  
      
 
Table 1. Clinical characteristics and prognostic factors of wild-type MLL infant ALL 
patients. *Other immunophenotypes included both acute undifferentiated and 
biphenotypic leukemias. WBC= white blood cell, and NA= not applicable.  
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Poor prednisone responses and a pro-B phenotype predict outcome in wild-type 
MLL infant ALL 
Next we assessed the prognostic relevance of the above described predictive 
parameters in terms of disease-free survival (DFS), overall survival (OS), and 
cumulative incidence of relapse (CIR) after 5 years from diagnosis in wild-type MLL 
infant ALL patients (n=76) for whom clinical follow-up data was available (Table 2). 
For the entire group of patients, outcome measures were: 0.71 DFS (SE=0.05), 
0.82 OS (SE=0.05), and 0.22 CIR (SE=0.05). Neither age <6 months at diagnosis, nor 
WBC counts >300 x 109 leukemic cells/L were predictive for clinical outcome 
within this group. In contrast, a poor prednisone response was marginally 
associated with an inferior outcome, whereas an immature pro-B 
immunophenotype was highly predictive for a poor clinical outcome. The 5-year 
OS in the wild-type MLL infant ALL patients diagnosed with pro-B ALL was 0.14, 
whereas this was 0.92 and 0.93 in wild-type MLL infants diagnosed with common 
BCP-ALL and pre-B ALL respectively (p<0.001) (Table 2). 
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 n 
5-year 
DFS 
SE P 
5-year 
OS 
SE P 
5-year 
CIR 
SE P 
Age at diagnosis    0.75   0.49   0.32 
< 6 months 17 76.5 10.3  76.5 10.3  11.8 8.1  
> 6 months 58 70.0 6.1  84.0 4.9  24.8 5.8  
           
WBC count (cells/L)    0.83   0.30   0.74 
< 100x109 49 72.6 6.5  87.2 4.9  25.4 6.4  
 100-300x109 19 68.4 10.7  73.7 10.1  15.8 8.6  
> 300x109 6 66.7 19.3  66.7 19.3  16.7 16.7  
           
Prednisone 
response 
   0.22   0.23   0.33 
good response 61 75.1 5.6  85.1 4.6  18.3 5.1  
poor response 10 56.3 16.5  67.5 15.5  32.5 16.7  
           
Immunophenotype    0.003   <0.001   0.03 
pro-B cell 7 14.3 18.7 <0.001* 14.3 18.7 <0.001* 57.1 22.7 0.02* 
common B cell 25 66.3 9.8  92.0 5.4  33.7 10.1  
pre-B cell 28 85.3 6.8  92.7 5.0  7.3 5.1  
T-lineage 9 66.7 15.7  64.8 16.5  22.2 14.8  
Other 4 - -  - -  - -  
           
 
Table 2. Univariate analysis of prognostic factors in wild-type MLL infant ALL patients. 
DFS: Disease event-free survival; OS: overall survival; CIR: cumulative incidence of relapse. 
*p-value for comparison of pro-B immunophenotype versus all other phenotypes. 
 
 
MEIS1 expression is a strong prognostic factor in wild-type MLL infant ALL patients 
In search for additional prognostic factors for wild-type MLL infant ALL, we 
applied Significance Analysis of Microarrays (SAM) to screen our gene expression 
profiles (Affymetrix HU133plus2.0 GeneChips) for genes predictive for clinical 
outcome. For 30 wild-type MLL infant ALL patients both gene expression profiles 
and clinical follow-up data was available. Interestingly, the level of MEIS1 
expression (Affymetrix probe set 242172_at) appeared highly predictive for 
clinical outcome. Patients expressing low levels (i.e. below the median of the 
5 
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entire patient group) of MEIS1 (n=16) had a superior outcome in terms of DFS 
(Figure 1A) and OS (Figure 1B), over patients expressing high levels (i.e. above the 
median of the entire patient group, n=14) of MEIS1 (DFS 88% versus 50% 
respectively, p=0.01). Remarkably, differential gene expression analysis between 
patients with high MEIS1-expression (n=18) and patients with low MEIS1-
expression (n=18), could not identify differentially expressed genes other than 
MEIS1 itself. Unfortunately, due to the small number of events (n=8), multivariate 
analysis of MEIS1 in combination with other known prognostic factors could not 
be performed. Distribution analysis of prognostic factors only showed a significant 
difference in distribution of immunophenotype with a more immature phenotype 
in the wild-type infant ALL patients with high-level expression (p=0.002) 
(Supplemental material Chapter 5 Table 2). Strikingly, high-level MEIS1 expression 
had no prognostic value in pediatric (non-infant) ALL patients. 
 
Figure 1. Survival in wild-type MLL infant ALL patients expressing low versus high levels 
of MEIS1. A. Disease-free survival (DFS) and B. overall survival (OS) for wild-type MLL 
infant ALL patients expressing low levels of MEIS1 (below the median of the entire patient 
group, n=16; continuous line) and high levels of MEIS1 (n=14; dotted lines). 
5 
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Submicroscopic DNA copy-number variations (array-CGH analysis) 
In order to detect submicroscopic deletions and amplifications in the DNA, we 
performed array-comparative genomics hybridization (array-CGH) on a cohort of 
wild-type MLL infant ALL patients (n=31) for whom genomic DNA was available 
(Supplemental material Chapter 5 Table 1). The results were compared with array-
CGH data from pediatric (non-infant) BCP-ALL patients (n=113) (Table 3). 
Remarkably, copy-number variations were detected in 68% of wild-type MLL 
infant ALL patients which is significantly lower than in pediatric (non-infant) 
precursor BCP-ALL patients (95%) (p<0.001).  
Furthermore we distinguished between numerical variations (i.e. loss or gain of 
whole chromosomes) and structural variations (i.e. partial 
deletions/amplifications, and translocations). The frequency of structural 
aberrations was much lower in wild-type MLL infants than in non-infant ALL 
patients (45% vs. 86%, respectively; p<0.001) (Table 3). The frequency of patients 
with numerical aberrations was higher among wild-type MLL infant ALL patients 
(23%) than in non-infant pediatric ALL patients (12%). This difference disappeared 
when correcting for the incidence of hyperdiploidy. 
Several of the structural aberrations found among the wild-type MLL infant ALL 
patients included known oncogenes and/or tumor suppressors. In 6/28 (21%) of 
the wild-type MLL infants deletions of 9p21.3, containing the tumor suppressor 
genes CDKN2A and CDKN2B, were observed. Two of these patients carried 
homozygous deletions, while these deletions in the remaining four patients were 
heterozygous.  
One wild-type MLL infant ALL patient with a numerically normal karyotype (so 
excluding hyperdiploid patients) carried an amplification of 17p13.1 containing 
GAS7, a gene known to be a translocation partner of MLL. Occasionally single and 
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unique wild-type MLL infant ALL patients were found to carry a deletion of 
1p36.11 including the tumor suppressor gene RUNX3, of 7p22.3 to 7p15.3 
including the EVI1 gene at 7p21.2, or of 3q25.2 to 3q26.33 starting at the MME 
gene encoding human CD10 (Supplemental material Chapter 5 Table 1).  
Finally, our cohort of wild-type MLL infant ALL patients included three patients 
diagnosed with T-ALL. One of these wild-type MLL infant T-ALL patients showed 
deletions of genes SIL and PTEN. Subsequent fluorescent in-situ hybridization 
(FISH) analysis demonstrated that this patient carried a SIL-TAL1 fusion. Another 
wild-type MLL infant T-ALL patient had a deletion of 11q14.1 to 11q22.1, including 
the PICALM (CALM) gene.  
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 wild-type MLL infant ALL pediatric non-infant BCP-ALL 
 
all 
(n=31) 
without HD 
(n=27) 
all 
(n=113) 
without HD 
(n=102) 
B-others 
(n=39) 
Type of aberration* 
No aberrations 10 (32%) 10 (37%) 6 (5%) 6 (6%) 2 (5%) 
Numerical aberrations 7 (23%) 3 (11%) 13 (12%) 8 (8%) 4 (10%) 
Structural aberrations 14 (45%) 14 (52%) 97 (86%) 96 (94%) 36 (92%) 
Structural aberrations by oncogene/tumor suppressor gene and immunophenotype 
 BCP-ALL patients (n=28)†    
CDKN2A (9p21.3)      
homozygous deletion 2 (7%) 2 (8%) 12 (11%) 11 (11%) 8 (21%) 
heterozygous deletion 4 (14%) 4 (16%) 21 (19%) 18 (18%) 9 (23%) 
RUNX3 (1p36.11)      
Deletion 1 (4%) 1 (4%) 6 (5%) 3 (3%) 3 (8%) 
GAS7  (17p13.1)      
Amplification 4 (13%) 1 (4%) 20 (18%) 11 (11%) 7 (18%) 
Deletion 1 (4%) 1 (4%) - - - 
MME  (3q25.2)      
Deletion 1 (4%) 1 (4%) 2 (2%) 1 (1%) 0 
ETV1 (7p21.2)      
Deletion 1 (4%) 1 (4%) 5 (4%) 3 (3%) 1 (3%) 
      
 T-ALL patients (n=3)  -  
STIL and PTEN‡      
Deletion 1 (33%) NA NA NA NA 
PICALM (11q14.2)      
Deletion 1 (33%) NA NA NA NA 
 
Table 3. Distribution of DNA copy-number variations in wild-type MLL infant ALL and 
pediatric non-infant precursor BCP-ALL patients. *As numerical and structural aberrations 
can occur combined in one patient, numbers mentioned don’t necessarily add up to 100%. 
†BCP-ALL patients including patients with unknown immunophenotype. ‡Fluorescent in-
situ hybridization (FISH) confirmed a SIL-TAL1 fusion caused by sub-deletion. HD = 
hyperdiploid karyotype. 
5 
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Screening of B-cell development genes in wild-type MLL infant ALL 
In pediatric (non-infant) precursor BCP-ALL, a number of genes involved in B-cell 
development are frequently altered, and several of these alterations (e.g. 
mutations, deletions and amplifications) are associated with high-risk ALL 
subtypes and implicated in clinical outcome.3, 18, 19 We performed multiplex 
ligation-dependent amplification (MLPA) analysis using specific probes for single 
gene alterations in CDKN2A, CDKN2B, IKZF1 PAX5, ETV6, BTG1, CRLF2, and the 
Xp22.33 locus (Table 4). In none of the wild-type MLL infant ALL samples (n=32) 
tested, alterations of IKZF1 were detected, whereas 17% of the pediatric non-
infant BCP-ALL patients is known to carry a IKZF1 deletion.20 A deletion of CDKN2A 
and CDKN2B on 9p21.3 was found in six (19%) of the infants. For five of these 
infants array-CGH analysis was performed which showed the same results. In 
contrast, in 30% and 34% of the pediatric non-infant ALL samples deletions of 
CDKN2A and CDKN2B were found, respectively. In four wild-type MLL infant ALL 
patients deletions of PAX5 were present together with  CDKN2A and CDKN2B, 
whereas in two infants the PAX5 deletion was the only observed abnormality as 
determined by MLPA. Interestingly, the frequency of PAX5 deletions was 
significantly higher in wild-type MLL infant ALL patients (19%) than in the pediatric 
precursor BCP-ALL (6%) (p=0.02). The incidence of ETV6 deletions was markedly 
lower in infants: 3% versus 11% of the pediatric precursor BCP-ALL patients. 
Likewise, amplifications of CRLF2, as well as the Xp22.3 locus containing 
pseudoautosomal region 1 (PAR1), appeared to be rare events among wild-type 
MLL infant ALL patients (both occurring in 3% of the patients tested), whereas 
these lesions occur in 25% and 21% pediatric (non-infant) precursor BCP-ALL 
patients. 
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 wild-type MLL 
infant ALL 
n=32 
pediatric non-
infant ALL 
n=232 
Deletions   
CDKN2A  6 (19%) 69 (30%) 
CDKN2B 6 (19%) 78 (34%) 
PAX5 6 (19%) 13 (6%)* 
ETV6 1 (3%) 25 (11%) 
BTG1 1 (3%) 0 
Amplifications   
CRLF2 1 (3%) 59 (25%)† 
Xp22.33 1 (3%) 48 (21%)* 
 
Table 4. Multiplex ligation-dependent probe amplification (MLPA) analysis of genes 
associated with B-cell differentiation. Significant differences between wild-type MLL 
infant ALL and pediatric non-infant precursor BCP-ALL patients are indicated by * (p<0.05) 
and † (p<0.01) (Fisher exact test). 
 
 
Finally, as JAK2R683 mutations have been associated with high-risk pediatric BCP-
ALL8, 11, we screened for JAK2R683 mutations in exon 16 by means of conventional 
PCR and subsequent sequencing analysis. No mutations in JAK2R683 were 
detected in a total of 28 wild-type MLL infant ALL patient samples, whereas 6% of 
the BCR-ABL1-negative, high-risk pediatric ALL cases have been  described to carry 
this specific  mutation.8 
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DISCUSSION 
 
In the present study we genetically characterized a large cohort of rare wild-type 
MLL infant ALL samples. The incidence of favorable clinical factors in wild-type 
MLL infant ALL turned out to be higher than in MLL-rearranged infant ALL, but 
lower than in pediatric precursor BCP-ALL. For instance, the incidence of a high 
WBC and the unfavorable pro-B (CD10-) immunophenotype are higher in MLL-
rearranged infant ALL compared to that in wild-type MLL infant and pediatric ALL 
patients. A favorable in vivo response to prednisone was more often observed in 
wild-type MLL infant ALL patients when compared with MLL-rearranged infant ALL 
patients. In addition, we recently showed that wild-type MLL infant ALL patients 
have a low incidence of genetic abnormalities associated with a favorable 
prognosis (i.e., hyperdiploidy and ETV6-RUNX1 (or TEL-AML1) translocations),7 
whereas these abnormalities occur in about half of the non-infant pediatric 
precursor BCP-ALL patients.21 These findings may contribute to the slightly worse 
outcome of wild-type MLL infant ALL patients compared with pediatric (non-
infant) precursor BCP-ALL patients.  
Gene expression analysis of wild-type MLL infant ALL revealed that the level of 
MEIS1 expression was highly predictive for clinical outcome. In fact, none of the 
cases expressing relatively low levels of MEIS1 experienced a 5-year disease-free 
survival of 88% and the 5-year overall survival rate for these patients appeared to 
be 100%. In contrast, for wild-type MLL infant ALL patients displaying relatively 
high levels of MEIS1 expression the disease-free and overall survival rates were 
50% and 71% respectively. This observation is in line with results of a study 
reported by the Children’s Oncology Group (COG), showing that MEIS1 expression 
was an independent predictor of clinical outcome in infant ALL including both 
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MLL-rearranged and wild-type MLL cases.22 Interestingly, high-level expression of 
MEIS1 is tightly associated with prognostically unfavorable MLL-rearranged 
leukemias5, 23 and has been demonstrated to be important in oncogenicity.24, 25 
Hence, the prognostic relevance of MEIS1 expression in wild-type MLL infant ALL 
patients may imply transformation events that to some extent resemble that of 
MLL-rearranged infant ALL cases. Furthermore, the strong influence on clinical 
outcome of MEIS1 expression suggests that infant ALL expressing high levels of 
MEIS1 represent a highly aggressive leukemia that require very few cooperative 
genetic lesion during leukemogenesis and/or leukemia maintenance. Taken 
together these data suggest that both MLL-rearranged infant ALL as well as wild-
type MLL infant ALL patients may benefit from MEIS1 inhibition. The level of 
MEIS1 expression had no prognostic significance in pediatric (non-infant) BCP-ALL. 
To further characterize wild-type MLL infant ALL, we searched for submicroscopic 
copy-number variations. Although our unsupervised gene expression profiling-
based clustering analysis recently indicated that these patients form a distinct 
entity distinguishable from both MLL-rearranged infant ALL and non-infant 
pediatric precursor BCP-ALL,4 we could not identify any unifying factors 
characterizing this group of patients. Nonetheless, wild-type MLL infant ALL 
displayed a distinctive pattern of DNA copy-number variations and genetic 
abnormalities in genes associated with B-cell development. Compared with 
pediatric (non-infant) precursor BCP-ALL patients, wild-type MLL infant ALL 
patients less frequently harbor DNA copy-number variations. In approximately 
one third of the wild-type MLL infant ALL patients no copy-number alterations 
were detected in array-CGH. Similarly, the frequencies of deletions or 
amplifications specifically in B-cell development genes was much lower in wild-
type MLL infant ALL compared with pediatric BCP-ALL patients, although higher 
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than in rearranged MLL infant ALL.13, 14 Hypothetically, a longer latency time to 
diagnosis combined with an insufficient cellular repair mechanism in pediatric 
BCP-ALL might explain the higher frequency of structural aberrations in this group. 
One exception is PAX5 gene deletions, which appeared in 19% of the infant ALL 
patients compared to 6% of pediatric BCP-ALL patients. We could not find an 
association between deletions of genes located on chromosome 9p and MEIS1-
expression (Supplemental material Chapter 5 Table 2).  
In conclusion, infant ALL patients carrying wild-type MLL genes form a distinct 
group from pediatric (non-infant) BCP-ALL patients, but is a very heterozygous 
patient group for which very few recurrent genetic abnormalities can be 
identified. The frequency of DNA copy number variations and molecular genetic 
lesions in genes involved in B-cell development are lower in wild-type MLL infant 
ALL compared to older children with ALL. Several poor clinical risk features are 
more frequent in wild-type MLL infant ALL. The strongest predictor of outcome in 
wild-type MLL infant ALL was the level of MEIS1 expression, which may point to 
new opportunities for novel strategies in treating wild-type MLL infant ALL.  
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ABSTRACT 
 
Introduction: MLL-rearranged acute lymphoblastic leukemia (ALL) in infants (<1 
year) is characterized by high relapse rates and a dismal prognosis. To facilitate 
the discovery of novel therapeutic targets, we here searched for genes directly 
influenced by the repression of various MLL fusions.  
Methods: For this, we performed gene expression profiling after siRNA-mediated 
repression of MLL-AF4, MLL-ENL, and AF4-MLL in MLL-rearranged ALL cell line 
models. The obtained results were compared with various already established 
gene signatures including those consisting of known MLL-AF4 target genes, or 
those associated with primary MLL-rearranged infant ALL samples.    
Results: Genes that were down-regulated in response to the repression of MLL-
AF4 and MLL-ENL appeared characteristically expressed in primary MLL-
rearranged infant ALL samples, and often represented known MLL-AF4 targets 
genes. Genes that were up-regulated in response to the repression of MLL-AF4 
and MLL-ENL often represented genes typically silenced by promoter 
hypermethylation in MLL-rearranged infant ALL. Genes that were affected in 
response to the repression of AF4-MLL showed significant enrichment in gene 
expression profiles associated with AF4-MLL expressing t(4;11)+ infant ALL patient 
samples. Conclusion: We conclude that the here identified genes readily 
responsive to the loss of MLL fusion expression potentially represent attractive 
therapeutic targets and may provide additional insights in MLL-rearranged acute 
leukemias.
6 
128             
INTRODUCTION 
 
A hallmark of acute lymphoblastic leukemia (ALL) in infants (<1 year of age) is a 
high incidence (~80%) of chromosomal translocations involving the Mixed Lineage 
Leukemia (MLL) gene 1, 2, in which the N-terminal portion of MLL fuses to the C-
terminal region of one of its many translocation partner genes. 3 The most 
common MLL translocations found among infant ALL patients are t(4;11), t(11;19), 
and t(9;11), fusing MLL to AF4, ENL and AF9, respectively. 2, 4 MLL-rearranged 
infant ALL is associated with an adverse outcome, with event-free survival rates of 
only ~30-40%. 2  
MLL-rearranged ALL cells display unique gene expression profiles, consisting of 
overwhelming numbers of differentially transcribed genes 5, 6, which make it 
difficult to distinguish between the actual “drivers” of the leukemia from the so 
called “bystanders”. Fortunately, recent advances allowed the identification of 
genes likely to be activated by MLL fusion proteins via the recruitment of DOT1L. 
7-9 Yet, apart from MLL fusion driven activation of gene transcription, inactivation 
of transcription also plays an important role in MLL-rearranged ALL. We and 
others, recently demonstrated that MLL-rearranged infant ALL is characterized by 
unique patterns of gene promoter DNA hypermethylation, leading to 
transcriptional silencing of associated genes. 10, 11 To make matters even more 
complicated, more than half of the t(4;11)-positive ALL patients not only carry the 
MLL-AF4 fusion transcript, but also express and translate the reciprocal AF4-MLL 
transcript, which has been proposed to  substantially contribute, or even being 
essential, for leukemia development.12, 13 
Here, we studied the direct transcriptional consequences of the loss of MLL fusion 
transcripts in order to identify potential target genes for therapeutic intervention. 
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For this, we performed gene expression profiling in MLL-rearranged ALL cell line 
models in which MLL-AF4, AF4-MLL or MLL-ENL expression was repressed by 
siRNA-mediated RNA interference. We postulate that genes directly responding to 
the loss of the MLL fusion represent important therapeutic targets and may 
provide additional insights into the actions of MLL fusion proteins. 
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METHODS 
 
Note: More detailed descriptions of all experimental procedures and data analysis 
methods can be found in the Supplemental Material Chapter 6. 
 
Cell line models 
The BCP-ALL cell lines RS4;11 and SEMK2 both carry translocation t(4;11) 
generating the MLL-AF4 and AF4-MLL fusion transcripts. KOPN-8 carries a t(11;19) 
translocation generating MLL-ENL transcripts. RS4;11 was established from the 
bone marrow of a 32-year-old woman 14, and was purchased from the German 
Collection of Microorganisms and Cell Cultures (DSMZ). SEMK2 is a subclone of 
the SEM cell line, which was originally derived from a 5-year-old girl at relapse 15 
and was kindly provided by Dr Scott Armstrong (Memorial Sloan Kettering Cancer 
Center, New York, USA). KOPN-8 was derived from a 3-month-old infant girl with 
B-cell precursor ALL and was purchased from DSMZ.16 
 
siRNA-mediated RNA interference 
Cells were transfected with siRNAs directed against MLL-AF4 17, AF4-MLL 13, or 
MLL-ENL (sense 5’-CCAAAAGAAAAGUCUGCCCAG-3; antisense 5’-
CUGGGCAGACUUUUCUUUUGGUU-3’), using electroporation. Control cells were 
transfected with siRNAs against AML1-MTG8 (AGF1) 18, a fusion transcript absent 
in both SEMK2 and RS4;11 cells. For the knock-down of MLL-AF4 and MLL-ENL, 
cells were harvested after two days. For the AF4-MLL knock-down, cells were 
transfected with siRNAs a second time after two days of culturing, and eventually 
harvested at day 4. All experiments were performed at least three times. 
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RNA extraction 
Total RNA was extracted from a minimum of 2x106 cells using TRIzol reagent 
(Invitrogen, Life Technologies, Breda, The Netherlands) according to 
manufacturer’s guidelines.  
 
Gene expression profiling 
Gene expression profiling was performed using HU133plus2.0 microarrays 
(Affymetrix) according to manufacturer’s guidelines. Gene expression profiles for 
the primary infant ALL patients samples were generated and published previously 
19. 
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RESULTS 
 
Transcriptional consequences of MLL fusion knock-down 
Compared to cells transfected with control siRNAs, MLL-AF4 mRNA expression 
was reduced to 45% and 37% in the t(4;11)-positive ALL cell lines RS4;11 and 
SEMK2, respectively, upon transfection with siRNAs directed against MLL-AF4. 
Using siRNAs directed against MLL-ENL, the level of MLL-ENL expression in KOPN-
8 cells was reduced to 5% (Figure 1A). Western blot analysis demonstrated a 
reduction of the MLL-AF4 protein expression (relative to control cells) of 28% and 
52% in RS4;11 and SEMK2 cells, respectively (Figure 1B).  
 
 
 
 
 
Figure 1. siRNA-mediated knock-down significantly decreases MLL fusion expression 
levels. A. mRNA expression levels of MLL-ENL (grey), wild-type MLL (white), and wild-type 
ENL  (black) in KOPN-8 cells, or MLL-AF4 (grey), wild-type MLL (white) and wild-type AF4 
(black) in RS4;11 and SEMK2 cells after transfection with active siRNA directed against the 
absent target AML1/MTG8 (siAGF1), empty pulse (no siRNAs), and siRNAs directed against 
MLL-ENL and MLL-AF4 respectively. Shown is the average mRNA expression of two 
experiments ± standard error of the mean. B. Protein expression levels of MLL-AF4 in 
RS4;11 and SEMK2 shown by western blot (left panel). The western blot was probed with 
antibodies against the N-terminus of MLL to detect MLL-AF4. Clathrin was used as a 
loading control. The graph (right panel) shows western blot quantification of MLL-AF4 
protein expression relative to clathrin with the empty pulse control set at 100%.  
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Figure 1. siRNA-mediated knock-down significantly decreases MLL fusion expression 
levels. 
 
 
Next, in order to identify genes directly responding to the loss of the MLL fusion, 
we generated gene expression profiles (HU133plus2.0 GeneChips, Affymetrix) in 
three independent experiments. Upon repression of MLL-ENL in KOPN-8 cells, 
significant differential expression was observed for 342 probe sets (p<0.001). 
Reduced expression of MLL-AF4 resulted in significantly (p<0.001) altered 
expression of 26 probe sets in RS4;11 cells, and 145 probe sets in SEMK2 cells. 
Figure 2 shows heatmaps displaying the most significantly altered probe sets for 
all three cell lines. 
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Figure 2. Differential gene expression in response to the repression of MLL-AF4 and MLL-
ENL. Heatmap visualization of gene expression profiles of the top 50 most differentially 
expressed genes in response to MLL-ENL knock-down in KOPN-8 cells, and MLL-AF4 knock-
down in RS4;11 and SEMK2 cells, as compared to control cells transfected with siAGF1 or 
electroporated in the absence of siRNAs. The presented data was derived from samples 
obtained from three independent experiments. Red depicts high expression, blue depicts 
low expression.  
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We searched for a core signature of genes consistently affected in all cell lines by 
performing a paired analysis of all samples in which the MLL fusion was 
suppressed (including SEMK2, RS4;11, and KOPN8), compared to all control 
samples, including cells transduced with control siRNAs directed against AML1-
MTG8 (AFG1), as well as control cells electroporated in the absence of siRNAs. 
Compared to cells transfected with control siRNAs, 101 probe sets appeared to be 
recurrently affected in all cell lines. Compared to cells only subjected to 
electroporation in the absence of siRNAs (i.e. pulse control), 86 probe sets were 
differentially expressed. Merging these analyses, we found 56 overlapping probe 
sets to be recurrently differentially expressed in all cell lines in which the MLL 
fusions were suppressed (Figure 3A). Hierarchical clustering analysis showed that 
these 56 probe sets effectively distinguished between cells in which the MLL 
fusion was knocked down and control samples, as separately shown for each cell 
line (Figure 3B). As these probe sets consistently responded to the loss of the MLL 
fusion, we postulate that this gene signature represents genes which are highly 
dependent on the presence of the MLL fusion, and as such may exert prominent 
functions in MLL fusion driven transformation. Probe set IDs, HGNC gene symbols, 
and log-fold changes of the obtained core signature consisting of the 56 probe 
sets are listed in the Supplemental material Chapter 6 (Table 1 and 2). HGNC gene 
symbols from these probe sets can also be found next to the heatmap in Figure 4.  
 
6 
136             
 
Figure 3. Differential gene expression in response to the repression of MLL-AF4 and MLL-
ENL. A. Venn diagram showing the number of differentially expressed genes (p<0.001) in 
KOPN-8, RS4;11, and SEMK2 cells transfected with siRNAs against MLL-ENL and MLL-AF4, 
combined (MLL fusion knock-down, n=9) versus control cells transfected with siAGF1 
(AGF1 control, n=9), versus control cells electroporated in the absence of siRNAs (pulse 
control n=9). All probe sets and gene symbols are listed in Table S1 and S2. B. Hierarchical 
clustering based on 56 differentially expressed probe sets recurrently affected in both 
KOPN-8, RS4;11, and SEMK2 cells upon MLL fusion knock-down (light grey), in control 
samples transfected with siAGF1 (dark grey), and control samples electroporated in the 
absence of siRNAs (black).  
 
 
Relevance of the MLL fusion knock-down signature 
To explore the relevance of the obtained gene signature consisting of 56 probe 
sets responsive to the knock-down of the MLL fusion, we compared our signature 
to that of earlier published gene sets associated with MLL-rearranged ALL. The 
first signature, published by Guenther et al 8, contains 42 genes occupied by the 
MLL-AF4 fusion protein. The second gene set published by Krivtsov et al 7 consists 
of genes associated with MLL fusion mediated H3K79 dimethylation. Gene set 
enrichment analysis (GSEA) showed significant enrichment of these genes in our 
MLL fusion knock-down gene signature (normalized enrichment scores (NES) of 
A B 
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1.92 and 2.11 respectively; leading edge in Table S3 and S4 respectively) (Figure 
3).  These data indicate that some, but not all, genes transcriptionally activated by 
the MLL fusion gene itself, rapidly respond to the loss of the MLL fusion. 
 
 
 
Figure 3. Genes responsive to the repression of MLL-ENL and MLL-AF4 often represent 
known MLL-AF4 target genes. Gene set enrichment analysis (GSEA) of the 56 differentially 
expressed probe sets recurrently affected in both KOPN-8, RS4;11, and SEMK2 cells upon 
MLL fusion knock-down in gene lists consisting of MLL-AF4 target genes as published by 
Guenther et al. (8) (left) and Krivtsov et al. (7) (right). NES=normalized enrichment score. 
 
 
Moreover, using our core signature consisting of 56 probe sets associated with 
knock-down of the MLL fusion, we performed hierarchical clustering on gene 
expression profiling data generated on a large cohort of primary MLL-rearranged 
infant ALL (n=71), wild-type MLL pediatric precursor BCP-ALL  (n=16), and wild-
type MLL infant ALL (n=20) samples, as well as healthy bone marrow samples 
(n=13) as non-leukemic controls. Based on these 56 probe sets, MLL-rearranged 
6 
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ALL samples could almost be flawlessly separated from ALL samples with wild-
type MLL genes (Figure 4). These data imply that our MLL fusion knock-down 
signature represents genes highly characteristic for MLL-rearranged ALL. Similarly, 
gene set enrichment analysis (GSEA) showed strong enrichment in the MLL-
rearranged patients of the 57 probe sets that are significantly lower expressed 
after MLL fusion knock-down (NES=1.95, p=0.002) (Figure 5, dataset in Table S5; 
leading edge in Table S6).  
 
Figure 4. Genes responsive to the repression of MLL-ENL and MLL-AF4 accurately 
characterize primary MLL-rearranged infant ALL samples. Heatmap visualization and 
hierarchical clustering of primary MLL-rearranged infant ALL samples (MLL-r, red, n=71), 
wild-type MLL pediatric ALL samples (both infants (n=20) and children >1 year of age 
(n=16)) (wt MLL, blue, n=36), and whole bone marrow samples derived from healthy 
children (healthy BM, dark blue, n=13) based on the  56 differentially expressed probe sets 
recurrently affected in both KOPN-8, RS4;11, and SEMK2 cells upon MLL fusion knock-
down. Up-regulated genes are depicted in red, down-regulated genes are depicted in blue.  
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Figure 5. Gene set enrichment analysis of genes responsive to the repression of MLL-ENL 
and MLL-AF4. Gene set enrichment analysis (GSEA) of the 57 probe sets that are 
significantly lower expressed upon knock-down of the MLL fusion in gene expression 
profiles of MLL-rearranged patients. Probe sets and HGNC Gene Symbols of the gene set 
are listed in Table S5.  
 
 
Pathway analysis using the database for annotation, visualization, and integrated 
discovery (DAVID) demonstrated a significant number of genes transcriptionally 
responsive to the loss of MLL fusion expression to be involved in the KEGG focal 
adhesion pathway (hsa04510, p<0.0001) and the KEGG small cell lung cancer 
pathway (hsa05222, p=0.008). Next, we used Ingenuity pathway analysis (IPA) to 
explore possible upstream regulators of the genes down-regulated upon the loss 
of MLL fusion expression. This revealed 30 potential regulators including 5 genes 
(i.e. HOXA7, LIN28B, UPF1, EZH2, and MBD1), and 25 miRNAs (see Table S7). 
Interestingly, the majority (i.e. 17 out of the 25) of the miRNAs that potentially 
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regulate the genes down-regulated upon MLL fusion knock-down, are predicted 
to target either MLL (i.e. KMT2A) or AF4 (i.e. AFF1), or both. Hence, the genes 
observed to be transcriptionally responsive to the loss of MLL fusions, likely 
represent genes controlled by the MLL fusion itself.  
 
Transcriptional consequences of AF4-MLL knock-down  
Using siRNAs directed against AF4-MLL previously reported by Kumar et al. 13, we 
managed to reduce expression of AF4-MLL mRNA to ~40% in RS4;11 and ~53% in 
SEMK2 cells, as compared with cells transfected with control siRNAs (Figure 6A). 
In these experiments, the expression of wild-type AF4 was not affected. However, 
despite numerous attempts, we were not able to prevent reduction of wild-type 
MLL expression to comparable levels of that of the AF4-MLL transcript (Figure 6A). 
Paired differential gene expression analysis between samples with a knock-down 
of AF4-MLL (n=6) and samples transfected with control siRNAs (n=6) revealed 80 
differentially expressed probe sets (p<0.001). The same analysis comparing AF4-
MLL knock-down samples with control cells electroporated in the absence of 
siRNAs (i.e. pulse control) (n=6), revealed 58 differentially expressed probe sets. A 
total of 36 overlapping probe sets (corresponding to 22 genes) were differentially 
expressed in both comparisons (Figure 6B). Probe set IDs, HGNC gene symbols, 
log-fold changes and p-values are listed in Table S8 and S9. Based on these 36 
probe sets, hierarchical clustering could effectively separate AF4-MLL knock-down 
samples from control samples (Figure 6C). To validate the AF4-MLL knock-down 
signature, we compared our signature to a gene set published by Gaussmann et al 
consisting of AF4-MLL fusion target genes, 20 GSEA showed a significant 
enrichment of these AF4-MLL target genes in our AF4-MLL gene signature 
(NES=1.68, p=0.002) (Figure 7). 
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Figure 6. Differential gene expression in response to the repression of AF4-MLL. A.  
mRNA expression levels of AF4-MLL (grey), wild-type MLL (white), and wild-type AF4 
(black) in RS4;11 and SEMK2 cells after transfection with siRNAs directed against AF4-MLL, 
siRNAs against the leukemic fusion gene AML1/MTG8 (siAGF1), or cells electroporated in 
the absence of siRNAs (pulse control). The average mRNA expression relative to the 
siAGF1 controls of two independent experiments ± standard error of the mean is shown. 
B. Venn diagram showing the number of differentially expressed genes (p<0.001)  in 
RS4;11 and SEMK2 cells in which AF4-MLL was repressed (AF4-MLL knock-down, n=6), 
versus cells transfected with control siRNA (siAGF1 control, n=6), and cells electroporated 
in the absence of siRNAs (pulse control, n=6). C. Hierarchical clustering based on 36 
overlapping differentially expressed probe sets responsive to AF4-MLL repression in 
RS4;11 and SEMK2 (light grey), control samples transfected with  siAGF1 (dark grey), and 
pulse control samples (black).  
6 
142             
 
Figure 7. Differential gene expression in response to the repression of AF4-MLL. Gene set 
enrichment analysis (GSEA) of AF4-MLL associated transcription factors (Gaussmann et al 
20) in AF4-MLL knock-down (‘na_neg’) versus control samples (‘na_pos’).  
 
 
Using our previously published gene expression profiling data, we compared 
t(4;11)-positive infant ALL samples which do and do not express the reciprocal 
AF4-MLL fusion product, as determined by PCR analysis. This comparison revealed 
403 probe sets differentially expressed between both patient groups (p=0.01). 
Figure 8A shows a heatmap of the top 50 most significant differentially expressed 
probe sets. Based on these 50 probe sets, principal component analysis (PCA) 
showed a clear separation of both patient groups. Furthermore, we observed that 
the gene expression patterns of patients expressing the AF4-MLL fusion transcript 
were enriched for genes that were down-regulated after knock-down of the AF4-
MLL in the cell line models RS4;11 and SEMK2 (GSEA; NES=1.67, p=0.02; leading 
edge in Table S12) (Figure 8B, upper panel). As a control we also analyzed 
enrichment of genes responsive to AF4-MLL knock-down in our MLL-AF4 knock-
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down signature, and found no significant enrichment (p=0.55) (Figure 8B, lower 
panel).  
 
 
 
Figure 8. Genes responsive to AF4-MLL repression characterize AF4-MLL expressing 
(4;11)+ infant ALL patients. A. Heatmap visualization and hierarchical clustering of primary 
t(4;11)+ infant ALL  samples exhibiting AF4-MLL expression (n=15, red), or lacking AF4-MLL 
expression (n=11, blue), based on the top 50 most differentially expressed genes between 
both patient groups. Up-regulated genes are depicted in red, down-regulated genes are 
depicted in blue. B. Gene set enrichment analysis (GSEA) of AF4-MLL (upper panel) and 
MLL-AF4 (lower panel) target genes in AF4-MLL positive patients (‘1’) versus AF4-MLL 
negative t(4;11) patients (‘0’). Probe sets and HGNC Gene Symbols are listed in Table S10 
and S11.  
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Genes up-regulated after MLL fusion knock-down are enriched for 
hypermethylated promoter regions  
Interestingly, while several known MLL-AF4 target genes were down-regulated 
after the loss of the MLL fusion, a substantial proportion of genes in our MLL 
fusion knock-down signature were up-regulated (Figure 2). Per definition these 
genes are not directly regulated by the MLL fusion protein via H3K79 mediated 
transcription activation. Therefore, we explored an alternative mechanism of 
transcriptional regulation. We recently demonstrated that MLL-rearranged infant 
ALL is characterized by severe aberrant DNA hypermethylation, leading to 
transcriptional silencing of numerous genes. 10 Using 165 probe sets associated 
with gene promoter methylation in the majority of MLL-rearranged infant ALL 
patients, we applied GSEA on our MLL fusion knock-down signatures. GSEA 
demonstrated significant enrichment of these genes among the genes up-
regulated after knock-down of MLL-AF4 and MLL-ENL (NES=1.36, p=0.03; leading 
edge in Table S13) (Figure 9). These data suggest that there is an active interplay 
between MLL fusion proteins and DNA methylation patterns in MLL-rearranged 
ALL cells.  
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Figure 9. Genes up-regulated in response to MLL-AF4 and MLL-ENL repression include 
genes normally silenced by promoter methylation in MLL-rearranged infant ALL. Gene 
set enrichment analysis (GSEA) of hypermethylated promoter regions in t(4;11) and 
t(11;19) patients (Stumpel et al 10) in MLL fusion positive (‘na_pos’) versus MLL fusion 
negative  (‘na_neg’) samples.  
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DISCUSSION 
 
The here identified genes which are transcriptionally responsive to the repression 
of MLL-AF4 and MLL-ENL represent a rich source of potential therapeutic targets 
for MLL-rearranged acute leukemia. Apart from gene signatures associated with 
the loss of MLL-AF4 and MLL-ENL, we also identified genes responsive to the 
repression of AF4-MLL. As it has been suggested that the AF4-MLL oncogene 
could be indispensable for the initiation of t(4;11)+ leukemias, our gene signatures 
associated with the presence and loss of AF4-MLL may well provide novel insights 
into the biology of this leukemia. Apart from genes down-regulated upon the loss 
of MLL fusions, we also identified a substantial number of genes which were up-
regulated in response to MLL fusion repression. Although MLL fusion proteins 
activate a variety of target genes (represented in the datasets of Guenther 7, 8 and 
Krivtsov 7, 8) by the recruitment of DOT1L and subsequent methylation of H3K79 7, 
8, these data suggest that the MLL fusion itself and/or its activated target genes 
also actively repress and activate other genes via alternative mechanisms. For 
instance, we found significant enrichment of the genes activated after knock-
down of the MLL fusions in our previously published gene signatures associated 
with promoter hypermethylation in t(4;11)+ and t(11;19)+ infant ALL samples. 10 
This underscores the importance of the role of DNA methylation in MLL-
rearranged infant ALL, as it appears, to some extent, to be influenced by the 
presence of the MLL fusion.  
Yet, the data presented here should be interpreted with caution as we were not 
able achieve complete repression of the MLL fusions, which may have affected 
the results. On the other hand, a full knock-down of the MLL fusion may not have 
provided better data per se, as that may have generated more non-specific effects 
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due to enhanced apoptosis induced by the loss of MLL-AF4. 13, 17 Other points of 
concern may be the slight down-regulation of wild-type AF4 in SEMK2 cells 
transfected with siRNAs against MLL-AF4, as well as the fact that siRNAs directed 
against AF4-MLL also affected wild-type MLL expression. A possible explanation 
for this phenomenon is that MLL and AF4 are downstream effectors of the fusion 
protein. However, we confirmed significant enrichment of differentially regulated 
genes upon repression of the different MLL fusions in recently published gene 
signatures consisting of MLL-AF4 target genes (7,8), and a gene signature 
associated with the loss of AF4-MLL. (17) Moreover, we also demonstrate that our 
identified genes accurately characterize MLL-rearranged ALL patient samples. 
Furthermore, Ingenuity pathway analysis (IPA) suggested that potential regulators 
of our gene signature consisting of genes transcriptionally responsive to the 
knock-down of MLL fusion genes, involve several miRNAs that supposedly target 
either MLL (i.e. KMT2A) and/or AF4 (i.e. AFF1). This again implies that our gene 
signatures indeed consist of genes controlled by MLL fusion proteins.          
Therefore we believe that the obtained data is valid and informative, despite the 
limited levels of knock-down and the induced suppression of either AF4 or MLL.  
Among the here observed genes that are down-regulated after knockdown of the 
MLL fusions we found several genes that potentially play important roles in 
leukemia maintenance and/or leukemogenesis. For instance, cyclin-dependent 
kinase 6 (CDK6), which was identified as one of the MLL fusion target genes, as 
the genomic region encompassing CDK6 revealed enhanced occupancy of both 
MLL-AF4 and H3K79 dimethylation.8 We recently reported data showing the 
important role of CDK6 in the proliferation of MLL-rearranged ALL cells, 
demonstrating experimentally that inhibition of CDK6 readily induces impairment 
of leukemic cell proliferation. 21 Other genes in our core signature of genes 
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transcriptionally responsive to the loss of MLL fusion expression are potentially 
important in leukemogenesis. For example, high expression of the Ets family 
transcription factor ERG, which is down-regulated after MLL fusion knock-down, is 
associated with a poor clinical outcome in both acute myeloid leukemia (AML) and 
T-cell acute lymphoblastic leukemia (T-ALL). 22, 23 Moreover, 
enforced ERG expression induces both T-ALL and AML in murine models 24, 25, 
suggesting that ERG contributes to leukemia development. As the inhibition of 
ERG could possibly benefit the survival of MLL-rearranged ALL patients as well as 
patients suffering from AML and T-ALL, this gene represents an interesting 
candidate target gene for therapeutic intervention. More genes that are down-
regulated after knockdown of the MLL fusions, and that have been associated 
with oncogenesis include SATB1 26-28, KAT7 29-31, ADA 32, PPM1F 33, 34, and HOXA7 
35. 
Likewise, potential therapeutic targets can also be found among genes that are 
up-regulated upon knock-down of the MLL fusions. Among these genes we found 
regulator of G-protein signaling protein-2 (RGS2), which has been demonstrated 
to contribute to myeloid differentiation and its repression is considered to be an 
important event in leukemic transformation of FLT3-ITD+ AML. 36 Moreover, RGS2 
functions as a tumor suppressor in various human cancers. 37-39 Hypothetically, 
induction of this protein may suppress MLL-rearranged ALL progression.  
In conclusion, we strongly believe that the genes identified in the present study 
represent genes which directly and readily respond to the loss of the MLL-AF4, 
MLL-ENL, or AF4-MLL, and that these genes potentially include attractive 
therapeutic targets and provide important insights into the biology underlying 
MLL-rearranged acute leukemias. 
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ABSTRACT 
 
Acute lymphoblastic leukemia in infants (<1 year of age) is characterized by a high 
incidence of MLL rearrangements. Recently, direct targets of the MLL fusion 
protein have been identified. However, functional validation of the identified 
targets remained unacknowledged. In this study we identify CDK6 as a direct 
target of the MLL fusion protein and an important player in the proliferation 
advantage of MLL-rearranged leukemia. CDK6 mRNA was significantly higher 
expressed in MLL-rearranged infant ALL patients compared with MLL wild-type 
ALL patients (p<0.001). Decrease of MLL-AF4 and MLL-ENL fusion mRNA 
expression by siRNAs resulted in down-regulation of CDK6, affirming a direct 
relationship between the presence of the MLL fusion and CDK6 expression. 
Knockdown of CDK6 itself significantly inhibited proliferation in the MLL-AF4 
positive cell line SEM, whereas knockdown of the highly homologous gene CDK4 
had virtually no effect on the cell cycle. Furthermore, we show in vitro sensitivity 
of MLL-rearranged leukemia cell lines to the CDK4/6-inhibitor PD0332991, 
inducing a remarkable G1 arrest, and down-regulation of its downstream targets 
pRB1 and EZH2. We therefore conclude that CDK6 is indeed a direct target of MLL 
fusion proteins, playing an important role in the proliferation advantage of MLL-
rearranged ALL cells. 
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INTRODUCTION 
 
Obtaining successful treatment results in infant (<1 year of age) acute 
lymphoblastic leukemia (ALL) remains a major challenge in pediatric cancer. Infant 
ALL is characterized by chromosomal translocations involving the Mixed Lineage 
Leukemia (MLL) gene,1 which occur in approximately 80% of the cases.2 As a result 
of such translocations, the N-terminal portion of the MLL gene becomes fused to 
the C-terminal region of one of its many translocation partner genes.3 The most 
recurrent MLL translocations found among infant ALL patients are t(4;11), 
t(11;19), and t(9;11),2, 4 giving rise to the fusion proteins MLL-AF4, MLL-ENL, and 
MLL-AF9, respectively. To date, long term event-free survival (EFS) rates for MLL-
rearranged infant ALL range between ~30% and 50%, depending on the treatment 
protocol.2 In infant ALL, the presence of MLL-rearrangements, and young age are 
the strongest predictors of an unfavorable outcome.2 Patients diagnosed with ALL 
below the age of 1 month have a 5-year overall survival of ~17%.5 
MLL-rearranged ALL cells display unique gene expression signatures.6, 7 Although 
this embodied an important finding, the overwhelming number of differentially 
expressed genes8 made it difficult to distinguish between the actual “drivers” of 
the leukemia, and by-stander effects. Recently, however, the biology underlying 
MLL fusion driven regulation of gene expression became better understood. MLL, 
a histone methyltransferase, normally catalyzes trimethylation of the fourth 
residue of histone 3 (H3K4me3).9, 10 In contrast, MLL fusion proteins have lost this 
ability.11 Nonetheless, most of the recurrent MLL translocation partners, like AF4, 
ENL, and AF9, are able to connect to another histone methyltransferase, i.e. 
DOT1L. Consequently, MLL fusion proteins recruit DOT1L, which leads to 
dimethylation of lysine 79 on histone 3 (H3K79me2) instead of H3K4me3.12-15 Both 
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H3K4me3 and H3K79me2 are associated with transcriptional activation.16 Hence, 
genomic regions displaying aberrant H3K79me2 enrichment are prone to mark 
genes transcriptionally activated by the MLL fusion protein itself.17 With this in 
mind, Guenther et al and Krivtsov et al independently identified signatures 
consisting of such genes, including for instance MEIS1, FLT3, and several HOXA-
cluster genes.17-19 Strikingly, based on H3K79 methylation profiles alone, MLL-
rearranged ALL could be distinguished from other ALL subtypes lacking MLL 
rearrangements.19 Thus, we now have access to smaller and more specific gene 
sets consisting of genes abnormally regulated by the MLL fusion protein itself. 
However, the question remains which of these genes contributed the most to 
leukemogenesis and/or leukemia maintenance. From this perspective, we here 
studied one of the identified MLL fusion target genes, i.e. CDK6 (encoding human 
cyclin-dependent kinase 6).18 Like its functional homologue CDK4, CDK6 is a 
serine/threonine kinase that is activated upon association with D-type cyclins (i.e. 
cyclin D1, D2 and D3) during the G1 phase of the cell cycle.20 Activation of this 
complex leads to partial inactivation (by phosphorylation) of retinoblastoma 
protein 1 (RB1),21 allowing progression to the S phase.22 Activation of CDK4 and 
CDK6 can be prevented by complex formation with cyclin-dependent kinase 
inhibitors CDKN2A and CDKN2B. In human cancers, deregulation of the cell cycle is 
often mediated by alterations in CDK activity (including that of CDK4 and CDK6), 
inducing unscheduled proliferation as well as genomic and chromosomal 
instability.23, 24 For instance, CDK4 or CDK6 overexpression has been demonstrated 
in several malignancies, including certain types of leukemia and lymphomas.25 
As CDK6, but not CDK4, has been proposed as a direct target of MLL fusion 
proteins, we postulated that MLL-rearranged ALL cells may gain a proliferative 
advantage from MLL fusion driven up-regulation of CDK6. As a major complication 
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in studying MLL-rearranged ALL is that there are no human models recapitulating 
the presence of the MLL-AF4 fusion protein.26-29 Therefore, we set out to explore 
to what extent MLL-rearranged ALL cells are dependent on CDK6 in terms of cell 
proliferation using the MLL-AF4 fusion protein positive cell line SEM. 
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MATERIALS AND METHODS 
 
RNA extraction and cDNA synthesis 
Total RNA was extracted from a minimum of 2x106 cells using TRIzol reagent 
(Invitrogen, Life Technologies, Breda, The Netherlands) according to the 
manufacturer’s guidelines. The quality of the extracted RNA was assessed on 1.5% 
agarose gels and cDNA was prepared for quantitative real-time PCR analysis as 
described earlier.8 
 
Gene expression data 
Bone marrow or peripheral blood samples were used from untreated infants 
(younger than 1 year) diagnosed with ALL included in the INTERFANT-99 
treatment protocol.2 For all primary patient samples used in this study, approval 
was obtained from the Erasmus MC Institutional Review Board, and authorization 
was acquired from the parents or legal guardians of the children via informed 
consent in accordance with the Declaration of Helsinki. All samples were 
processed within 24 hours after sampling as described recently.30 All leukemia 
samples used in this study contained more than 90% leukemic cells. Total RNA 
was synthesized into biotinylated cRNA. Labeled cRNA was then fragmented and 
hybridized to HU133plus2.0 GeneChips (Affymetrix) according to the 
manufacturer’s guidelines. The infant ALL gene expression data presented in this 
study have been deposited in National Center for Biotechnology Information Gene 
Expression Omnibus31 and is accessible via GEO Series accession number 
GSE19475,8 and the pediatric precursor BCP-ALL profiles were deposited as 
GSE13351.32 
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Quantitative real-time PCR analysis 
CDK4, CDK6, MLL-AF4 and MLL-ENL mRNA expression levels were determined by 
quantitative real-time PCR analysis33 using the DyNAmo SYBR Green qPCR kit 
(Finnzymes, #F-400) as described before. Oligonucleotide primers used for PCR 
amplification were purchased from Eurogentec. Primer sequences were as 
follows: CDK4 forward: 5’-TGGGCAGAAGTCTGTTTT-3’ and reverse: 5’-
GGAGGGGAATGTCATTAAG-3’; CDK6 forward: 5’-ACTGCCAAGAACTATGACTGT-3’ 
and reverse: 5’-CTGCTGGGATTTGTTTTATT-3’; MLL-AF4 forward: 5’- 
CCCCGCCCAAGTATC-3’, reverse: 5’-GGCGGCCATGAATG-3’; MLL-ENL forward: 5’-
CCCCGCCCAAGTATC-3’, reverse: 5’-GCTCGAAGTCTGAGTCTGA-3’. B2M was used 
as a reference gene: forward: 5’-GGAGCATTCAGACTTGTCTT-3’, reverse: 5’-
ATGCGGCATCTTCAAA-3’. 
 
Cell culturing and in vitro sensitivity testing 
The ALL cell lines SEM, BEL-1, RS4;11 (translocation t(4;11)-positive; generating 
fusion protein MLL-AF4), and KOPN-8 (translocation t(11;19)-positive generating 
the MLL-ENL fusion protein), were maintained as suspension cultures in RPMI 
1640 with glutamax (Invitrogen, #61870036) supplemented with 10% (v/v) FCS 
and 2% penicillin/streptomycin/fungizone (PSF; Invitrogen, #15140-122) at 37°C in 
humidified air-containing 5% CO2. In vitro cytotoxicity to PD0332991 (Pfizer) was 
determined by 4-day MTT assays as described before.34 Drug exposure treatment 
was performed using 1 μM PD0332991 for 48 hours under standard culture 
conditions, unless mentioned otherwise. 
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ChIP and ChIP-seq procedure 
ChIPs on SEM cells (50x106) were performed using the SimpleChIP Enzymatic 
Chromatin IP kit (Cell signaling technology, #9003) according to the 
manufacturer’s instructions with minor modifications. The cells were fixed in 
RPMI medium containing 1% formaldehyde with gentle rotation for 10 minutes at 
room temperature and the reaction was stopped by glycine quenching (125mM 
final concentration). Nuclei were collected and digested with micrococcal  
nuclease (2µl, provided by the SimpleChIP kit) followed by 8´ of sonication (8 
cycles of 30´´ of sonication and 30´´ without sonication) using a BioRuptor UCD-
200 (Diagenode). Pull downs were performed on DNA fragments (ranging from 
100 to 600 bp) using antibodies against N-terminal MLL (Bethyl laboratories inc., 
#A300-086A), C-terminal AF4 (AbCam. #ab60054), H3K4me3 (Millipore, 
#cs200554) and H3K79me2 (AbCam, #ab3594). ChIP-Seq samples were sequenced 
(36 bp reads) on the illumine GII platform and analyzed by NARWHAL.35 The data 
was visualized using the UCSC genome browser (hg19).  
 
DNA content and apoptosis measurement 
DNA content (i.e. cell cycle distribution) measurement was done using the 
CycleTEST PLUS DNA Reagent Kit (BD Biosciences, #340242). 0.5x106 cells were 
treated with 225 µl of solution A (containing trypsine) for 5’ at room temperature, 
175 µl of solution B (containing trypsine inhibitor) for 10’ at room temperature, 
and 175 µl of solution C (containing propidium iodide (PI) and spermine 
tetrahydrochloride) for 15’ on ice.  
Induction of apoptosis was assessed by an Annexin V/PI assay. For this, 0.2x106 
cells were incubated in annexin binding buffer (10 mM HEPES, pH 7.4; 0.14 M 
NaCl; 2.5 mM CaCl 2) and centrifuged at 1500 RPM at 4°C for 5’. Buffer was 
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removed and a solution of Annexin V (1:1000) and PI (2 μg/ml) (BD Biosciences, 
#556570) was added to the cell culture. 
For both assays, detection of positive staining was performed on a FACSCalibur 
(Becton Dickinson) flow cytometer.  
 
Transfection with siRNA 
Leukemic cells (4x106) were transfected with specific siRNAs by electroporation in 
4 mm electroporation cuvettes (Bio-Rad Laboratories, #1652081) containing 400 
μL of RPMI medium supplemented with 10% fetal calf serum, in the presence of 
10 μL of siRNAs (20 μM) directed against CDK4, CDK6 (ON-TARGET plus 
SMARTpool, Dharmacon), MLL-AF4, or AML1-MTG8 fusion protein (AGF1) as 
nonsense control (as described previously36), or in the presence of 50 μL of siRNAs 
(20 μM) directed against MLL-ENL: sense 5’-CCAAAAGAAAAGUCUGCCCAG-3; 
antisense 5’-CUGGGCAGACUUUUCUUUUGGUU-3’. For the latter experiment, 
control cells were transfected with 50 μL siAGF1 (20 μM). Electroporation was 
carried out applying a rectangular pulse of 300 V for 10 milliseconds, using a Gene 
Pulser MXcell Electroporation System (Bio-Rad Laboratories). After incubating for 
15 minutes at room temperature, the cells were diluted to 1x106 cells/ml and 
cultured under standard culture conditions. Transfection of siMLL-ENL and siMLL-
AF4 was repeated after two days to reach maximum knock-down and cells were 
harvested and RNA isolated after 96 hours. Transfection experiments were 
repeated multiple times with similar results to those published in this manuscript. 
 
Western blot 
Cell pellets were snap-frozen in liquid nitrogen and stored at −80°C until further 
use. After thawing,  cells were resuspended in 50 μL of lysis buffer containing: 5 
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mM EDTA, 10% glycerol, 10 mM sodium pyrophosphate (Merck), 25 mM Tris, 150 
mM NaCl, 1% Triton X-100, 1 mM sodium orthovanadate, 10 mM 
glycerolphosphate, 1 mM dithiothreitol, 1 mM phenylmethylsulfonyl fluoride, 1% 
aprotinin, 10 mM sodium fluoride  (Sigma-Aldrich) and 50 μM of freshly prepared 
sodium pervanadate. Cells were lysed for 30’ on ice. After lysing cells were 
centrifuged  for 15’ at 13.000 rpm and 4°C. Protein concentration was determined 
by BCA protein assay (Pierce Biotechnology, #23225) with different 
concentrations of bovine serum albumin as standards. Cell lysates containing 25 
μg of protein were separated on 10% polyacrylamide gels and transferred onto 
nitrocellulose membranes (Schleicher & Schuell). Western Blots were probed with 
mouse anti-CDK4, anti-CDK6, anti-pRB1 S608 and anti-EZH2 (Cell Signaling, #2906, 
#3136, #2181, and #4905) and mouse anti-beta actin (as a control for equal 
loading) (Abcam) for 2 hours at room temperature. Next the western blots were 
incubated in fluorescently labeled secondary antibodies (LI-COR Biosciences) for 1 
hour and subsequently detected using the Oddyssey Infrared Imaging System (LI-
COR Biosciences). 
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RESULTS 
 
The CDK6 locus is occupied by MLL and AF4, and associated with H3K79me2 
Confirming recent observations18, 19 we validated binding of the MLL-AF4 fusion 
protein at the genomic localization of CDK6. For this, ChIP-sequencing analyses 
was performed on chromatin precipitations (using antibodies against MLL, AF4, 
H3K4me3, and H3K79me2) obtained from MLL-AF4 positive SEM cells. We found 
pronounced co-occupancy of both the N-terminal domain of MLL and the C-
terminal domain of AF4 at the transcriptional start site of CDK6. In contrast, at the 
CDK4 locus, binding of MLL and AF4 appeared largely absent, suggesting MLL-AF4 
occupancy at the CDK6, but not the CDK4 locus (Figure 1, upper panel). Moreover, 
the presence of MLL and AF4 at the genomic CDK6 locus appeared to be 
associated with both H3K4me3, as well as H3K79me2, whereas the CDK4 locus did 
not seem to be marked by these histone modifications (Figure 1, lower panel). In 
addition, these histone marks were present on broad domains throughout CDK6. 
Similar spreading of both histone modifications at key leukemia and stem cell-
associated genes has been described by Guenther et al.18 
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Figure 1. CDK6 is marked by occupation of MLL, AF4, H3K79me2 and H3K4me3 in 
SEM. Graph visualizing number of annotated 36 base pair reads obtained from ChIP-seq 
analysis at the CDK6 locus (left) and CDK4 locus (right) using antibodies against the N-
terminal domain of MLL and the C-terminal domain of AF4 (upper panel), H3K4 
trimethylation and H3K79 dimethylation (lower panel) in MLL-AF4 positive cell line SEM. 
An additional 1kb upstream and downstream of CDK4 and an additional 10kb upstream 
and downstream of CDK6 is given.  
 
Elevated CDK6 expression in MLL-rearranged infant ALL 
Using our recently published gene expression profiling data (Affymetrix 
HU133plus2.0 GeneChips),8 we evaluated CDK6 and CDK4 expression levels in 
MLL-rearranged infant ALL. CDK6 appeared significantly higher expressed in the 
MLL-rearranged infant ALL patients when compared with infant ALL patients 
(p=0.001), pediatric non-infant (>1 year of age) precursor BCP-ALL patients 
(p<0.0001) carrying wild-type MLL genes, or healthy bone marrow samples 
(p<0.0001) (Figure 2A; left panel). All probe sets of CDK6 had an FDR-adjusted p-
value of 0.002 or smaller (Table 1).  
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ID logFC T P.Value adj.P.Val B 
224848_at 1.035591 7.564293 7.52E-12 3.29E-09 16.59254 
243_g_at 0.546159 7.028207 1.22E-10 3.11E-08 13.91603 
224847_at 0.892852 7.00689 1.36E-10 3.40E-08 13.81122 
235287_at 1.072996 6.819905 3.53E-10 7.54E-08 12.89764 
224851_at 0.961323 6.218592 6.99E-09 8.41E-07 10.03769 
231198_at 0.566643 5.643918 1.07E-07 7.03E-06 7.433588 
207143_at 0.573842 4.655778 8.15E-06 0.000215 3.320232 
214160_at 0.438097 3.898921 0.000157 0.002164 0.547444 
 
Table 1. All CDK6 probe sets significantly higher expressed in MLL-r infant ALL patients. 
Table representing all probe sets of CDK6 on the HGU133plus2.0 microarray with results 
from linear modelling for microarrays (LIMMA) searching for differentially expressed 
probe sets between MLL-rearranged infant ALL patients (n=68) and MLL wild-type samples 
(consisting of MLL wild-type infant ALL patients (n=18), pediatric (non-infant) BCP-ALL 
patients (n=16) and healthy bone marrow samples n=13). MLL-r = MLL-rearranged; ID = 
probe set; logFC = estimate of the log2-fold-change; T = moderated T-statistic; P.Value = 
raw p-value; adj.P.Val = FDR-adjusted p-value or q-value; B = log odds. 
 
In contrast to CDK6, CDK4 expression was not upregulated in MLL-rearranged 
infant ALL compared to infant ALL with wild-type MLL (Figure 2B; left panel). 
Among MLL-rearranged infant ALL patients, CDK6 expression is higher than the 
expression of CDK4 (p<0.0001) (Figure2A-B). The downstream CDK4/CDK6 target 
RB1 also appeared significantly higher expressed in MLL-rearranged infant ALL 
patients when compared with pediatric precursor BCP-ALL patients and healthy 
bone marrow samples (p<0.0001). However, RB1 expression levels in MLL wild-
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type infant ALL patients appeared comparable to that of the MLL-rearranged 
infant ALL cases (Figure 2C).  
 
 
 
 
 
 
 
 
 
 
 
Figure 2. CDK6 mRNA expression values are higher in MLL-rearranged infant ALL 
patients. Graphical representation of VSN-normalized expression values of CDK6 mRNA 
(224848_at) (A), CDK4 mRNA (202246_s_at) (B), and RB1 mRNA (203132_at) (C) from 
gene-expression profiling data (Affymetrix HU133plus2 GeneChips) in patient material. 
CDK6 is significantly higher expressed in MLL-rearranged infant ALL patients (MLL-r infant 
ALL, n=68) compared to MLL wild-type infant ALL (MLL wt infant ALL, n=18), pediatric 
(non-infant) precursor BCP-ALL patients (pre-BCP-ALL, n=16) and healthy bone marrow 
(healthy bone marrow, n=13). CDK4 is only significantly higher expressed in MLL-
rearranged infant ALL patients compared to pediatric BCP-ALL patients. RB1 is significantly 
higher expressed compared to pediatric BCP-ALL patients and healthy bone marrow 
samples, but not compared to wild-type MLL infant ALL patients. The differences between 
patient groups were statistically analyzed using the Mann-Whitney U test. Probe sets with 
the largest difference between MLL-rearranged and MLL wild-type are shown in the 
graph; all probe sets of CDK6 had an FDR-adjusted p-value of 0.002 or smaller 
(Supplemental Table 1). Error bars represent the mean ± standard error of the mean.  
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Figure 2. CDK6 mRNA expression values are higher in MLL-rearranged infant ALL 
patients.  
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WBC higher in patients with high CDK6 mRNA expression 
Although the white blood cell (WBC) count at diagnosis obviously is subjected to 
many variations, this parameter may reflect some degree of leukemic cell 
proliferation and disease aggressiveness. For instance, among infant ALL patients, 
high WBC counts are highly characteristic and represents an independent 
predictor of an adverse outcome.2 Thus, with WBC counts as a suggestive marker 
for leukemic blast proliferation, we determined whether high-level CDK6 
expression was associated with increased WBC at diagnosis. For this, we 
compared MLL-rearranged infant ALL patients with a “low” (< median) and “high” 
(≥ median) CDK6 expression, and found that patients expressing high levels of 
CDK6 presented with significantly higher WBC counts at diagnosis (p=0.027) 
(Figure 3, left panel). A similar association with the expression of CDK4 was not 
observed (Figure 3, right panel). 
 
 
 
Figure 3. WBC count is higher in patients with high CDK6 mRNA expression. Graph shows 
white blood cell (WBC) count (X-axis) in MLL-rearranged patients with low (<median, n=31) and high 
(≥median, n=31) expression of CDK6 (left panel) and CDK4 (right panel). The difference between 
patient groups were statistically analyzed using the Mann-Whitney U test. 
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CDK6 expression is regulated by the MLL fusion 
To confirm that CDK6 indeed is regulated by the MLL fusion itself, we transfected 
the MLL-rearranged ALL cell lines KOPN-8 and SEM with siRNAs directed against 
MLL-ENL or MLL-AF4 respectively. Transfection with siMLL-ENL in KOPN-8 resulted 
in a 92% decrease of the MLL-ENL transcript as compared with transfections with 
non-silencing siRNAs directed against AGF1. Similar experiments using siMLL-AF4 
in SEM cells showed a 67% reduction in MLL-AF4 mRNA expression (Figure 4A). 
Knockdown of MLL-ENL and MLL-AF4 led to pronounced decreases in CDK6 
expression in both KOPN-8 and SEM cells, whereas CDK4 expression largely 
remained unaffected (Figure 4B). Similarly, upon knockdown of the MLL fusion, 
protein levels of CDK6 were affected to a greater extent than that of CDK4 (Figure 
4C). Hence, these data are in line with our confirmatory ChIP-seq data (Figure 1), 
and clearly demonstrate that transcription of CDK6, but not CDK4, is driven by the 
MLL fusion itself.  
 
 
Figure 4. CDK6 is downregulated after knockdown of MLL fusion by siRNA. Graphical 
representation of (A) expression values of MLL-ENL mRNA in KOPN-8 (left) and MLL-AF4 
mRNA in SEM (right) after knockdown by siRNA of MLL-ENL and MLL-AF4 respectively 
(white bars) measured by RT-PCR relative to control siRNA AGF1 (siAGF1, grey bars); and 
(B) expression values of CDK6 mRNA (left) and CDK4 mRNA (right) in MLL fusion 
knockdown samples (white bars) measured by RT-PCR relative to control siAGF1 (grey 
bars). Expression of mRNA was measured relative to housekeeping gene B2M as loading 
control. Error bars represent the mean ± standard error of the mean. C. Protein levels of 
CDK4 and CDK6 after transfection with siRNA directed against MLL-ENL (right panel) and 
MLL-AF4  as shown by western blot (left panel) and graph visualizing quantification of 
western blot (right panel). β-actin is shown as loading control. 
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Figure 4. CDK6 is downregulated after knockdown of MLL fusion by siRNA. 
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CDK6 drives proliferation in MLL-rearranged ALL 
To assess to what extent proliferation in MLL-rearranged ALL cells depends on the 
elevated expression of CDK6, we separately knocked down CDK6 and CDK4 in the 
t(4;11)-positive ALL cell line SEM. This led to the transient reduction of CDK6 and 
CDK4 protein expression to approximately 50% for 24 to 48 hours, whereupon 
protein expression was almost completely recovered (Figure 5A). Cell cycle 
analysis showed that suppression of CDK4 hardly affected proliferation. In 
contrast, knock-down of CDK6 led to marked increases in the number of cells 
present in the G0/G1 phase, at the expense of the percentage of cells in the S 
phase or G2/M phase (Figure 5B). Cell cycle analysis alternatively assessed by 
BrdU-staining at 48 hours after transfection, showed similar results with an 
increase in number of cells in the G1 phase and decrease of number of cells in the 
S phase after transfection with CDK6, while knockdown of CDK4 practically had no 
effect on the cell cycle (Figure 5C). These data establish a role for CDK6, but not 
for its homologue CDK4, in the proliferation of MLL-rearranged ALL cells. 
Moreover, neither CDK4 nor CDK6 suppression affected cell viability as 
determined by Annexin V/PI-staining (Figure 5D). 
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Figure 5. Proliferation of the MLL-rearranged cell line SEM depends on CDK6 but not on 
CDK4. 
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Figure 5. Proliferation of the MLL-rearranged cell line SEM depends on CDK6 but not on 
CDK4. A. Protein levels of CDK4 (upper panel) and CDK6 (lower panel) followed over three 
days (D0 to D3) after transfection with siRNA directed against CDK4 and CDK6 respectively 
as shown by western blot (left panel) and graphic visualization of quantification of western 
blot (right panel). β-actin is shown as loading control. B. Graph visualizing number of cells 
in the G0/G1 phase (grey), S phase (white) and G2/M phase (black) after knockdown by 
siRNA of CDK4 and CDK6  and transfection with siAGF1 and empty pulse control measured 
over four days (represented on the X-axis). Cell cycle phase assessment was done by DNA 
content measurement by means of proprium iodide staining quantified by flow cytometry. 
Bars represent mean - standard error of the mean. C. Graph visualizing cell cycle analysis 
results (G0/G1 phase, grey; S phase, white; G1/M phase, black) through 
bromodeoxyuridine (BrdU) staining quantified by flow cytometry at 48 hours after 
transfection with either siRNAs directed against CDK4, CDK6, nonsense target AGF1 and 
empty pulse in MLL-AF4 cell line SEM. D. Quantitative measurement of alive, early 
apoptotic, late apoptotic and dead cells 48 hours after transfection with siRNAs directed 
against CDK4 (upper left), CDK6 (upper right), nonsense target AGF1 (lower left) and 
empty pulse control (lower right) as measured by Annexin V (discriminating between alive 
and apoptotic/dead cells) on the X-axis and propidium iodide (PI, discriminating between 
apoptotic and dead cells) on the Y-axis. 
 
 
In vitro sensitivity of MLL-rearranged ALL cell lines to PD0332991 
Next we tested the in vitro sensitivity to the CDK4/CDK6 inhibitor PD0332991 of 
MLL-rearranged ALL cell lines SEM, KOPN-8, BEL-1, and RS4;11. All MLL-
rearranged ALL cell lines tested appeared highly responsive to PD0332991 
treatment, with IC50 values (i.e. the concentration required to inhibit 50% of the 
viable cells) ranging from ~0.08 – 8 M (Figure 6).  
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Figure 6. In vitro sensitivity of MLL-rearranged cell lines to CDK4/6-inhibitor PD0332991. 
Graph showing results of 4-day MTT assay with PD0332991 (in µM on X-axis) on MLL-
rearranged ALL cell lines KOPN-8 (MLL-ENL), RS4;11, SEM and BEL-1 (MLL-AF4). Dotted line 
represents concentration needed to inhibit 50% of the viable cells (IC50). 
 
Next we exposed t(4;11) SEM cells and t(11;19) KOPN-8 cells to 1 µM of 
PD0332991 for 48 hours. In SEM and KOPN-8 cells, this resulted in a considerable 
G1 arrest, almost doubling the percentage of cells residing in the G0/G1 phase, 
while the number of cells in the S phase dropped to less than 20% as compared to 
unexposed control cells (Figure 7). Likewise, the number of cells in G2/M phase 
was also markedly reduced.  
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Figure 7. G1-arrest in MLL-rearranged ALL cell lines after PD0332991 treatment. A. 
Visualization of cell cycle phases as measured by DNA content through propidium iodide 
(PI) staining quantified by flow cytometry after exposure of MLL-AF4 positive cell line SEM 
to 1 µM PD0332991 (lower panel) and blank control (upper panel) for 48 hours. Cell cycle 
phases are pointed out by arrows in the graph. Both S phase and G2/M phase are 
significantly reduced, indicating a G1 arrest. B. Graphical representation of the number of 
cells that are in G0/G1 phase (grey), S phase (white) or G2/M phase (black) after 
treatment with 1 µM PD0332991 and blank control for 48 hours as measured by DNA 
content in KOPN-8 (left bars) and SEM (right bars). MLL-AF4 positive cell line SEM and 
MLL-ENL positive cell line KOPN-8 have a significant increase in number of cells in G0/G1 
phase and decrease of cells in the S and G2/M phase. 
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PD0332991 inhibits downstream targets pRB1 and EZH2 in MLL-rearranged ALL 
cell lines 
As pRB and EZH2 are downstream targets of CDK6, we determined protein levels 
of the pRB and EZH2 in the MLL-rearranged ALL cell lines SEM and KOPN-8 in the 
presence and absence of PD0332991 (1 M). Exposure to PD0332991 did not 
affect CDK6 protein levels itself, which is hereditary to the working mechanism of 
PD0332991, but effectively suppressed RB1 phosphorylation and EZH2 expression 
in all three cell lines (Figure 8).  
 
 
 
Figure 8. Treatment with CDK4/6-inhibitor PD0332991 affects downstream targets pRB 
and EZH2. Protein levels of CDK6, RB1 phosphorylation at serine 608 (pS608) and EZH2 in 
MLL-ENL positive cell line KOPN-8 and MLL-AF4 positive cell line SEM after 0 hours, 24 
hours and 48 hours of treatment with 1 µM CDK4/6-inhibitor PD0332991 as shown by 
western blot. β-actin is shown as loading control. 
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DISCUSSION 
 
We here confirm that, as proposed by previous reports, 18, 19 the cell cycle 
dependent kinase CDK6 represents a direct target of the MLL fusion protein in 
MLL-rearranged ALL. Furthermore, we show that the transcriptional activation of 
CDK6 provides MLL-rearranged ALL cells with a proliferative advantage, which can 
effectively be counteracted by inhibiting CDK6. Hence, CDK6 may be an attractive 
therapeutic target for this aggressive type of leukemia, with the CDK4/CDK6 
inhibitor PD0332991  as a potential active drug. Furthermore, this study 
demonstrates the importance of public databases (e.g. ChIP-seq and gene 
expression databases) for furthering research faster. 
PD0332991 is a well-tolerated oral CDK4/6-inhibitor with myelosuppression37 and 
neutropenia38 as dose-limiting toxicities. Clinical benefit of PD0332991 has been 
shown with progression-free survival for over a year in 5 out of 17 mantle cell 
lymphoma patients39, and partial response in patients with a progressive 
teratoma;40 both tumors are characterized by high CDK4 and RB1 expression 
respectively. PD0332991 also significantly reduced tumor load in several Rb-
positive human xenograft models in vivo.41 In concordance with our results, Wang 
et al42 showed that PD0332991 established a cell cycle block in AML cell line 
MV4;11, containing the MLL-AF4 fusion protein as well as an internal tandem 
duplication (ITD) of FLT3. They showed that CDK4/6 activation is a downstream 
effector of FLT3-ITD-mediated oncogenic pathways, and argue that sensitivity of 
MV4;11 to PD0332991 may be explained by activation of this pathway. 
Additionally we now argue that it is very well imaginable that MLL-AF4 is able to 
bind and upregulate CDK6 directly also in MLL-rearranged AML, and via this 
contributing to the sensitivity of MV4;11 to PD0332991. Further studies with 
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PD0332991 now are warranted to assess whether it can also effectively inhibit 
proliferation of MLL-rearranged ALL cells in vivo. Similarly to other inhibitors 
moving into the clinic, cautious testing of the effect on normal residual 
hematopoetic stem cells and progenitors is required due to the high bone marrow 
involvement of ALL.  
Where CDK6 plays an important role in the proliferation of MLL-rearranged ALL, 
the highly homologous CDK4 does not seem to affect the proliferation to a great 
extent. Non-overlapping functional roles of CDK4 and CDK6 have been 
demonstrated earlier, and may be tissue-specific and depend on different 
complexes each kinase forms.43-46 Also the present study suggests that CDK4 and 
CDK6 are not functionally redundant, with only CDK6 playing a critical role in the 
proliferation of MLL-rearranged ALL. Another possible explanation for a lack of 
effect on the proliferation after abrogation of CDK4 may lie in a compensatory 
mechanism, where the highly expressed CDK6  in MLL-rearranged ALL may 
possibly surmount the absence of CDK4.  
Further, this study raises questions about the role of the polycomb group protein 
EZH2 in MLL-rearranged leukemia. Although we demonstrate a significant 
decrease in the protein levels of EZH2 and proliferation arrest after exposure to 
the CDK4/6 inhibitor, recent studies in MLL-AF9 rearranged acute myeloid 
leukemia (AML) have shown that inactivation of this gene can compromise but 
not fully abrogate leukemic growth.47, 48 This would suggest either the implication 
of other downstream targets of CDK6 and the RB1 gene, aspecific effects of 
PD0332991 or possibly a more important role of EZH2 in MLL-rearranged ALL. 
Experiments using inactivation of EZH2 in MLL-rearranged ALL could possibly shed 
more light on this specific issue. 
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There has been debate whether the “two hit” model – one hit activating an 
oncogene and one hit inactivating a tumor suppressor gene49, 50 – applies to MLL-
rearranged leukemia. Yu et al51 already noted that the MLL rearrangement as a 
single event can result in two hits; an MLL fusion product with a partner gene 
could confer gain-of-function activity, and simultaneous MLL haploinsufficiency 
would contribute to the disordered cell fate of the leukemia. In this study we 
present an alternative way in which the MLL fusion confers gain-of-function 
activity; the MLL fusion upregulates expression of CDK6 and by this drives the 
continued proliferation in MLL-rearranged leukemia. 
In conclusion, CDK6 is a direct target of the MLL fusion protein and plays an 
important role in the proliferation advantage of MLL-rearranged ALL cells. 
Additionally we show that the proliferation advantage of MLL-rearranged ALL 
gained by CDK6 can be effectively targeted in vitro by the CDK4/6 inhibitor 
PD0332991. 
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ABSTRACT 
 
Introduction: Acute lymphoblastic leukemia in infants is characterized by a poor 
prognosis and a high incidence of MLL rearrangements. Infant ALL has been 
recognized to generate distinct gene expression profiles. In search for new 
treatment targets, we analyzed these gene expression signatures for differential 
expression. Results: EP300-interacting inhibitor of differentiation (EID1) mRNA 
was significantly higher expressed in infant ALL patients compared with pediatric 
(non-infant) BCP-ALL patients and healthy bone marrow samples (p<0.001). 
Subsequently, we performed shRNA mediated knockdown of EID1 in human MLL-
fusion gene leukemia cell line SEM, which resulted in reduced cell growth through 
both an induced G1-arrest and apoptosis. Gene expression profiling of cells 
transduced with EID1 shRNA demonstrated reduced expression of E2F-driven 
genes, needed for cell cycle progression to the S-phase. Furthermore, EP300-
associated factor KAT2B (a.k.a. PCAF) was downregulated upon knockdown of 
EID1. Both knockdown of KAT2B and EP300 induced apoptosis in MLL-rearranged 
cell line SEM. Results: These results show that EID1 expression is important for 
continued growth of MLL-rearranged ALL. Due to the critical role in growth and its 
specific expression in the leukemic blasts of infant ALL patients, EID1 appears to 
be a good target for the development of new treatment strategies in infant ALL.  
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INTRODUCTION 
 
Although overall survival among children diagnosed with acute lymphoblastic 
leukemia (ALL) nowadays exceeds 80% 1, the prognosis for infants (<1 year of age) 
with ALL remains dismal. 2 Infant ALL is characterized by chromosomal 
translocations of the Mixed Lineage Leukemia (MLL) gene, occurring in ~80% of 
the cases. In infant ALL, the most recurrent MLL translocation partner genes are 
AF4, ENL, and AF9. 2, 3 The prognosis for MLL-rearranged infant ALL patients (i.e. 
EFS rates of 30-40% 2) is considerably worse than that for infants not carrying 
translocations of the MLL gene (EFS ~75% 2). Hence, improved therapeutic 
strategies, especially for MLL-rearranged infant ALL patients, are urgently needed.  
Genome-wide transcriptome studies have shown that MLL-rearranged ALL 
patients display highly unique gene expression profiles. 4-6 In search of new and 
valid therapeutic targets we screened our gene expression profiling data. 6 In the 
present study we set out to investigate EID1, which we found highly and 
specifically expressed in infant ALL cells. The EID1 (EP300 interacting inhibitor 
of differentiation 1) protein binds and interacts with the histone acetyltransferase 
(HAT) EP300. In normal physiology, EP300 is widely expressed and involved in the 
regulation of many cellular processes, including cell growth, differentiation and 
apoptosis. 7-10 By blocking the HAT activity of EP300, EID1 is a potent inhibitor of 
differentiation. 11, 12 EID1 also binds the retinoblastoma (RB) protein. 11 In complex 
with members of the E2F family of DNA-binding transcription factors, RB 
represses the transcription of genes required for cell cycle progression, and as 
such represents an important gate keeper of the cell cycle. 13 Thus, binding of EID1 
to both EP300 and RB suggests a link between tissue-specific differentiation and 
cell cycle exit, and has led to the assumption that EID1 confers inhibitory effects 
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on both cellular processes. 11, 12 High-level expression of EID1 in infant ALL cells 
may fulfill a crucial role in blocking differentiation and at the same time stimulate 
uncontrolled proliferation. If so, EID1 represents an attractive therapeutic target 
in infant ALL. In this study, we investigated to what extent MLL-rearranged ALL 
cells are dependent on the expression of EID1. 
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MATERIALS AND METHODS 
 
Note: A more elaborate and detailed description of all experimental procedures 
and data analysis methods can be found in the Supplemental Material Chapter 8. 
 
Gene expression profiling data 
EID1 mRNA expression levels in primary samples from infants with ALL were 
derived from our previously published gene expression array data (HU133plus2.0 
GeneChips; Affymetrix; probe set ID: 211698_at). 6 Raw array data were 
collectively normalized using variance-stabilizing normalization 14 and differential 
gene expression was statistically evaluated using linear models for microarray 
analyses (LIMMA). 15 Gene set enrichment analysis (GSEA) was performed using 
GSEA software. 16 
 
Quantitative real-time PCR analysis 
Total RNA was extracted from a minimum of 2x106 cells using TRIzol reagent 
(Invitrogen, Life Technologies, Breda, The Netherlands) according to the 
manufacturer’s guidelines. The quality of the extracted RNA was assessed on 1.5% 
agarose gels, and cDNA was synthesized for quantitative real-time PCR analysis as 
described earlier. 6 EID1 and KAT2B mRNA expression was measured by 
quantitative real-time PCR analysis using the DyNAmo SYBR Green qPCR kit 
(Finnzymes, Espoo, Finland) as described before. 17  
 
Cell line culturing and RNA interference 
All knockdown experiments were performed in the leukemia cell line SEM, 
carrying the MLL translocation t(4;11), generating MLL-AF4 fusion proteins.  
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RNA interference was performed by means of lentiviral transduction. After 24 
hours the DMEM medium was replaced with RPMI medium, and virus-containing 
medium was harvested 48 hours after transfection. Upon filtration through a 
0.45-μm cellulose acetate filter, the virus stock was used to infect SEM cells. The 
pLKO.1 puromycin resistance marker allows selection for stably transduced cells. 
Puromycin (1 µg/ml) was added to the medium after 96 hours. Infected cells were 
analyzed for knockdown by RT-PCR and western blot analyses. All knockdown 
experiments were repeated at least two times. 
 
Flow cytometry and cell cycle analysis 
Induction of apoptosis was assessed by an Annexin V/PI assay. Cell cycle analysis 
was performed by BrdU labeling using the FITC BrdU Flow Kit (#559619, BD 
Pharmigen) according to manufacturer’s protocol. Analysis of the flowcytometry 
data was performed using the FlowJo software version 7.6.5 (Tree Star). 
 
Western blot analyses 
Western Blots were probed with KAT2B rabbit monoclonal antibody 
(CellSignaling,) and beta actin mouse monoclonal antibody (as a control for equal 
loading) (Abcam) for 2 hours at room temperature. Next the western blots were 
incubated in fluorescently labeled secondary antibodies (LI-COR Biosciences) for 1 
hour and subsequently detected using the Oddyssey Infrared Imaging System (LI-
COR Biosciences). 
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RESULTS 
 
High-level EID1 expression in infant ALL 
Our recent gene expression profiling study revealed high-level expression of EID1 
(or CRI1) in MLL-rearranged infant ALL when compared with pediatric (>1 year of 
age) precursor B-cell ALL. 6 Further analysis showed that high-level expression of 
EID1 was not exclusively restricted to MLL-rearranged infant ALL samples, but also 
appeared present in infant ALL cells bearing germline MLL genes. Compared with 
both pediatric precursor B-cell ALL (n=16) and healthy bone marrow samples 
(n=13), infant ALL cells (either with or without MLL translocations) significantly 
expressed higher levels of EID1 (Figure 1A) (p<0.0001). Next, in order to validate 
these gene expression profiling data, we performed quantitative real-time PCR 
analysis. Again, EID1 was significantly (p=0.002) higher expressed in primary MLL-
rearranged infant ALL samples (n=6) as compared with samples from pediatric 
precursor B-cell ALL patients (n=6) (Figure 1B). 
 
 
 
 
Figure 1. High expression of EID1 in infant leukemia. 
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Figure 1. High expression of EID1 in infant leukemia. A. Graphical representation of VSN-
normalized expression values of EID1 mRNA (211698_at) from gene-expression profiling 
data (Affymetrix HU133plus2 GeneChips) in patient material. EID1 is significantly higher 
expressed in MLL-rearranged infant ALL patients (MLL-r infant ALL, n=68) and MLL wild-
type infant ALL patients (MLL wt infant ALL, n=18) compared with healthy bone marrow 
(healthy bone marrow, n=13) and pediatric (non-infant) precursor BCP-ALL patients 
(pediatric BCP-ALL, n=16). The difference between patient groups was statistically 
analyzed using the Mann-Whitney U test. Probeset with the largest difference between 
MLL-rearranged and MLL wild-type are shown in the graph; all probesets of EID1 had an 
FDR-adjusted p-value of <0.0001 (Supplementary material Chapter 8). B. Graphical 
representation of EID1 mRNA expression in MLL-rearranged infant ALL (n=6) and pediatric 
(non-infant) precursor BCP-ALL patients (n=6) as determined by RT-PCR. Error bars 
represent the mean ± standard error of the mean. 
 
 
Knockdown of EID1 induces cell cycle arrest and apoptosis in MLL-rearranged ALL 
To determine whether MLL-rearranged ALL cells are dependent on high-level EID1 
expression, we performed EID1 knockdown experiments in the MLL-AF4 positive 
ALL cell line SEM. SEM cells were transduced with shRNAs directed against EID1 
(shEID1), or with non-silencing control shRNAs (shNSC). Selection of cells stably 
expressing the shRNAs was established by exposure to puryomycin. Compared 
with the non-silencing control, transduction with shEID1 led to an 82% reduction 
in EID1 expression three days after puromycin selection (Figure 2A). Knockdown 
of EID1 resulted in marked decreases in the number of viable cells as determined 
by trypan blue dye exclusion staining (Figure 2B). To investigate the cause of this 
remarkable decline in cell viability, the effects of EID1 knockdown were assessed 
by apoptosis and cell cycle analysis. Annexin V/propidium iodide (PI) staining 
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revealed a dramatic induction of apoptosis. Within two days after puromycin 
selection, virtually all cells challenged with shRNA against EID1 were either 
apoptotic or necrotic (i.e. PI-positive) compared to the non-silencing control 
(Figure 3A). At the same time, BrdU/7-AAD staining showed an abrupt blocking 
cell cycle progression. After EID1 knockdown, the percentage of SEM cells residing 
in the S phase was reduced to only 1% compared with ~23% in non-silencing 
control cells  (Figure 3B). Collectively these data imply that MLL-rearranged ALL 
cells are highly dependent on high-level EID1 expression.   
 
 
 
 
Figure 2. EID1 knockdown inhibits growth in MLL-rearranged ALL. A. Expression values of 
EID1 mRNA in SEM after knockdown by shRNA directed against EID1 measured by RT-PCR 
relative to non-silencing control shNSC. Expression of mRNA was measured relative to 
housekeeping gene B2M as loading control. B. Average live cell counts/ml (including cells 
undergoing apoptosis) determined over four days after puromycin selection in SEM cells 
transduced with EID1 shRNA (shEID1) or non-silencing control virus (shNSC). Non-infected 
control: wild-type SEM cells without puromycin resistancy marker. Data represented are 
the means of three independent experiments. Error bars represent the standard error of 
the mean. 
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Figure 3. EID1 knockdown induces apoptosis and cell-cycle arrest in MLL-rearranged ALL. 
A. Quantitative measurement of alive, apoptotic and dead transduced SEM cells two days 
(upper panel) and five days (lower panel) after puromycin selection with shRNAs directed 
against EID1 (shEID1, right) and non-silencing control (shNSC, left) as measured by 
Annexin V on the X-axis and propidium iodide on the Y-axis. B. Cell cycle analysis indicating 
G0/G1-phase, S-phase and G2/M-phase of transduced SEM cells two days after puromycin 
selection with shRNAs directed against EID1 and non-silencing control as measured by 
BrdU incorporation on the X-axis and 7-AAD (measuring total DNA content) on the Y-axis. 
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Transcriptional consequences of EID1 knockdown 
To gain more insight into the effects of EID1 repression in MLL-rearranged ALL 
cells, we performed genome-wide transcriptome analysis (using Affymetrix 
HGU133plus2.0 microarrays) in SEM cells transduced with shEID1 or non-silencing 
shNSC. These experiments revealed differential expression (p<0.001) of 39 probe 
sets, corresponding to 26 genes, after EID1 knockdown. Importantly, three of the 
probe sets corresponded to EID1 itself, confirming successful repression of the 
target gene (Figure 4A). Moreover, 22 of the genes were down-regulated upon 
loss of EID1 expression, whereas only four genes became up-regulated. 
Subsequently, we performed gene set enrichment analysis (GSEA) of gene 
expression in EID1 knockdown samples versus control samples using gene sets 
that contain genes that share a transcription factor binding site as defined in the 
TRANSFAC database (C3: motif gene sets/TFT). In the downregulated genes, we 
found a significant enrichment of promoter regions containing the motif matched 
with E2F-related proteins, specifically E2F1 (normalized enrichment score (NES)=-
1.77, q=0.01) (Figure 4B and Supplemental material Chapter 8).  
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Figure 4. Gene expression profiling of EID1 demonstrates downregulation of KAT2B. 
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Figure 4. Gene expression profiling of EID1 demonstrates downregulation of KAT2B. A. 
Heatmap visualization of gene expression profiles (Affymetrix HGU133plus2.0 GeneChips) 
of EID1 knockdown samples (n=2, red columns, shEID1) and non-silencing control samples 
(n=2, blue columns, shNSC) using 42 significantly different expressed probe sets (p<0.001). 
Upregulated genes are depicted in red, downregulated genes are depicted in blue. B. 
Gene set enrichment analysis (GSEA) of gene expression in EID1 knockdown samples 
(‘na_pos’) versus control samples (‘na_neg’) using gene sets that contain genes that share 
a transcription factor binding site defined in the TRANSFAC database (C3: motif gene 
sets/TFT). Demonstrated is an enrichment of genes with promoter regions [-2kb,2kb] 
around transcription start site containing the motif TTTSGCGS which matches annotation 
for E2F1. The E2F-related gene set with the highest normalized enrichment score (NES) is 
shown here; out of 19 E2F-related gene sets analyzed 15 had nominal p-value <0.05 
(Supplemental material Chapter 8). q = FDR-adjusted p-value. C. Expression values of 
KAT2B mRNA in SEM after knockdown by shRNA directed against EID1 measured by RT-
PCR relative to non-silencing control shNSC. Expression of mRNA was measured relative to 
housekeeping gene B2M as loading control. 
 
 
Knockdowns of histone acetyltransferases KAT2B and EP300 induce apoptosis in 
MLL-rearranged ALL 
Interestingly, one of the down-regulated genes in our EID1 knockdown expression 
signature was KAT2B (or PCAF: EP300-associated factor), which like EP300 
encodes a histone acetyltransferase important in regulating differentiation. 
Quantitative real-time PCR analysis confirmed KAT2B down-regulation in SEM 
cells transduced with shEID1 (Figure 4C). While EID1 is believed to block 
differentiation by inhibiting EP300 activity, KAT2B seems to prevent 
differentiation via acetylation of RB. 18 On the other hand, Puri and co-workers 19 
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demonstrated that the HAT activity of KAT2B, but not of EP300, is essential for 
muscle differentiation. Therefore, to elucidate the contribution of KAT2B down-
regulation to the observed EID1 knockdown phenotype in infant ALL, we assessed 
apoptosis induction and cell cycle distribution in KAT2B and EP300 knockdown 
experiments. In comparison with the non-silencing control, transduction of MLL-
AF4 positive SEM cells with shKAT2B or shEP300 reduced the mRNA expression of 
these genes with 70% and 58% respectively (Figure 5A). Furthermore, Western 
blot analysis confirmed successful knockdown of KAT2B at the protein level 
(Figure 5B). Suppression of both KAT2B and EP300 reduced the number of viable 
cells as determined by trypan blue dye exclusion, but the most dramatic effects 
were observed after knockdown of EP300 (Figure 5C). In line with these findings, 
apoptosis induction and cell cycle inhibition were most prominently triggered in 
cells in which EP300 expression was reduced (Figure 5D and 5E). These data show 
that the loss of KAT2B to some extent contributes to the anti-leukemic phenotype 
of EID1 inhibited SEM cells, but at the same time also imply that MLL-rearranged 
ALL cells are more dependent on the presence of EP300. 
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Figure 5. KAT2B and EP300 induce apoptosis in MLL-rearranged ALL. A. Expression of 
KAT2B mRNA (left, light grey) and EP300 (right, dark grey) in SEM after knockdown by 
shRNA directed against KAT2B and EP300 respectively, measured by RT-PCR relative to 
non-silencing control shNSC with B2M as loading control. B. Protein levels of KAT2B in 
non-silencing control (shNSC) and after knockdown by shRNA of KAT2B (shKAT2B) as 
shown by western blot. β-actin is shown as loading control. C. Average live cell counts/ml 
determined over five days from puromycin selection in SEM cells transduced with KAT2B 
shRNA (shKAT2B), EP300 shRNA (shEP300) or non-silencing control shRNA (shNSC). D. 
Quantitative measurement of alive, apoptotic and dead transduced SEM cells five days 
after puromycin selection with shRNAs directed against KAT2B (shKAT2B, light grey), 
EP300 (shEP300, dark grey) and non-silencing control (shNSC, white) as measured by 
Annexin V and PI, discriminating between apoptotic and dead cells.  
 
EID1 in infant ALL               211 
 
 
 
Figure 6. Cell cycle analysis after knockdown of KAT2B and EP300. Cell cycle analysis 
(gated on live cells) indicating G0/G1 phase, S phase and G2/M phase of transduced SEM 
cells two days after puromycin selection with shRNAs directed against KAT2B (shKAT2B, 
light grey), EP300 (shEP300, dark grey) and non-silencing control (shNSC, white) as 
measured by BrdU incorporation on the X-axis and 7-AAD (measuring total DNA content) 
on the Y-axis. 
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DISCUSSION 
 
We here show that among childhood ALL patients, EID1 (EP300-interacting 
inhibitor of differentiation) is specifically expressed in patients <1 year of age (i.e. 
infants). Although the presence of MLL translocations is firmly associated with a 
poor clinical outcome and represents a hallmark of infant ALL, EID1 expression 
was not restricted to MLL-rearranged infant ALL alone. Infant ALL patients not 
carrying translocations of the MLL gene displayed EID1 expression levels 
comparable to that of MLL-rearranged cases. Hence, elevated EID1 expression 
cannot be ascribed to the presence of the MLL fusion protein, which was to be 
expected as MLL fusion proteins do not seem to bind to the genomic region 
where the EID1 gene resides. 20, 21 Moreover, the consistent up-regulation of EID1 
in infant ALL can neither be explained by a commonly shared and specific 
immunophenotype. In contrast to CD10 positive common/precursor BCP-ALL cells 
from children older than 1 year of age, MLL-rearranged infant ALL cells usually 
display a pro-B (i.e. CD10-) phenotype. However, like precursor BCP-ALL cells in 
older children, infant ALL cells lacking translocations of the MLL gene, often 
display common/pre-B (CD10+) phenotypes. In line with this, throughout normal 
B-cell differentiation, no particular compartment seems to exhibit signs of 
differential expression of EID1. 22 Thus, at this point the etiology of high-level EID1 
expression in infant ALL remains obscure, yet as a therapeutic target its potential 
seems evident, as repression of EID1 immediately triggers leukemic cell death and 
cell cycle arrest. 
Unfortunately, still little is known on the expression or role of EID1 in human 
disease. One study demonstrated an association of increased nuclear 
translocation of EID1 with the pathogenesis of Alzheimer’s disease, 23 and another 
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study found a correlation of EID1 expression with the malignant potential of 
intraductal papillary mucinous neoplasms of the pancreas.24 To the best of our 
knowledge, this is the first study reporting on EID1 expression in hematological 
cell types or hematologic disorders. 
Normally, EID1 protein is able to block the histone acetyltransferase activity of 
EP300, and with that inhibits differentiation 11, 12. Overrepresentation of EID1 in 
infant ALL cells may therefore have contributed to a block in differentiation 
required for leukemic transformation. However, our data showed that MLL-
rearranged ALL cells require EP300, as knockdown of this protein immediately 
triggers massive induction of leukemic cell death. Therefore, it seems unlikely that 
EID1 is inhibiting EP300 in MLL-rearranged ALL, as these cells apparently are 
highly dependent on functional EP300.  
Apart from inhibitory actions on EP300, EID1 has also been reported to bind to 
retinoblastoma protein (RB), and with that inhibiting differentiation by preventing 
the activation of tissue-specific transcription.11 To date it remains unclear whether 
RB binds to E2F and EID1 simultaneously, and thereby integrating cellular stimuli, 
or whether E2F and EID1 interact with RB separately.25 Although our data is 
limited, the here observed down-regulation of E2F-regulated genes upon 
repression of EID1, at least suggests integrated actions of EID1 and E2F. Thus, in 
MLL-rearranged ALL cells, the function of EID1 as a regulator of E2F-related genes 
seems more important than the inhibition of the HAT activity of EP300. Yet, 
elucidating the exact function of EID1 in infant ALL cells using knock-down 
experiments will proof to be difficult due to the rapid and severe induction of 
leukemic cell death. Perhaps the introduction of high-level EID1 expression in 
normal B-cell progenitors may be more informative. Nonetheless, our data 
indisputably demonstrate that MLL-rearranged ALL cells require EID1, and fail to 
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sustain viability when EID1 is repressed. Obviously, this makes EID1 an attractive 
therapeutic target in (MLL-rearranged) infant ALL, and warrants further studies 
exploring the possibility of developing small molecule inhibitors targeting EID1.   
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SUMMARY AND GENERAL DISCUSSION 
 
Survival rates for pediatric acute lymphoblastic leukemia (ALL) have greatly 
increased over the last decades, and nowadays approaches 90%.1 Despite great 
efforts, the survival rates for infant (<1 year of age) acute lymphoblastic leukemia 
(ALL) to date is still poor with an overall survival of 55%.2 Neonatal (<1 month of 
age) ALL and neonatal AML are rare. Etiology, symptoms, diagnosis, treatment 
and prognosis are extensively reviewed in chapter 2. 
Chapter 3 elaborates on neonatal ALL. Analysis of thirty patients with neonatal 
ALL treated with the uniform Interfant-99 protocol shows that neonatal ALL was 
characterized by a significantly higher white blood cell count, a trend towards a 
higher incidence of MLL gene rearrangements, and a CD10-negative B-lineage (i.e. 
pro-B) immunophenotype than ALL in older infants. All of these factors are 
associated with a dismal outcome. A higher relapse rate in neonatal ALL was 
demonstrated, also after adjustment for these risk factors. Hypothetically, the 
high relapse rates can be explained by the administration of reduced 
chemotherapy dosages in these very young patients in the fear of severe side-
effects. As pharmacokinetic studies in this particular population are very limited, 
determination of the right dosage represents a challenge. Both the Interfant-99 
study7 and the AML-BFM-98/-200441 apply dose reductions in their protocol. This 
study demonstrates an long term survival of 17%, and we therefore advocate 
treating neonatal ALL with curative intent. Early death in complete remission and 
treatment delays due to toxicity did not differ from that in older infant ALL 
patients, which may allow for dose intensification in neonates diagnosed with ALL. 
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Despite the strong association of the occurrence of MLL translocations in infant 
ALL patients, ~20% of all infant ALL cases carry wild-type (or germline) MLL genes.  
Chapter 4 shows that wild-type MLL infant ALL carries a different gene expression 
profile from that of MLL-rearranged infant ALL as well as from pediatric precursor 
BCP-ALL. In the current Interfant-06 protocol, infant ALL patients carrying wild-
type MLL genes are treated uniformly, stratified as a low-risk group. However, in 
chapter 5 we demonstrate that these wild-type MLL infant ALL patients form a 
distinct but very heterozygous patient group for which very few recurrent genetic 
abnormalities can be identified. A subgroup of the wild-type MLL infant ALL 
patients shows homology with the high-risk MLL infant ALL patients with high-
level expression of MEIS1 and an immature pro-B phenotype. We show that high-
level expression of MEIS1 predicts poor outcome, and low-level expression of 
MEIS1 predicted an EFS of 100% in wild-type MLL infant ALL patients. If this can be 
confirmed in an independent set of patients we suggest a novel risk stratification 
strategy in which the expression of MEIS1 serves as a stratifier for this particular 
sub-group of patients. Currently, wild-type MLL infant ALL patients are by default 
treated as low risk infant ALL patients. Using MEIS1 as a risk stratifier, treatment 
can potentially be more individualised with ultimately a lower toxicity profile for 
the good prognosis group and improved survival for the high-risk group with high-
level expression of MEIS1 using an intensified treatment protocol. Alternatively, 
improving survival for this particular group would involve better targeted 
treatment rather than more intensive treatment. MEIS1 has previously been 
demonstrated to be important in the oncogenicity of MLL-rearranged leukemia.3, 4 
The down-regulation of MEIS1 in leukemic cell lines impaired engraftment in 
NOD/SCID mice and reduced proliferation.4, 5 These data suggest that both MLL-
rearranged infant ALL as well as wild-type MLL infant ALL patients may benefit 
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from MEIS1 inhibition. To date there is no known effective inhibitor of MEIS1, and 
a differential gene expression analysis between patients with high MEIS1-
expression and patients with low MEIS1-expression did not identify obvious 
downstream effectors that can be targeted. The discovery of an effective small 
molecule inhibitor of MEIS1 should therefore now be the next step studying the 
potency of targeting MEIS1.  
 
Infant ALL is still in urgent need for more optimal, targeted treatment strategies. 
Despite an intensive 2-year treatment protocol for these very young children, 
overall survival of MLL-rearranged infant ALL is around 50%. Despite good initial 
responses to current therapies, high relapse rates in these infants contribute 
greatly to an overall poor prognosis.2 In search for new targets for therapy, 
current literature focuses on the biology of MLL-fusion driven gene expression 
and direct MLL-fusion protein binding sites. We hypothesise that MLL-rearranged 
leukemia is not per se dependent solely on such direct targets. We earlier showed 
that that for example S100A8/S100A9, which is not a direct target of MLL-AF4, 
induces prednisolone resistance and S100A8/S100A9 inhibitors may improve 
outcome in MLL-rearranged ALL.6 Also additional genetic events may be involved 
in the oncogenicity such as RAS mutations.7 Indirect targets may further 
potentially contribute to the oncogenicity of MLL-rearranged leukemia. In search 
for new targets for therapy, we used gene expression profiling before and after 
RNA interference mediated knockdown of the MLL-fusion for the identification of 
a novel set of genes influenced by the presence of the MLL-fusion protein 
(chapter 6). Interestingly, the set of obtained genes that rapidly responded to the 
loss of the MLL fusion protein was enriched for hypermethylated promoter 
regions in t(4;11) and t(11;19) infant ALL patients. Our group earlier demonstrated 
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that aberrant DNA methylation is abundant in MLL-rearranged infant ALL.8 The 
rapid activation of these genes after removal of the MLL-fusion protein suggests a 
direct role of the MLL-fusion protein in the inactivation of these genes through 
hypermethylation. Possibly, the inactivation of these genes is part of the 
leukemogenicity of the MLL-fusion. For example, NKX2 homeobox 1 (NKX2.1) is 
hypermethylated in the presence of the MLL-fusion protein and becomes 
upregulated after the removal of the MLL-fusion protein. NKX2.1 is besides a 
known oncogene also a recognized suppressor of malignant progression.9 The 
inactivation of NKX2.1 by the MLL-fusion protein could possibly contribute to 
tumor progression. Reactivation of NKX2.1 may contribute to suppression of 
tumor progression in MLL-rearranged leukemia. The various ways in which the 
MLL-fusion can exert its’ leukemogenic gene expression other than through direct 
DNA binding thus generates interesting new treatment strategies to explore. 
Similarly, we used the approach to reveal direct and indirect effects on gene 
expression through the AF4-MLL fusion protein. Besides the value of this gene set 
as source for discovering new targets for treatment of a subset of t(4;11) infant 
ALL patients, this particular set might also be of value shedding light on the role of 
the AF4-MLL protein in the initiation of t(4;11) infant ALL. It has been proposed 
that AF4-MLL is indispensable for the initiation of t(4;11) leukemias as the AF4-
MLL protein was able to induce leukemia without the requirement of the 
reciprocal MLL-AF4 protein,10 but this achievement has yet to be reproduced. 
Careful examination of this particular set of genes can possibly contribute to a 
better understanding of the biology underlying this protein. 
An important note to make, when discussing the search of new treatment 
strategies in MLL-rearranged ALL, is that there is no good mouse model available. 
Despite various attempts by several laboratories, there are still no mice faithfully 
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imitating the origin of the disease. Results vary from no leukemogenesis at all11 to 
a too long latency time12 or a B-cell ALL phenotype that differs from the pro-B 
phenotype in MLL-rearranged ALL.13, 14 Therefore we chose to identify the 
important players in MLL-rearranged ALL by the use of knockdown models and 
consecutive gene expression profiling. Nevertheless, we are aware of the 
outweighing results a proper mouse model would bring to this field.  
 
Following through on the gene expression profiles derived from chapter 6, in 
chapter 7 we validated the functional role of CDK6, one of the genes influenced 
by the presence of the MLL-fusion protein in MLL-rearranged ALL. As we show 
dependency of proliferation of MLL-rearranged ALL cell lines on CDK6, we suggest 
PD0332991, a CDK4/CDK6-inhibitor, as potential drug in the treatment of MLL-
rearranged ALL. The next critical step in studying the role of CDK6 in MLL-
rearranged ALL is testing the efficacy of PD0332991 in a xenograft mouse model 
of MLL-rearranged ALL before testing such a drug in the clinic. As PD0332991 
induces a cell cycle arrest but not apoptosis, we propose testing this drug as part 
of chemotherapy regimen rather than as monotherapy. Due to the necessity of 
cell cycling for the cytotoxic effect of many of the chemotherapeutics used in ALL, 
this drug ideally should be combined with a drug able to induce cell death in non-
cycling cells. Recently, it was reported that CDK6 is also a critical effector of MLL 
fusions in acute myeloid leukemia and knockdown of CDK6 could successfully be 
mimicked with PD0332991.15 Combined efforts of research in MLL-rearranged ALL 
and MLL-rearranged AML research would possibly fasten bringing this promising 
drug to the clinic. 
Another interesting target for treatment in MLL-rearranged ALL is EID1 as 
described in chapter 8. EID1 is highly expressed in both leukemic cells of MLL-
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rearranged ALL patients and wild-type MLL infant ALL patients, and turns out to 
be critical for sustained growth in MLL-rearranged ALL cell lines. EID1 therefore 
appears to be a good therapeutic target for the development of new treatment 
strategies in infant ALL, even though we have very little understanding of the 
working mechanism of EID1 in this type of leukemia.  
Several initiatives are being deployed to search for new specific therapeutic 
compounds. A promising initiative is the Connectivity Map database,16 (or cmap) 
which is a collection of genome-wide transcriptional expression data from four 
different cultured human cells treated with over 1300 bioactive small molecules. 
Through the search of common gene-expression changes, it enables the discovery 
of drug candidates. This technique can possibly form the hub in translational 
research between gene expression profiling and the discovery of drugs targeting 
genes of interest. The value of cmap was demonstrated by our group by the 
identification of PI3K inhibitors17 and HDAC inhibitors18 in infant acute 
lymphoblastic leukemia.  
Alternatively, our group is currently applying a drug library-based identification of 
therapeutics that potentiate the treatment of MLL-rearranged infant acute 
lymphoblastic leukemia. This drug library consists of readily tested and approved 
therapeutics available in the clinic. By testing which of these therapeutics are able 
to effectively and specifically eliminate MLL-rearranged infant leukemic cells, we 
possibly find in a revolved manner the compounds that are activating or 
deactivating those genes responsible for the initiating and maintaining the 
leukemia. Moreover, this would reach the final goal of finding a targeted 
treatment for this poor-prognosis disease that is MLL-rearranged infant ALL. 
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In conclusion, infants suffering from acute lymphoblastic patients are in need for 
better treatment strategies. Gene expression profiling creates a powerful tool for 
screening for new treatment targets as shown in this thesis. Translation from  the 
laboratory into the clinic remains a major challenge though various initiatives are 
undertaken to reduce the distance. Nevertheless continued research that bridges 
these potential treatment targets and a drug available in the clinic is still urgently 
needed.  
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NEDERLANDSE SAMENVATTING VOOR DE NIET-INGEWIJDE 
 
LEUKEMIE 
 
Bloed wordt gemaakt in het beenmerg, dat zich bevindt in de lange pijpbeenderen 
van het lichaam. Een moederbloedcel begint te delen en bij elke deling 
veranderen de eigenschappen van de cel tot er geleidelijk verschillende soorten 
bloedcellen zijn, onder andere witte en rode bloedcellen. Als de bloedcellen rijp 
zijn, worden ze vanuit het beenmerg naar de bloedvaten getransporteerd. De 
rode bloedcellen zorgen dan bijvoorbeeld dat er zuurstof naar de weefsels en 
organen wordt gebracht en de witte bloedcellen zorgen voor de afweer van het 
lichaam tegen bacteriën en virussen. Soms ontstaan er bij deze delingen in het 
beenmerg fouten in het DNA, de code die de cel aanstuurt. Fouten in het DNA 
kunnen ervoor zorgen dat de bloedcel niet meer stopt met delen. Zo ontstaat 
leukemie, kanker van bloedcellen. Bij kinderen is er meestal sprake van een 
bepaald soort leukemie, zogenaamde acute lymfatische leukemie (ALL).  
 
 
ZUIGELINGENLEUKEMIE 
 
Heel soms komt acute leukemie ook voor bij kinderen jonger dan 1 jaar (ofwel 
zuigelingen), we spreken dan over zuigelingenleukemie. In Nederland zijn er 
ongeveer vier tot vijf kinderen per jaar die de diagnose zuigelingenleukemie 
krijgen. Zuigelingenleukemie is in veel opzichten anders dan de leukemie die 
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oudere kinderen krijgen. Zo overleeft slechts ongeveer de helft van de zuigelingen 
hun ziekte, terwijl dit ruim 80% is bij de kinderen met ALL ouder dan 1 jaar. Ook 
de fouten in het DNA van de leukemiecel zijn bij zuigelingen anders dan bij oudere 
kinderen. Zo is er bij ongeveer 80% van de zuigelingen met ALL sprake van een 
breuk in het zogenaamde MLL-gen, terwijl dit slechts bij 1% van de kinderen 
boven de 1 jaar het geval is. Een gen is een code in de cel die beschrijft hoe een 
eiwit voor de cel gemaakt moet worden. Als het gebroken MLL-gen aan een ander 
gen bindt, ontstaat er dus een foute code en daarmee een fout eiwit. Dit foute 
eiwit kan aanleiding geven tot een ongecontroleerde deling van de witte bloedcel 
en daarmee oorzaak zijn van leukemie. In zuigelingenleukemie zien we 
bijvoorbeeld het MLL-AF4 eiwit, waarbij een stuk van het gebroken MLL-gen vast 
is komen te zitten aan het AF4-gen. Er zijn sterke aanwijzingen dat dit MLL-AF4 
combinatie-gen de oorzaak is van de agressieve vorm van leukemie bij 
zuigelingen.  
In een van de vijf zuigelingen komt zo’n fout MLL-eiwit echter niet voor. Er wordt 
vaak gedacht dat deze jonge kinderen een leukemie hebben die lijkt op die van 
oudere kinderen met leukemie, maar dit is nooit goed uitgezocht. Deze kinderen 
zonder fout MLL-eiwit hebben wel een betere overlevingskans van ongeveer 80%. 
Sommige zuigelingen krijgen al binnen een maand na de geboorte de diagnose 
leukemie, ook wel neonatale leukemie genoemd. Er wordt onder artsen vaak 
gedacht dat deze hele jonge kinderen altijd dood gaan en artsen zijn vaak bang 
om bij deze kinderen intensieve chemotherapie te geven. Echter, omdat het zo 
weinig voorkomt is eigenlijk niet goed bekend of en hoe deze kinderen behandeld 
moeten worden.  
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OP NAAR NIEUWE THERAPIE VOOR MLL-HERSCHIKTE 
ZUIGELINGENLEUKEMIE 
 
We zoeken naar een therapie die beter de leukemiecellen doodt, zonder de 
gezonde cellen te beschadigen. Hiermee willen we de overlevingskansen van 
kinderen met de diagnose zuigelingenleukemie verbeteren.  
Door speciale technieken te gebruiken in het laboratorium kunnen we zien hoe 
actief een gen in een cel is. Dit noemen we de genexpressie van de cel. Als we de 
genexpressie van leukemiecellen met een MLL herschikking vergelijken met 
leukemiecellen van oudere kinderen met ALL, met leukemiecellen van zuigelingen 
zonder MLL herschikking, en met gezonde beenmergcellen, zien we grote 
verschillen tussen welke genen aan en uit staan in de deze cellen. Door te 
vergelijken welke genen aan en uit staan in de leukemiecel met MLL herschikking, 
kunnen we beter begrijpen hoe de leukemie ontstaat en betere 
aanknopingspunten vinden om nieuwe en vooral meer specifieke 
behandelmethoden te ontwikkelen voor deze vorm van leukemie.  
 
 
NEONATALE LEUKEMIE 
 
Hoofdstuk 2 beschrijft wat er tot nu toe bekend is over neonatale leukemie. Er 
bestaat neonatale acute myeloide leukemie (AML) en neonatale ALL. Het verschil 
tussen myeloide en lymfatische leukemie zit hem in het type witte bloedcel dat 
ongecontroleerd is begonnen met delen en leukemiecel is geworden. Neonatale 
AML heeft een betere prognose dan neonatale ALL. De eerste symptomen van 
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neonatale leukemie zijn vaak een vergrote lever en milt, en huidafwijkingen. In 
het bloed worden grote hoeveelheden leukemiecellen gezien. Ook bij neonatale 
leukemie is er vaak sprake van een breuk in het MLL-gen. Het wordt behandeld 
met chemotherapie, maar vaak komen de leukemiecellen ondanks de therapie 
snel weer terug. Hoofdstuk 3 gaat dieper in op neonatale acute lymfatische 
leukemie. Het beschrijft de data van een dertigtal kinderen met de diagnose ALL 
jonger dan 1 maand, welke zijn gevolgd en behandeld in de internationale 
Interfant-99 studie. We zagen dat 20% van deze kinderen met neonatale ALL na 
twee jaar na diagnose nog in leven was. Dit geeft voldoende reden om deze 
kinderen ondanks hun jonge leeftijd toch intensieve chemotherapie te geven.  
 
 
GENEXPRESSIE IN ZUIGELINGENLEUKEMIE 
 
Hoofdstuk 4 laat zien dat in de cellen van zuigelingen met een fout MLL-eiwit 
andere genen tot expressie komen dan in gezonde beenmergcellen, maar ook 
komen andere genen tot expressie vergeleken met leukemiecellen van oudere 
kinderen en leukemiecellen van zuigelingen zonder fout MLL-eiwit. De genen die 
aan en uit worden gezet in deze cellen dragen mogelijk bij aan het feit dat de cel 
niet meer kan stoppen met delen en/of ongevoelig zijn voor de huidige 
chemotherapie. Verder onderzoek naar deze genen moet helpen een betere 
therapie te vinden om kinderen met zuigelingenleukemie te genezen.  
 
10.6 Zuigelingenleukemie zonder MLL-herschikking 
Een op de vijf zuigelingen met leukemie, heeft geen foutief MLL-eiwit. Er wordt 
vaak gedacht dat de leukemie bij deze kinderen lijkt op de leukemie bij kinderen 
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ouder dan 1 jaar. In hoofdstuk 5 laten we echter zien dat deze vorm van leukemie 
verschilt van de leukemie bij oudere kinderen en ook verschilt van 
zuigelingenleukemie met een foutief MLL-eiwit. Er zijn bijvoorbeeld minder vaak 
afwijkingen in het DNA bij deze kinderen dan bij oudere kinderen. Ook is minder 
goed te voorspellen bij welke van deze kinderen de leukemiecellen terugkomen 
na behandeling. Als een bepaald gen, genaamd MEIS1, erg actief is bij deze groep 
zuigelingen, komt de leukemie veel vaker terug na behandeling dan als dit gen 
minder actief is. Verder onderzoek naar dit gen kan wellicht bijdragen aan het 
vinden van een betere therapie voor deze kinderen. 
 
 
DE CEL NA HET UITZETTEN VAN HET FOUTE MLL-GEN 
 
In het laboratorium kunnen soms cellen afkomstig van patiënten ook buiten het 
lichaam gekweekt worden; gekweekte cellen worden ook wel cellijnen genoemd. 
In deze cellijnen kunnen we met behulp van virus als boodschapper van RNA naar 
de kern van de cel, genen aan en uit zetten. In hoofdstuk 6 zetten we met behulp 
van zo´n virus met een specifiek stukje RNA in drie cellijnen het foute MLL-gen uit. 
Door hierna te bekijken welke genen aan- en uitgaan, hopen we te begrijpen hoe 
de MLL herschikking bijdraagt aan het ontstaan van de leukemie. Een voorbeeld 
van zo’n gen wat beïnvloedt wordt door het herschikte MLL-gen is cyclin-
dependent kinase 6 (CDK6). Het CDK6-eiwit zorgt ervoor dat een cel kan blijven 
delen. In cellen met het foute MLL-eiwit staat CDK6 hoog aan en als we de MLL-
herschikking in de cellijnen uitzetten, gaat CDK6 ook uit. Het lijkt er dus op dat het 
foute MLL-eiwit zorgt dat CDK6 aan en uit gaat. Met andere woorden, de MLL 
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herschikking lijkt het CDK6 gen te gebruiken om ongecontroleerd te kunnen 
delen. 
 
 
CDK6 IN MLL-HERSCHIKTE ZUIGELINGENLEUKEME 
 
In hoofdstuk 7 wordt dieper ingegaan op hoe CDK6 bijdraagt aan de leukemie in 
patiënten met een fout MLL-eiwit. In cellijnen met het foute MLL-eiwit hebben we 
het CDK6-gen uitgezet. Hierop gingen de cellen veel langzamer delen, hoewel het 
MLL-eiwit nog gewoon aanwezig was. Dit wijst erop dat het foute MLL-eiwit onder 
andere leukemie veroorzaakt door het CDK6-gen aan te zetten. Als we de cellijnen 
met het foute MLL-eiwit behandelden met een medicijn, genaamd PD0332991, 
dat in staat is het CDK6 eiwit te remmen, bleken deze veel minder snel te groeien. 
Verder onderzoek zal moeten laten zien of dit medicijn ook in muizen de groei van 
leukemie kan remmen. Als dat zo is, zou dat medicijn vervolgens in zuigelingen 
met leukemie onderzocht kunnen worden.  
 
 
EID1 IN MLL-HERSCHIKTE ZUIGELINGENLEUKEMIE 
 
Ook EID1 is een voorbeeld van een gen dat hoog aanstaat in zuigelingenleukemie, 
maar niet in oudere kinderen met ALL of in gezonde beenmergcellen. In 
hoofdstuk 8 laten we zien dat als we het EID1-gen uitzetten in cellijnen, de 
leukemiecellen stoppen met delen en zelfs dood gaan. We denken daarom dat 
EID1 een belangrijke rol zou kunnen spelen in een nieuwe behandeling van 
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zuigelingenleukemie. Omdat EID1 een relatief onbekend eiwit is, hebben we (nog) 
geen medicijnen die EID1 kunnen remmen. We vinden daarom dat verder 
onderzoek naar dit eiwit erg belangrijk is.  
 
 
CONCLUSIE 
 
Concluderend is het nog steeds hard nodig dat er nieuwe behandelingen komen 
voor een betere overleving van zuigelingen met leukemie. Het bestuderen van 
welke genen aan en uit staan in zuigelingenleukemie heeft ons erg geholpen om 
te snappen welke genen belangrijk zijn voor de leukemie zoals blijkt uit dit 
proefschrift. Echter, het blijft erg moeilijk om de stap te maken van ontdekkingen 
in het laboratorium naar een werkzaam medicijn dat gegeven kan worden aan 
kinderen. Het blijft daarom belangrijk om verder onderzoek te doen dat deze 
afstand tussen het laboratorium en de kliniek overbrugt. 
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dan eens hebben we (soms wel heel duistere) kanten ontdekt aan onszelf, 
waardoor ik ook mezelf beter heb leren kennen afgelopen jaren. Naast dat ik je 
(uiteraard) een enorm gezellige collega vind, vind ik je ook nog eens een heel 
goede onderzoeker met een hele kritische kijk op je data. Meer dan 
vanzelfsprekend behoor jij dan ook mijn paranimf te zijn vandaag! 
MTQ, unique, magnifique en heel ludique (?), ik ben zo blij dat ik met jullie mijn 
studententijd heb mogen doen! Met deze periode toch maar mooi in de pocket, 
kan ik nu het serieuzere leven aan, waar onder andere het schrijven van dit boekje 
het resultaat van is. Dat we later als oude vrouwtjes maar weer aan het strand van 
Salou, Llorret da Mar of Miami (..misschien nu wel echt Florida ) mogen liggen! 
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Lieve familie, hoe truttig het dan ook moge klinken, ik voel me oprecht gezegend 
met een familie waarin het (meestal) enorm gezellig is, heftig gediscussieerd kan 
worden zonder ruzie te maken en waarin iedereen ook nog eens echt altijd voor 
elkaar klaar staat. Door jullie ben ik opgegroeid tot iemand die redelijk met twee 
benen op de grond staat, wat meer dan wie of wat dan ook ten grondslag ligt aan 
dit boekje. Lieve mama, zonder jou was ik nu nooit zo gelukkig geweest!  
Lieve Tiede-Jan, hier dan het resultaat van waar ik zes jaar lang mee bezig ben 
geweest en waar jij de afgelopen drie jaar niet meer naar hebt mogen vragen. 
Hoewel dit boekje er vast ook wel had gekomen zonder jou, door jou is het leuk 
gebleven, ook als we tussendoor besluiten nog een huis te verbouwen (óns huis!) 
of na maanden slaaptekort door een nieuw klein meisje in ons leven. Samen 
kunnen wij alles! Lieve Saar en Sophie, jullie zijn met stip het beste wat ik ooit 
bereikt heb! 
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SUPPLEMENTAL MATERIAL CHAPTER 4 
 
Table 1. Patient characteristics 
# Chip name / 
color code 
MLL 
translocation 
age 
(months) 
sex Immuno- 
Phenotype 
1 1488_4-11 t(4;11) 4.21 female pro-B 
2 1227_4-11 t(4;11) 10.28 female pro-B 
3 1442_4-11 t(4;11) 1.94 male pro-B 
4 VU9815_4-11 t(4;11) 3.22 male pro-B 
5 1587_4-11 t(4;11) 0.62 female pro-B 
6 1776_4-11 t(4;11) 0.66 female pro-B 
7 178_4-11 t(4;11) 5.59 male pro-B 
8 1817_4-11 t(4;11) 0.00   B-lineage not 
specified 
9 1966_4-11 t(4;11) 1.91 female pro-B 
10 1977_4-11 t(4;11) 6.41 female pro-B 
11 1990_4-11 t(4;11) 6.44 male pro-B 
12 2582_4-11 t(4;11) 1.61 female pro-B 
13 2864_4-11 t(4;11) 0.79 female pro-B 
14 300_4-11 t(4;11) 6.83 female B-lineage not 
specified 
15 3218_4-11 t(4;11) 8.05 male pre-B 
16 3230_4-11 t(4;11) 5.91 female pro-B 
17 3595_4-11 t(4;11) 3.45 male pro-B 
18 3686_4-11 t(4;11) 1.87 female pro-B 
19 3814_4-11 t(4;11) 1.61 male pro-B 
20 385_4-11 t(4;11) 9.43 female pro-B 
21 3980_4-11 t(4;11) 3.09 female pro-B 
22 3939_4-11 t(4;11) 1.22 female pro-B 
23 4669_4-11 t(4;11) 0.00 female pro-B 
24 4190_4-11 t(4;11) 4.37 male pro-B 
25 4757_4-11 t(4;11) 0.00 female pro-B 
26 4773_4-11 t(4;11) 0.00 female pro-B 
27 929_4-11 t(4;11) 3.58 male pro-B 
258                                                                                           
 
 
28 788v_4-11 t(4;11) 9.43 female pro-B 
29 635_4-11 t(4;11) 2.83 male pro-B 
30 vr39_11-19 t(11;19) 7.72 male pro-B 
31 1037_11-19 t(11;19) 8.77 female common 
32 1060_11-19 t(11;19) 5.72 female pre-B 
33 1191_11-19 t(11;19) 9.10 male pre-B 
34 1225_11-19 t(11;19) 3.65 female common 
35 1679_11-19 t(11;19) 2.30 female pro-B 
36 1702_11-19 t(11;19) 11.01 male pro-B 
37 2009_11-19 t(11;19) 0.00 female pro-B 
38 2458_11-19 t(11;19) 6.01 female pro-B 
39 2346_11-19 t(11;19) 3.35 female pro-B 
40 2146_11-19 t(11;19) 5.65 female pro-B 
41 2571_11-19 t(11;19) 0.00 male B-lineage not 
specified 
42 3922_11-19 t(11;19) 4.14 male common 
43 3831_11-19 t(11;19) 2.00 female pre-B 
44 4483_11-19 t(11;19) 0.00 male B-lineage not 
specified 
45 54_11-19 t(11;19) 3.09 female pro-B 
46 474_11-19 t(11;19) 0.00 male B-lineage not 
specified 
47 668_11-19 t(11;19) 0.03 female pro-B 
48 618_11-19 t(11;19) 5.39 male pro-B 
49 711_11-19 t(11;19) 10.74 male pro-B 
50 743_11-19 t(11;19) 7.79 male pre-B 
51 888_11-19 t(11;19) 5.32 female pro-B 
52 148_9-11 t(9;11) 0.36 female B-lineage not 
specified 
53 1501_9-11 t(9;11) 10.25 female pro-B 
54 1656_9-11 t(9;11) 6.01 female pre-B 
55 2088_9-11 t(9;11) 11.66 male pro-B 
56 3921_9-11 t(9;11) 4.14 male B-lineage not 
specified 
57 4919_9-11 t(9;11) 0.00 male B-lineage not 
specified 
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58 620_9-11 t(9;11) 9.82 female pre-B 
59 656_9-11 t(9;11) 4.21 male pre-B 
60 2249_germline MLL germline 6.34 female B-lineage not 
specified 
61 2624_germline MLL germline 11.33 female pre-B 
62 2807_germline MLL germline 11.07 male pre-B 
63 3310_germline MLL germline 0.00 male B-lineage not 
specified 
64 382_germline MLL germline 0.00 female B-lineage not 
specified 
65 4159_germline MLL germline 2.53 male pre-B 
66 4927_germline MLL germline 0.00 male B-lineage not 
specified 
67 512_germline MLL germline 5.49 male pre-B 
68 560_germline MLL germline 5.98 male pre-B 
69 1093_germline MLL germline 0.00 male B-lineage not 
specified 
70 682_germline MLL germline 5.95 male pre-B 
71 824_germline MLL germline 9.07 male pro-B 
72 943_germline MLL germline 7.36 female pre-B 
73 927_germline MLL germline 8.97 female pre-B 
74 3663_B-ALL MLL germline 64.56 female common 
75 3665_B-ALL MLL germline 182.4 male pre-B 
76 3700_B-ALL MLL germline 44.04 female pre-B 
77 3708_B-ALL MLL germline 52.32 male pre-B 
78 3716_B-ALL MLL germline 26.88 male common 
79 3720_B-ALL MLL germline 25.2 female common 
80 3738_B-ALL MLL germline 65.76 female common 
81 3739_B-ALL MLL germline 101.64 male pre-B 
82 3740_B-ALL MLL germline 13.92 male pre-B 
83 3744_B-ALL MLL germline 28.2 female pre-B 
84 3752_B-ALL MLL germline 62.04 male pre-B 
85 3753_B-ALL MLL germline 184.56 male pre-B 
86 3754_B-ALL MLL germline 51.84 female common 
87 3769_B-ALL MLL germline 92.28 male common 
88 3791_B-ALL MLL germline 52.32 female common 
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89 3799_B-ALL MLL germline 58.32 male pre-B 
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Table 2. Probe set IDs, gene names, log-fold changes and p-values, ALL samples 
Gene name HU133plus2.0 
probe ID 
logFC adj. p-value 
(FDR<0.01) 
CD10 203434_s_at -3.49466 1.90E-13 
DKFZP586H0519 203593_at -1.7241 1.16E-06 
CD24 209772_s_at -1.87863 2.09E-05 
DYRK3 210151_s_at -0.72122 0.003989125 
KIAA0867 211789_s_at -1.92882 3.03E-11 
ITPR1 211323_s_at -1.09037 2.01E-06 
DNTT (TDT) 210487_at -2.11708 0.000680043 
SPTA1 206937_at -0.98777 2.62E-06 
CD22 204581_at -1.08489 0.000269759 
cDNA 13f12 (RBQ-1) 205178_s_at -0.89437 1.47E-06 
DKFZp564I083 215164_at -2.44457 1.40E-08 
FOXO1A 202723_s_at -1.26208 3.77E-06 
FHIT 206492_at -2.16086 3.53E-15 
MYH10 212372_at -0.99061 3.71E-08 
SPTBN1 215918_s_at -1.47501 2.21E-11 
LIG4 206235_at -1.20202 5.92E-08 
NPR1 204648_at -1.19589 3.08E-06 
PRKCH 206099_at -1.08029 1.12E-06 
PARD3 (qb92h04) 210094_s_at -1.58949 2.34E-10 
KIAA0959 (RGL1) 209568_s_at -0.73142 0.000176538 
TERF2 203611_at -0.24117 0.355355289 
ITPR1 203710_at -0.72207 0.001656473 
PIK3C2B 204484_at -0.22589 0.417294927 
MYLK 202555_s_at -2.00744 3.04E-10 
SPTAN1 208611_s_at -1.07247 5.45E-12 
Cosmid TN62 
(TNFSF3) 
207339_s_at -0.62413 0.043504 
ITPR3 201188_s_at -1.66796 8.32E-13 
POU2AF1 205267_at -0.69591 0.025510066 
MADH1 210993_s_at -3.36853 5.19E-12 
SMARCA4 212520_s_at -0.97677 1.02E-08 
HLA-DQB1 209480_at -0.3784 0.661531493 
KIAA0250 201794_s_at -0.18079 0.198515005 
APP (Amyloid A4) 214953_s_at -1.11575 6.60E-05 
MADH1 227798_at -2.93574 1.39E-08 
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LARGE 215543_s_at -1.55638 3.05E-07 
ZNF45 207304_at -0.53137 0.014406606 
DBN1 217025_s_at -0.98332 1.32E-06 
KIAA0212 203279_at -0.79365 3.41E-09 
ALOX5 204446_s_at -2.23795 1.03E-10 
KIAA0093 213012_at -0.17579 0.524138429 
Chromosome 1 PAC 207826_s_at -2.72038 4.01E-07 
cDNA wg66h09 207971_s_at -0.40222 0.003024465 
VAMP5 204929_s_at -0.32312 0.10523592 
cDNA YY38E04 213766_x_at -0.99807 0.000217517 
NEDDL4 212445_s_at -0.79196 4.57E-05 
LDOC1 204454_at -0.22459 0.482524024 
FGFR1 211535_s_at -1.38079 1.57E-10 
HLA-DQB1 211654_x_at -0.3086 0.351706056 
LGALS1 201105_at 3.410196 3.57E-16 
cDNAqf71b11 200872_at 2.303216 3.76E-18 
AHNAK 212992_at 0.194004 0.420820516 
NKG2D 205821_at 1.639294 1.11E-08 
CCNA1 205899_at 2.725713 1.18E-08 
CD44 212063_at 1.177711 2.95E-10 
PMX1 (PHOX1) 226695_at -0.27321 0.260110668 
KIAA0027 213395_at 0.894091 2.23E-05 
cDNA tn15f08cDNA 203781_at 1.585328 2.67E-13 
cDNA zd69b10 203186_s_at 1.812345 2.90E-15 
HOXA9 214651_s_at 3.57721 4.00E-06 
CD44 204490_s_at 1.006367 1.10E-05 
CD44 204489_s_at 0.699904 0.00128117 
Chromosome 7 
Clone 
213823_at 0.64659 0.029421521 
ANXA1 201012_at 1.939072 4.42E-08 
Chromosome X 
Clone 
205504_at 0.384011 0.051790236 
PTPRC (CD45) 212588_at 1.175792 2.97E-10 
CD44 212014_x_at 0.648347 0.002602935 
PTPRC (CD45) 207238_s_at 1.049341 1.73E-06 
LILRB1 229937_x_at 0.746738 0.00668284 
cDNA zd27g05 204122_at 1.016228 0.000274492 
RNASE3 206851_at 2.042179 1.47E-06 
SERPINB1 212268_at 1.194162 1.73E-07 
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PROML1 204304_s_at 3.376316 2.40E-10 
Chromosome 22 
sequence 
201105_at 3.410196 3.57E-16 
DKFZp586K1720 214752_x_at 0.779126 4.25E-06 
cDNA oq40b07 209610_s_at 0.701223 0.000133648 
KIAA0120 210978_s_at 0.644645 5.17E-06 
EBI2 205419_at 1.427619 0.000940803 
IGFBP7 201162_at 3.351629 4.32E-14 
ANXA2 208816_x_at 1.012687 2.84E-12 
DAD1 200046_at 1.674455 2.20E-08 
SCGF 211709_s_at 1.640905 2.11E-07 
cDNA qe04b02 203837_at 1.040053 8.32E-08 
MAP7 202890_at 2.55388 2.07E-08 
ITPA 209171_at 0.618455 0.000170319 
PRG1 213496_at 0.017213 0.949528842 
GLUD1 200947_s_at 0.631157 3.04E-08 
FEZ1 203562_at 1.155458 7.96E-05 
LILRA1 207872_s_at 0.545992 0.009583201 
KIAA0428 201153_s_at 1.281491 7.30E-19 
MT1B 217165_x_at 1.683759 1.18E-07 
HOXA5 213844_at 3.198684 4.27E-07 
DKFZp564A032 204502_at 1.666619 1.35E-09 
cDNA 03h03 212859_x_at 0.635986 0.06471336 
DKFZp586B2022 202720_at 1.664821 1.30E-09 
cDNA ou23f10 205081_at 2.27626 6.92E-12 
ANXA2P2 211241_at 0.828735 1.97E-05 
DKFZp586C1619 232624_at -0.37853 0.004537581 
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Table 3. Probe set IDs, gene names, log-fold changes and p-values, B-ALL 
samples 
Gene name U95A probe 
ID 
HU133plus2 
probe ID 
logFC adj. p-value 
(FDR<0.01) 
MBNL 34306_at 201153_s_at 1.281491 7.30E-19 
ADAM10 40797_at 202603_at 1.118213 2.77E-09 
LGALS1 33412_at 228416_at -0.07693 0.758135211 
S100A10 39338_at 200872_at 2.303216 3.76E-18 
IGFBP7 2062_at 204253_s_at -0.84478 6.55E-05 
PLXNC1 32193_at 206470_at 0.88019 0.000748791 
PTPRC 40518_at 212588_at 1.175792 2.97E-10 
D12S2489E 36777_at 205821_at 1.639294 1.11E-08 
MPP1 32207_at 202974_at -0.02838 0.907767139 
SAP18 33859_at 208741_at 0.52054 0.005668646 
CAPG 38391_at 201850_at 1.251809 8.46E-07 
MEIS1 40763_at 204069_at 4.199016 7.99E-28 
CD44 1126_at 212063_at 1.177711 2.95E-10 
FKBP5 34721_at 224840_at 1.220177 0.000124693 
HOXA9 37809_at 214651_s_at 3.57721 4.00E-06 
GOLGA3 34861_at 226949_at -0.05704 0.650787509 
IGKC 38194_s_at 224795_x_at -0.86087 0.000306183 
PCDHGC3 657_at 215836_s_at 0.651789 0.00113155 
GUCY1A3 36918_at 229530_at 0.665482 0.040991331 
KIAA0878 32215_i_at 225202_at 1.710707 1.24E-07 
LY75 38160_at 205668_at 1.12421 1.18E-05 
DAD1 38413_at 200046_at 1.674455 2.20E-08 
MME 1389_at 203434_s_at -3.49466 1.90E-13 
DNTT 34168_at 210487_at -2.11708 0.000680043 
CD44 2036_s_at 204490_s_at 1.006367 1.10E-05 
GLUL 40522_at 215001_s_at 0.666713 0.000791835 
BLK 854_at 206255_at 0.888812 4.53E-06 
ELF1 40067_at 212420_at -0.36957 0.078609658 
XBP1 39756_g_at 200670_at 0.043623 0.808221545 
TIAF1 36940_at 202039_at -0.71642 8.71E-06 
RASA1 36935_at 202677_at 0.276024 0.159642266 
DKFZP586B2022 32134_at 202720_at 1.664821 1.30E-09 
DKFZp586C1019 39379_at 212371_at 0.367991 0.006577485 
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CD44 40493_at 204489_s_at 0.699904 0.00128117 
ANXA2 769_at 208816_x_at 1.012687 2.84E-12 
ACAA1 40415_at 214274_s_at 0.50277 8.39E-05 
R32184_1 35983_at 209461_x_at 0.898273 0.000886448 
PTPRC 40519_at 212588_at 1.175792 2.97E-10 
PTPN6 794_at 206687_s_at 0.490544 0.005199699 
DNAJB6 41234_at 209015_s_at 0.700531 0.012168026 
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Table 4. Probe set IDs, gene names, log-fold changes and p-values corresponding 
to Fig. 2 
 
Gene name HU133plus2.0 
probe ID 
logFC adj. p-value 
(FDR<0.01) 
C20orf103 219463_at 5.086355852 5.19E-43 
MEIS1 1559477_s_at 4.202263797 3.49E-27 
MEIS1. 204069_at 4.199004835 3.65E-27 
MEIS1.. 242172_at 3.393844331 7.76E-25 
C16orf54 1559584_a_at 1.871648724 7.74E-20 
LGALS1 201105_at 3.479053576 5.94E-19 
MBNL 201153_s_at 1.291895405 7.81E-19 
S100A10 200872_at 2.302110256 2.88E-18 
IGFBP7 201163_s_at 3.341882785 1.65E-17 
CRI1 211698_at 1.464354162 1.74E-16 
COMMD8 218351_at 1.952872849 2.81E-16 
C20orf118 235529_x_at 2.289038674 1.05E-15 
SMT3H2 213879_at 0.852744138 1.52E-15 
ARPC3 208736_at 0.972323597 4.22E-15 
S100A4 203186_s_at 1.823768435 4.29E-15 
MBNL. 235879_at 1.359727641 4.29E-15 
LOC389203 225014_at 1.287510226 1.17E-14 
NDUFC2 206936_x_at 0.651835075 1.48E-14 
CTSC 225647_s_at 1.899361672 4.34E-14 
SRD5A1 204675_at 1.260205611 4.73E-14 
IGFBP7. 201162_at 3.374287701 7.02E-14 
SCP2 211733_x_at 1.251595913 7.31E-14 
RPL38 202028_s_at 0.878550714 7.67E-14 
MBNL.. 235173_at 1.085835956 8.82E-14 
MDS027 224575_at 0.992232272 9.30E-14 
CTSC. 201487_at 2.080800234 1.03E-13 
C19orf42 224717_s_at 0.927622926 1.03E-13 
KCNK12 220448_at 2.193352061 1.18E-13 
CLPTM1L 226935_s_at 0.769917526 1.30E-13 
NDUFC2. 222521_x_at 0.890885477 1.32E-13 
MVK 36907_at 0.570506672 1.42E-13 
HAAO 205657_at 0.903401219 2.39E-13 
TOR2A 227972_at 1.550603876 2.81E-13 
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KIAA0141 201978_s_at 0.710897378 3.37E-13 
C2orf1 203781_at 1.590817778 4.33E-13 
GHITM 209248_at 0.87751713 4.60E-13 
ITM2B 217731_s_at 1.01223592 5.32E-13 
Unknown 
(1570185_at) 
1570185_at 0.759764607 5.36E-13 
Unknown 
(235901_at) 
235901_at 1.300217381 6.28E-13 
Unknown 
(226789_at) 
226789_at 1.580648571 6.85E-13 
TLP19 223017_at 0.781353543 6.85E-13 
SNRPE 215450_at 1.072435973 7.48E-13 
RNAHP 213629_x_at 1.45165087 9.23E-13 
LOC54499 208716_s_at 1.468452539 1.06E-12 
COX7AP2 217249_x_at 0.906253199 1.08E-12 
PPAP2A 210946_at 1.054668698 1.13E-12 
SRP19 205335_s_at 0.817362746 1.42E-12 
COX7A2 201597_at 0.801864974 1.47E-12 
METTL7A 207761_s_at 1.687467961 1.48E-12 
FAM78A 227002_at 1.35316581 1.48E-12 
AKAP12 1555395_at -2.643127448 1.06E-22 
MYO5C 218966_at -1.305441477 2.64E-21 
SHANK3 227923_at -3.76397613 5.00E-21 
ZNF827 243618_s_at -3.167649282 1.04E-19 
AKAP12. 241679_at -3.212610217 2.64E-18 
AKAP12.. 227530_at -2.648595041 2.34E-17 
FHIT 206492_at -2.200485527 2.48E-17 
AKAP12… 210517_s_at -3.907135431 6.57E-17 
ZNF827. 228046_at -2.017206814 7.16E-17 
STK32B 219686_at -3.069238994 8.69E-17 
Unknown 
(244740_at) 
244740_at -2.198463872 1.97E-16 
Unknown 
(227388_at) 
227388_at -1.869299136 2.31E-16 
ZNF91 206059_at -1.411647206 2.66E-16 
Unknown 
(230441_at) 
230441_at -1.927226199 8.06E-16 
AKAP12…. 227529_s_at -2.416001719 9.12E-16 
Unknown 215028_at -2.511394633 2.20E-15 
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(215028_at) 
ZNF667 207120_at -2.116303401 2.20E-15 
ZNF667. 236635_at -1.345140336 2.81E-15 
ARID1A 210649_s_at -1.165698911 4.68E-15 
POMFIL3 224771_at -2.240146612 6.24E-15 
NFAT5 215092_s_at -2.104686291 6.63E-15 
ZNF827. 226764_at -2.232241484 7.74E-15 
EFNA1 202023_at -2.094204389 9.10E-15 
YES1 202932_at -2.625443852 1.18E-14 
CALN1 230698_at -2.258640782 1.18E-14 
UBL3 201534_s_at -1.37815028 2.58E-14 
APOL2 221013_s_at -1.363346757 3.12E-14 
PRKCZ 202178_at -2.581065357 4.71E-14 
MME 203434_s_at -3.530878734 5.94E-14 
POMFIL3. 224773_at -2.552668536 9.41E-14 
RASD1 223467_at -2.102175015 9.42E-14 
AKAP12….. 231067_s_at -2.574167828 1.04E-13 
DAGLB 225833_at -1.365151723 1.04E-13 
NYX 234496_x_at -1.412919122 1.17E-13 
DKFZp434P0235 231902_at -1.370237301 2.13E-13 
NAV1 224772_at -2.360986107 2.15E-13 
CALN1. 223885_at -2.148017117 2.17E-13 
YES1. 202933_s_at -2.743102242 2.44E-13 
GFOD1 219821_s_at -1.658227745 3.02E-13 
PDE4B 211302_s_at -1.806891159 4.33E-13 
Unknown 
(241816_at) 
241816_at -1.180486004 4.33E-13 
ANGPT2 211148_s_at -1.873862688 4.67E-13 
SPTB2 212071_s_at -1.426532627 4.67E-13 
DAGLB. 225832_s_at -1.098623437 5.14E-13 
SPTBN1 200671_s_at -2.343033058 5.36E-13 
CDC2L2 215329_s_at -0.968128295 6.55E-13 
POU4F1 211341_at -2.282947956 6.96E-13 
Unknown 
(244741_s_at) 
244741_s_at -1.780574222 7.91E-13 
RAB2 208730_x_at -0.784504074 8.05E-13 
CHD7 226123_at -1.183746619 1.12E-12 
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Table 5. Probe set IDs, gene names, log-fold changes and p-values corresponding 
to Fig. 4 
Gene name HU133plus2.0 
probe ID 
logFC adj. p-value 
(FDR<0.01) 
C20orf103 219463_at 4.496028591 4.64E-36 
MEIS1  204069_at 3.475319004 4.08E-22 
MEIS1 . 1559477_s_at 3.452660911 1.02E-21 
MEIS1 .. 242172_at 2.858976873 1.02E-21 
KCNK12 220448_at 2.284088949 4.37E-19 
LGALS1 201105_at 2.748692614 7.09E-17 
MBNL 201153_s_at 1.03307555 6.19E-15 
FLT3 206674_at 2.067097531 6.78E-15 
Unknown(243605_at) 243605_at 1.982931386 9.46E-15 
Unknown(204304_s_at) 204304_s_at 3.217498592 9.79E-15 
NUDT7 228855_at 1.658193543 3.62E-14 
CCNA1 205899_at 2.89291088 4.68E-14 
S100A10 200872_at 1.723441249 7.98E-14 
Unknown (234032_at) 234032_at 1.376165898 8.35E-14 
MBNL. 235173_at 0.854609698 1.10E-13 
IGFBP7 201163_s_at 2.475715661 1.11E-13 
MBNL.. 235879_at 1.197917647 1.11E-13 
FAM78A 227002_at 1.125156839 4.55E-13 
HSCP1 218217_at 1.160329207 5.99E-13 
NKG2D 205821_at 1.652298539 9.59E-13 
C20orf118 235529_x_at 1.660988391 1.07E-12 
METTL7A 207761_s_at 1.401316307 1.21E-12 
ZCCHC7 1555562_a_at 1.192352353 1.54E-12 
CPEB2 226939_at 1.49657958 1.75E-12 
GREM1 218468_s_at 2.773842337 1.85E-12 
CD44 212063_at 1.123775805 1.97E-12 
C20orf118. 1559883_s_at 1.367480064 2.41E-12 
Unknown (1552665_at) 1552665_at 1.327997132 2.42E-12 
VAT1L 226415_at 2.903226028 2.42E-12 
C11orf24 52164_at 0.701723316 2.88E-12 
PAN3 225563_at 0.997766635 3.42E-12 
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IGFBP7. 201162_at 2.640903861 3.97E-12 
RPL33L 203781_at 1.183702192 7.00E-12 
Unknown (226789_at) 226789_at 1.320430935 8.71E-12 
CORO1C 222409_at 1.295663476 1.52E-11 
TECT1 218584_at 0.947469049 1.79E-11 
CKLFSF3 224733_at 0.958636382 1.82E-11 
Unknown (1555392_at) 1555392_at 1.60386068 1.83E-11 
CD72 215925_s_at 1.810496724 2.39E-11 
C20orf118.. 204502_at 1.499926812 2.49E-11 
LOC219688 1559266_s_at 1.882003671 2.57E-11 
PPAP2A 210946_at 0.8079595 3.01E-11 
LOC219688. 1559265_at 1.647289119 3.14E-11 
MBNL… 1558111_at 1.154555727 3.14E-11 
Unknown (226413_at) 226413_at 0.646134752 3.27E-11 
MBNL…. 201152_s_at 0.920890371 3.53E-11 
RNASE6 213566_at 2.231902816 5.09E-11 
SERPINB1 213572_s_at 1.219791703 5.79E-11 
CPEB2. 235479_at 1.207289953 6.80E-11 
GREM1. 218469_at 2.625424931 6.83E-11 
PTRF 208789_at 0.886125075 7.16E-05 
SCD 200832_s_at 1.390183259 8.65E-05 
CMTM7 226017_at 1.051200988 0.000235686 
TNFSF3 207339_s_at 1.42215701 0.000299884 
P2Y14 206637_at 1.36502195 0.000390702 
HNRPLL 225386_s_at 1.30473207 0.000390702 
MYL4 210395_x_at 0.797261557 0.000390702 
SPEC2 224709_s_at 0.530992075 0.000390702 
PLEKHG4B 230671_at 1.093216829 0.000426285 
CMTM7. 235099_at 2.15475961 0.000436216 
WSB2 201760_s_at 0.696565857 0.000605921 
COBL 213050_at 0.964554956 0.001099439 
WSB2. 213734_at 0.634303395 0.001446517 
Deltex homolog 1 
(Drosophila) 
1559618_at 1.260813821 0.001524853 
Unknown (228528_at) 228528_at 0.62742243 0.001834701 
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SPEC2. 1552613_s_at 0.655077446 0.001958731 
NRN1 218625_at 1.524230398 0.002040378 
ELFN2 1559072_a_at 1.004144111 0.002040378 
MYL4. 216054_x_at 0.613076445 0.002208751 
CD158K 207314_x_at 1.071722302 0.002468029 
CASP8 213373_s_at 0.682993768 0.003067496 
WDR38 243900_at 0.501769801 0.003067496 
DOCK9 212538_at 1.051387026 0.004345185 
SH2D1A 211209_x_at 0.872446985 0.005107091 
SEC15L1 232599_at 0.768120099 0.005549215 
PRL3 206574_s_at 1.376636931 0.005653317 
REPIN1 219041_s_at 0.681680653 0.005754645 
RYK 202853_s_at 1.061888889 0.006104664 
T-cell receptor beta C 
gene segment 
211796_s_at 1.211717656 0.006677468 
SH2D4B 1563849_at 0.725902423 0.007191717 
KIR2DL1 210890_x_at 0.530675354 0.007271407 
Unknown (221773_at) 221773_at 1.207076779 0.00736279 
TP53INP1A 225912_at 1.533384709 0.007655558 
LZTS2 1555881_s_at 0.530522084 0.007902655 
ICAM3 204949_at 0.99224382 0.008007863 
CD27 206150_at 0.89864279 0.008180476 
Unknown (232951_at) 232951_at 1.02446043 0.008478862 
ABLIM1 200965_s_at 0.7503754 0.008661745 
SPEC2.. 234260_at 0.656905905 0.008848429 
GNPDA1 202382_s_at 0.889163034 0.009258671 
Unknown (244375_at) 244375_at 0.61879128 0.00946457 
SPR-1 236265_at 0.70376123 0.0096611 
HOXB2 205453_at 1.017011133 0.009766752 
UEV3 1554396_at 0.652376127 0.010414273 
T-cell receptor beta C 
gene segment. 
213193_x_at 0.740538672 0.010733429 
CD3Z 210031_at 1.132155362 0.011137508 
CKLFSF7 1560754_at 0.819553574 0.012046886 
PLEKHF2 218640_s_at 0.679038624 0.012046886 
SH3P12 218087_s_at 0.992758199 0.012571455 
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CD3G 206804_at 0.837705322 0.012571455 
AKAP12 1555395_at 2.445440415 5.25E-16 
NYX 234496_x_at 1.435416127 1.91E-15 
ARID1A 210649_s_at 1.121271433 1.91E-15 
ZNF91 206059_at 1.331838524 1.13E-14 
RAB2A 208730_x_at 0.786920002 1.65E-14 
RASD1 223467_at 2.088478771 2.68E-14 
EFNA1 202023_at 2.001846724 2.68E-14 
NFAT5 215092_s_at 2.048052481 3.43E-14 
UBL3 201534_s_at 1.363691523 3.43E-14 
APOL2 221013_s_at 1.334369446 3.43E-14 
CDC2L2 215329_s_at 0.985832306 3.43E-14 
CALN1 230698_at 2.160466521 9.11E-14 
GGT1 209918_at 0.954882312 1.11E-13 
Unknown (244491_at) 244491_at 1.063219407 1.58E-13 
DAGLB 225833_at 1.299517309 1.76E-13 
ZNF667 207120_at 2.005419594 2.72E-13 
Unknown (227388_at) 227388_at 1.740422312 2.72E-13 
MYLIP 223129_x_at 1.054861704 5.20E-13 
SHANK3 227923_at 3.384060651 5.27E-13 
HDAC3 227510_x_at 1.170891013 5.70E-13 
ACIN1 201715_s_at 0.657718319 5.70E-13 
PDE4B 211302_s_at 1.777677119 6.59E-13 
GFOD1 219821_s_at 1.565474067 6.59E-13 
ZNF667. 236635_at 1.256605046 6.59E-13 
CDCREL1 209768_s_at 1.273608094 9.19E-13 
NXF1 208922_s_at 0.949875647 1.39E-12 
Unknown (244793_at) 244793_at 2.002411851 1.69E-12 
SPTAN1 208611_s_at 1.018334408 2.63E-12 
CALN1. 223885_at 2.02908685 2.91E-12 
POMFIL3 224771_at 2.098774158 2.93E-12 
MYO5C 218966_at 1.151360846 3.38E-12 
IER5L 226552_at 1.741002346 3.56E-12 
SLC38A2 220924_s_at 0.953419074 3.56E-12 
DAGLB. 225832_s_at 1.044825568 3.59E-12 
Supplemental material chapter 4              273            
 
 
SLC38A2. 218041_x_at 0.935145477 4.07E-12 
Unknown (237374_at) 237374_at 1.772348178 4.08E-12 
FLJ31614 1553185_at 1.391684664 4.33E-12 
MCART1 219480_at 2.104674304 5.85E-12 
AKAP12. 241679_at 2.897861416 7.32E-12 
STK32B 219686_at 2.732787621 9.41E-12 
RNA exonuclease 1 
homolog (S. cerevisiae)  
244281_at 1.000907484 9.98E-12 
AKAP12.. 227530_at 2.417079866 1.24E-11 
POU4F1 211341_at 2.182371857 1.24E-11 
LOC100128252 244740_at 2.008494047 1.24E-11 
NEDD9 202150_s_at 1.540484513 1.49E-11 
IER3 201631_s_at 1.761438273 1.54E-11 
SPTB2 200671_s_at 2.197947386 1.95E-11 
SFRS7 213649_at 0.984624698 1.97E-11 
SMARCF1 212152_x_at 0.737661675 2.18E-11 
EHD1 209038_s_at 1.626907923 2.32E-11 
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Table 6. Probe set IDs, gene names, log-fold changes and p-values corresponding 
to Fig. 5 
Gene name HU133plus2.0 
probe ID 
logFC adj. p-value 
(FDR<0.01) 
TOCA1 215017_s_at 2.559953 6.89E-15 
TPD52L2 201379_s_at 1.488809 2.15E-13 
DNTT 210487_at 3.063569 6.35E-10 
DNTT. 1566363_at 2.572288 7.28E-10 
CCNJ 229091_s_at 0.926719 1.43E-09 
TOCA1. 242310_at 1.374711 3.44E-09 
LHFP 218656_s_at 1.694537 7.26E-09 
CCNJ. 219470_x_at 0.796031 7.26E-09 
DKFZp451A211 1556114_a_at 1.285373 7.95E-09 
CDKN2A 209644_x_at 0.923952 2.24E-08 
DNTT.. 1566362_at 1.746103 6.74E-08 
MOCS2B 218212_s_at 1.363284 1.90E-07 
S100A16 227998_at 1.278861 6.31E-07 
CDKN2A. 207039_at 1.090366 1.45E-06 
C5orf33 229299_at 1.090741 1.51E-06 
CYB5R2 220230_s_at 1.498323 1.71E-06 
NEK6 223158_s_at 0.806739 2.21E-06 
C5orf33. 226946_at 1.080412 2.86E-06 
LHFP. 232935_at 1.218228 4.48E-06 
RNU19 1567681_at 0.885787 7.92E-06 
MYC 202431_s_at 1.013794 8.47E-06 
SYNGR1 210613_s_at 0.792152 8.47E-06 
NPM1 221923_s_at 0.528623 1.12E-05 
Matrin 3 242260_at 0.954129 1.49E-05 
RPP40 213427_at 0.778875 1.63E-05 
TBC1D16 222116_s_at 1.107452 2.23E-05 
NUDT5 . 222824_at 0.842525 2.25E-05 
GNG11 204115_at 1.534628 2.81E-05 
DHX33 222875_at 0.606983 2.83E-05 
HSPC111 203023_at 0.738846 2.84E-05 
ABHD4 218581_at 0.970173 3.53E-05 
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LDHB 201030_x_at 0.499643 3.53E-05 
AHCY 200903_s_at 0.615318 3.76E-05 
BAG2  209406_at 0.818315 4.57E-05 
COBLL1 203642_s_at 0.969948 4.62E-05 
IGF1R 225330_at 0.74695 5.00E-05 
NUDT5 223100_s_at 0.830156 5.53E-05 
HMGIY 206074_s_at 0.674514 5.53E-05 
Unknown 
(236238_at) 
236238_at 1.062795 5.64E-05 
DNAJC5 224612_s_at 0.545687 6.61E-05 
PAK1IP1 218886_at 0.622538 7.12E-05 
CACNA2D4. 228083_at 1.459348 8.65E-05 
NPM3 205129_at 0.706398 8.70E-05 
FLJ38678 228249_at 1.219178 0.000104108 
CACNA2D4.. 1552690_a_at 0.953812 0.000104108 
ABHD4. 242023_at 1.289658 0.000109934 
FLJ25521 1564151_at 0.809965 0.000125932 
PABPC4 201064_s_at 0.52496 0.000125932 
C1QBP 208910_s_at 0.621309 0.000131157 
FLJ14028 224603_at 0.727887 0.000131732 
IL12RB2  1560999_a_at 2.718085 2.81E-07 
RUNX2 236859_at 2.629947 1.85E-05 
SUPT3H 206506_s_at 1.27754 1.85E-05 
REN 206367_at 1.393712 3.81E-05 
RUNX2. 236858_s_at 1.994329 4.75E-05 
FAM110C 226863_at 1.820986 4.82E-05 
IL12RB2  206999_at 1.700688 4.82E-05 
RUNX2 232231_at 2.324295 6.65E-05 
BMI1 202265_at 1.278213 6.65E-05 
KHDRBS3 209781_s_at 1.33512 9.59E-05 
FLJ11572 232544_at 1.883434 0.000100591 
Unknown 
(230986_at) 
230986_at 1.618617 0.000112542 
KHDRBS3 230249_at 1.244589 0.000159193 
SUPT3H. 211106_at 1.022298 0.000319877 
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FLJ13387 1557285_at 1.715535 0.000371065 
DNAJC1 242216_at 1.321202 0.000371065 
HOXB9 216417_x_at 0.90293 0.000371065 
CACNA2D2 204811_s_at 1.042558 0.000440239 
Unknown 
(236764_at) 
236764_at 1.031713 0.000440239 
SPON2 218638_s_at 1.030903 0.000509256 
KIAA1257 1554852_a_at 0.655182 0.000620548 
TMEM64 225972_at 0.775037 0.000641599 
TFAP2C 205286_at 1.44508 0.000672777 
LTK 207106_s_at 0.833476 0.000672777 
SH3PXD2A 224817_at 0.746945 0.000672777 
Unknown 
(231369_at) 
231369_at 0.567252 0.000672777 
DNAJC1. 222621_at 0.977505 0.000737038 
Unknown 
(243931_at) 
243931_at 0.94868 0.000776962 
HOXA3 235521_at 2.001119 0.000792966 
TNFRSF14 209354_at 0.562151 0.000809727 
PLCB4 203896_s_at 1.347276 0.000924533 
TNFRSF18 224553_s_at 1.068249 0.000937889 
LTK. 217184_s_at 0.930905 0.001145713 
HOXA4 206289_at 1.382214 0.00115584 
CPNE8 241706_at 1.237197 0.0012408 
FLJ12053 233259_at 1.04071 0.0012408 
DNAJC1.. 222620_s_at 0.937347 0.0012408 
LOC643977  235291_s_at 1.20954 0.001342176 
HOXA2 214457_at 1.04513 0.001438474 
TGFA 205016_at 1.038809 0.001495606 
PLCB4. 203895_at 1.482765 0.001554123 
FLJ42957 237591_at 0.635692 0.001554123 
SPG3A 223340_at 0.999075 0.00160921 
CLEC2B  209732_at 1.072006 0.001733017 
TMF1 213024_at 0.566226 0.001841754 
SNX30 226249_at 0.963997 0.001888555 
CPNE8. 228365_at 1.372333 0.001898577 
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SERPINE1  1568765_at 1.101198 0.001899276 
HOXA5 213844_at 2.250199 0.001956651 
AREG 205239_at 1.908526 0.001985735 
ZNF521 226677_at 4.473705 4.87E-22 
ZNF521. 226676_at 4.180613 1.85E-21 
CARD11 223514_at 1.969846 1.94E-09 
COL9A1 243932_at 2.018196 1.11E-08 
PBX3 204082_at 1.885843 2.09E-08 
TBL1X 213400_s_at 2.677367 1.26E-07 
OCIAD2 225314_at 1.47741 2.83E-07 
SLU7 212592_at 3.915242 3.16E-07 
PIP4K2C 218942_at 2.098933 4.54E-07 
FLJ23834 235650_at 2.101898 5.38E-07 
SCN3A 210432_s_at 2.920688 1.20E-06 
SEF2 212387_at 1.872205 4.51E-06 
Unknown 
(230441_at) 
230441_at 1.178759 4.51E-06 
Unknown 
(242846_at) 
242846_at 1.346623 7.20E-06 
CSMD1 241960_at 2.504962 7.39E-06 
ADARB1 203865_s_at 2.530064 1.16E-05 
HZF12 1552634_a_at 1.009475 1.16E-05 
SEF2. 213891_s_at 2.138735 1.20E-05 
KIF21B 204411_at 1.83281 1.20E-05 
RAB11FIP4 224482_s_at 1.589028 1.20E-05 
VMD2L3 1555492_a_at 1.47805 1.23E-05 
Unknown 
(213808_at) 
213808_at 1.87021 2.06E-05 
BTBD3 202946_s_at 1.369698 2.12E-05 
DLM1 242020_s_at 1.362838 2.14E-05 
TBL1  201869_s_at 1.635954 2.17E-05 
IGLJ3 215379_x_at 2.317115 2.73E-05 
Unknown 
(240143_at) 
240143_at 1.843791 4.81E-05 
TIEG2 218486_at 1.910182 7.33E-05 
DTX3 235721_at 1.611847 7.33E-05 
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SEF2.. 212386_at 2.028266 7.86E-05 
PIP5K1B 229116_at 1.614346 7.86E-05 
CSMD1. 231223_at 2.998008 8.79E-05 
GOLGA8E 213737_x_at 1.982831 8.99E-05 
C13orf18 44790_s_at 2.412767 0.000103745 
TCF4 222146_s_at 1.889432 0.000111127 
Unknown 
(236815_at) 
236815_at 1.478541 0.000150806 
ZAP70  214032_at 1.105778 0.00015567 
Unknown 
(1569652_at) 
1569652_at 1.623276 0.000157557 
BEST3 224520_s_at 1.75102 0.000174297 
PLEKHG4B 236255_at 1.306582 0.000184462 
CSMD1 1553405_a_at 2.094623 0.000190994 
JAG1 209099_x_at 1.86105 0.000239029 
ZNF521.. 1561002_at 1.468551 0.000282193 
IGLJ3. 209138_x_at 2.305006 0.000282473 
SEF2… 212385_at 2.017211 0.000323629 
IGLJ3.. 214677_x_at 2.22554 0.000344195 
IGLL3 215946_x_at 1.631147 0.000344195 
JAG1. 216268_s_at 2.019343 0.000360234 
NFATC4 213345_at 1.516531 0.000364207 
GOLGIN-67 210425_x_at 1.19848 0.000421966 
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Table 7. Probe set IDs, gene names, log-fold changes and p-values corresponding 
to Fig. 6 
Gene name HU133plus2.0 
probe ID 
logFC adj. p-value 
(FDR<0.01) 
HOXA9 209905_at -5.642306392 5.56E-15 
HOXA7 235753_at -2.867714705 1.71E-13 
HOXA9 214651_s_at -5.278173137 4.72E-13 
HOXA10 213150_at -4.405201631 1.62E-12 
HOXA5 213844_at -3.675623612 1.62E-12 
HOXA3 235521_at -2.918100349 1.62E-12 
HOXA10 213147_at -2.643718186 3.16E-10 
HOXA4 206289_at -1.933258806 2.24E-07 
HOXA7 206847_s_at -1.846205431 2.17E-06 
unknown 
(1569348_at) 
1569348_at -1.463720025 4.60E-05 
EMR2 207610_s_at -1.198090592 4.81E-05 
CPNE8 228365_at -2.111623139 4.81E-05 
unknown (24706_at) 241706_at -1.836454698 6.47E-05 
HOXB9 216417_x_at -1.122875687 7.14E-05 
VAT1L 226415_at -2.023043589 0.000136835 
unknown (236662_at) 236662_at -1.394690852 0.000174828 
SPINK2 206310_at -2.356185682 0.000255723 
IRXA1 230472_at 3.130165841 0.000255723 
H2BFQ 202708_s_at -1.446241383 0.00049311 
CRAMP1L 225172_at -0.811165772 0.000843264 
LMO5 211126_s_at -1.024684095 0.001376281 
IGFBP8 209101_at -2.268610841 0.001452582 
unknown (229716_at) 229716_at 1.493845075 0.002288068 
unknown (240930_at) 240930_at -1.247027131 0.002288068 
LMO5 207030_s_at -1.30824137 0.002469476 
unknown 
(1556599_s_at) 
1556599_s_at -1.971865713 0.002596639 
CPVL 208146_s_at 1.669370028 0.003764845 
JMY 226352_at 1.535434485 0.004418689 
H2AFQ H2AFO) 218280_x_at -1.305749006 0.004838001 
JMY 241985_at 1.494108489 0.005213742 
unknown 
(1557164_a_at) 
1557164_a_at -0.923353222 0.00526384 
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unknown (242201_at) 242201_at -0.915141147 0.00526384 
unknown (240116_at) 240116_at -0.943012023 0.006252255 
RUNX2 232231_at -2.175688771 0.006822942 
PRDX4 201923_at 1.302297581 0.007423354 
H2A.2 214290_s_at -1.096544544 0.008498623 
PNMAL1 218824_at -1.868179415 0.008498623 
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SUPPLEMENTAL MATERIAL CHAPTER 5 
 
 
MATERIALS AND METHODS 
 
 
Patient samples and sample preparation 
Samples from pediatric ALL patients older than 1 year (i.e., non-infants) were 
selected from our cell bank present at the Erasmus MC – Sophia Children’s 
Hospital, Rotterdam, The Netherlands. All samples were freshly processed within 
24 hours after sampling as previously described. 1 Briefly, mononuclear cells were 
isolated by density gradient centrifugation using Lymphoprep (NycomedPharma), 
and non-leukemic cells were removed using immunomagnetic beads. 2 All 
leukemia samples used in this study contained more than 90% leukemic cells, as 
determined morphologically on May-Grünwald-Giemsa (Merck)-stained cytospins. 
 
RNA and DNA extraction 
Total RNA and gDNA were extracted from a minimum of 5x106 leukemic cells 
using TRIzol reagent (Invitrogen Life Technologies) according to the 
manufacturer’s instructions with minor modifications. Quantification of DNA was 
performed using a spectrophotometer. Quantification and assessment of integrity 
of the extracted RNA was assessed using the Agilent 2100 Bio-analyzer (Agilent). 
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Gene expression profiling 
Raw array data were collectively normalized using variance-stabilizing 
normalization 3 and additionally corrected for batch effects using ComBat4. 
Removal of batch effects was visually verified by unsupervised principle 
component analysis. Differential gene expression was statistically evaluated using 
linear models for microarray analyses. 5, 6 
 
In vitro prednisone response  
The in vitro response to prednisolone (the active metabolite of prednisone) 
response was determined by 4-day MTT cytotoxicity assays as extensively 
described before.7 Patients were deemed prednisolone sensitive in case the LC50 
value (i.e. the concentration of prednisolone lethal to 50% of the leukemic cells) 
was <0.1 μg/mL, intermediate to prednisolone at LC50 values 0.1-150 μg/ml, and 
resistant to prednisolone at LC50 values >150 μg/ml. 
 
Oligo array-CGH 
Raw microarray image files were processed with Feature Extraction (Agilent 
Technologies, Santa Clara, CA). Results were analyzed using Agilent Genomic 
Workbench version 6.5 (Agilent Technologies, Santa Clara, CA). 
 
Multiplex ligation-dependent probe amplification 
Results were analyzed using GeneMarker 1.85 (SoftGenetics, State College, USA). 
Peak intensities of the probes in the patients were compared to peak intensities in 
healthy controls; a ratio >1·3 was defined as an amplification, a ratio <0.75 
defined as a mono-allelic deletion, and a ratio <0.25 was defined as a bi-allelic 
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deletion. When multiple exons of a gene were screened, only the samples with 
deletion or amplification of all exons were considered to be altered.   
 
JAK2 mutation screening 
Purified polymerase chain reaction products of JAK2 exon 16 were bi-directionally 
sequenced on an ABI Prism 3100 genetic analyzer (Applied Biosystems Inc., Foster 
City, CA, USA). The sequence data were assembled and analyzed for mutations 
using CLC Workbench version 3.5.1 (CLC Bio, Aarhus, Denmark).  
 
TCF3-PBX1 PCR 
TCF3-PBX1 was determined positive upon detection of a band after PCR using the 
following primers: forward: 5’-CACCAGCCTCATGCACAA-3’, reverse: 5’-
TCGCAGGAGATTCATCACG-3’. 
 
Statistical analyses 
Disease free survival (DFS) was calculated from date of first remission to the date 
of event which included relapse, death in complete remission, or second 
malignancy, whichever occurred first. Overall survival (OS) was calculated from 
the date of first remission to the date of death from any cause. Observations of 
patients were censored at the date of last contact when no events were observed. 
Follow-up was on December 31th 2009 for the Interfant-99 cohort, and on 
December 31th 2013 for the Interfant-06 cohort, with a median (interquartile 
range) follow-up of 7·0 years  
(5·1 – 8·0) and 4·6 years (3·8 – 5·5), respectively. The Kaplan-Meier method was 
used to estimate the probabilities of DFS and OS, with standard errors (SE) 
calculated according to Greenwood. Curves were compared using the log-rank 
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test. Cumulative incidence of relapse (CIR) were estimated adjusting for 
competing risks of death and second malignancy were statistically analyzed by the 
Gray test. We used the Fisher exact test to assess the association between 
patients’ characteristics and cohorts. All tests were two-sided. Analyses were 
performed using SAS 9.2 (SAS institute, Cary, NC, USA) and R 3.1.0 (R Core Team, 
R Foundation for Statistical Computing, Vienna, Austria) at the Interfant Trial 
Center. The significance analysis of microarray (SAM) 8 was used to identify probe 
sets significantly associated with EFS, score was calculated with 200 permutations. 
Gene set enrichment analysis (GSEA) was performed using GSEA software 9.  
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Table 1. Summary of array-CGH data of 31 wild-type MLL infant ALL patients 
Case 
(n) 
Sex 
Age 
(months) 
Immuno-
phenotype 
Chromosome Cytoband Start Stop 
+/
- 
1 F 11 unknown NO ABERRATIONS  
      
2 M 5 pre-B 7 p22·3 - p15·3 149068 20814521 - 
    9 p24·3 - p13·2 193993 36847230 - 
    9 p21·3 21827673 21998367 -- 
         
3 M 5 pre-B 9 p21·3 - p21·2 21482343 27254039 - 
    16 p13·3 70150 4404795 + 
    16 p13·3 - p13·2 5622326 8521959 - 
         
4 F 6 T NO ABERRATIONS  
      
5 M 8 pro-B 9 q31·1 - q34·3 
10510936
9 
14019387
4 
+ 
    17 p13·3 - p13·1 28969 8074153 - 
         
6 F 8 pre-B 14 complete chromosome + 
    22 complete chromosome + 
       
7 F 7 pre-B NO ABERRATIONS  
      
8 M 6 unknown 1 complete chromosome - 
    2 complete chromosome - 
    4 complete chromosome - 
    9 complete chromosome - 
    13 complete chromosome - 
    15 complete chromosome - 
    16 complete chromosome - 
    18 complete chromosome + 
    19 complete chromosome - 
    20 complete chromosome - 
    X complete chromosome + 
    Y complete chromosome - 
       
9 F 7 pre-B 9 p24·3 - p21·2 152931 26455189 -- 
    9 p24·3 - p24·1 345879 6206019 - 
    9 p24·1 6234464 6781084 -- 
    9 p24·1 - p23 6967740 9962217 - 
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    9 p23 - p22·3 10013642 14387386 -- 
    9 p22·3 14496495 16425025 - 
    9 p22·3 - p22·2 16437991 18063498 -- 
    9 p22·2 - p21·3 18490144 21537536 - 
    9 p21·3 21573783 22755422 -- 
    9 p21·3 - p21·2 22889384 26264718 - 
    9 p21·2 - p11·1 27498421 47002387 - 
    9 q12 - q21·11 67701166 72430420 - 
    9 
q21·13 - 
q21·2 
78718532 80054660 - 
    9 q22·1 - q22·32 90543552 98124268 - 
    9 q33·1 
11912557
5 
12055068
5 
- 
    20 
q11·21 - 
q13·33 
31170057 62363774 - 
         
10 F 6 T 1 p33 47475493 47540696 - 
    10 q23·31 89615444 89666862 - 
         
11 F 11 pre-B 9 p24·3 - p13·2 193993 37317972 - 
    13 q14·11 - q34 40064678 
11412406
2 
- 
         
12 F 9 unknown NO ABERRATIONS  
      
13 M 7 common 4 complete chromosome + 
    6 complete chromosome + 
    10 complete chromosome + 
    14 complete chromosome + 
    17 complete chromosome + 
    18 complete chromosome + 
    21 complete chromosome + 
    X complete chromosome + 
       
14 M 10 pre-B NO ABERRATIONS  
      
15 M 0 unknown 1 p36·11 24235782 25193094 - 
         
16 F 10 unknown 4 complete chromosome + 
    6 complete chromosome + 
    14 complete chromosome + 
    17 complete chromosome + 
    18 complete chromosome + 
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    21 complete chromosome + 
       
17 M 2 pre-B 14 complete chromosome + 
    22 complete chromosome + 
       
18 F 5 unknown 22 q11·22 20730547 21443935 - 
         
19 F 7 common 3 
q25·2 - 
q26·33 
15624269
9 
18075998
1 
- 
         
20 M 10 Other 1 p35·3 - p35·2 29103090 31160825 - 
    16 p11·2 30849299 33517567 - 
    17 p13·1 9934363 10343321 + 
    18 q21·32 55088482 55882821 + 
         
21 F 10 pro-B NO ABERRATIONS 
         
22 M 10 common 6 complete chromosome + 
    14 complete chromosome + 
    17 complete chromosome + 
    18 complete chromosome + 
    21 complete chromosome + 
       
23 F 9 common 9 p24·3 - p13·2 229226 36930463 - 
         
24 M 10 T 11 q14·1 - q22·1 84284829 99548539 - 
         
25 F 11 common NO ABERRATIONS  
      
26 M 5 unknown 8 
complete chromosome                                           
+ 
    19 
complete chromosome                                           
+ 
      
27 F 9 common NO ABERRATIONS  
      
28 F 5 common  1 complete q-arm                                  + 
      
29 M 9 pre-B NO ABERRATIONS  
      
30 F 11 common 9 p24·1 - p21·1 6631559 32777373 - 
    9 p21·3 20375131 22638651 -- 
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    9 p21·3 21399600 21490892 - 
         
31 M 4 pro-B NO ABERRATIONS 
 
Overview of aberrations found by array-CGH. Alterations in copy-number 
variation regions are omitted. + = amplification of one allele, - = loss of 
heterozygosity, -- = loss of both alleles. UK = unknown. 
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Table 2. Distribution of prognostic factors in low versus high MEIS1 expressing 
wild-type infant ALL patients 
 
MEIS1 < median 
n=18 
MEIS1 > median 
n=18 
P* 
Age at diagnosis   0·356 
< 6 months 4 (22%) 6 (33%)  
> 6 months 14 (78%) 12 (67%)  
    
WBC count (cells/L)   0·168 
< 100x109 9 (60%) 9 (56%)  
 100-300x109 2 (13%) 6 (38%)  
> 300x109 4 (27%) 1 (6%)  
    
Prednisone response   0·327 
good response 12 (92%) 11 (79%)  
poor response 1 (8%) 3 (21%)  
    
Immunophenotype   0·002 
pro-B cell 0 3 (20%)  
common B cell 2 (15%) 8 (53%)  
pre-B cell 9 (69%) 1 (7%)  
T-lineage 2 (15%) 3 (20%)  
    
 
All data are number (%). *P-value comparing the distribution of poor prognostic 
factors between low-level expression of MEIS1 (n=18) and high-level expression of 
MEIS1 (n=18) in wild-type MLL infant ALL using the Fisher’s Exact test.  
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Table 3. Analysis of chromosome 9p gene deletions in low versus high MEIS1 
expressing wild-type infant ALL patients.  
 
 MEIS1-
expression < 
median (n=13) 
MEIS1-
expression > 
median (n=11) 
p-value* 
Deletion    
CDKN2A  4 (31%) 2 (18%) 0·65 
CDKN2B 3 (15%) 2 (18%) 1 
PAX5 4 (31%) 2 (18%) 0·65 
CDKN2A, CDKN2B 
and/or PAX5 
6 (46%) 2 (18%) 0·21 
 
All data are number (%). *P-value comparing the distribution of gene deletions 
between low-level expression of MEIS1 (n=13) and high-level expression of MEIS1 
(n=11) in wild-type MLL infant ALL using the Pearson Chi-Square test.  
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SUPPLEMENTAL MATERIAL CHAPTER 6 
 
 
METHODS AND MATERIALS 
 
 
Cell culturing 
Leukemia cell lines were maintained as suspension cultures in RPMI 1640 with 
glutamax (Invitrogen, Life Technologies) supplemented with 10% (v/v) FCS and 
2% penicillin/streptomycin/fungizone (PSF; Invitrogen, Life Technologies) at 37°C 
in humidified air containing 5% CO2.  
 
Transfection with siRNA 
4x106 cells were transfected by electroporation in 4 mm electroporation 
cuvettes (Bio-Rad Laboratories, Benicia, USA) 400 μL of RPMI medium plus 10% 
fetal calf serum together with 10 μL of esiRNA (20 μM) directed against MLL-AF4 
(siMA6) (1), AML1-MTG8  fusion protein (siAGF1) as an  active siRNA control 
which is non-silencing in this cellular context  (as described previously (2)), AF4-
MLL (as described previously (3)), or 50 μL  siRNA (20 μM) directed against MLL-
ENL: sense 5’-CCAAAAGAAAAGUCUGCCCAG-3; antisense 5’-
CUGGGCAGACUUUUCUUUUGGUU-3’ with 50 μL siAGF1 (20 μM) as an active 
non-silencing control . siRNAs were purchased from Eurogentec (Seraing, 
Belgium). Electroporation was performed with the Gene Pulser MX cell 
Electroporation System (Bio-Rad Laboratories, Benicia, USA) with a rectangle 
pulse of 350 V for 10 milliseconds. After incubating for 15 minutes at room 
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temperature, the cells were diluted to 1x106 cells/ml and cultured under 
standard culture conditions. Cells transfected with siRNAs directed against MLL-
AF4 and MLL-ENL and the relative controls were harvested after two days. Cells 
transfected with siRNAs directed against AF4-MLL and the relative controls were 
repeatedly transfected by electroporation after two days under the same 
conditions and harvested at day 4. All knock-down experiments were performed 
at least three times. 
 
RNA extraction and cDNA synthesis 
Total RNA was extracted from a minimum of 2x106 cells using TRIzol reagent 
(Invitrogen, Life Technologies, Breda, The Netherlands) according to the 
manufacturer’s guidelines. The quality of the extracted RNA was assessed on 
1.5% agarose gels and cDNA was prepared for quantitative real-time PCR 
analysis as described earlier (4).   
 
 
-PCR analysis 
MLL-AF4, MLL-ENL and AF4-MLL mRNA expression was quantified by real-time 
PCR analysis  using the DyNAmo SYBR Green qPCR kit (Finnzymes, Espoo, 
Finland) as described before (5). Oligonucleotide primers used for PCR 
amplification were purchased from Eurogentec (Seraing, Belgium). Primer 
sequences were as follows: MLL-AF4 forward (MLL exon 8): 5’- 
CCCCGCCCAAGTATC-3’, reverse (AF4 exon 5): 5’-GGCGGCCATGAATG-3’; MLL-
ENL forward (MLL exon 8): 5’-CCCCGCCCAAGTATC-3’, reverse (ENL exon 7): 5’-
GCTCGAAGTCTGAGTCTGA-3’; AF4-MLL forward (AF4 exon 3): 5’-
CAGGCCCCTAGTGAATC-3’, reverse (MLL exon 12: 5’-TTTCGGCACTTATTACACTC-
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3’; MLL forward (exon 9): 5’-GCAGGCACTTTGAACATC-3’, reverse (exon 11): 5’-
AAGGGCTCACAACAGACTT-3’; AF4 forward (exon 3): 5’-AATCCCCTGAACTGAAAC-
3’, reverse (exon 6): 5’-TTTGGGTTACAGAACTGACA-3’; ENL forward (exon 6): 5’-
CGGCCAAGGACAAGA-3’, reverse (exon 7): 5’-ATGGCTCGAAGTCTGAGT-3’. B2M 
was used as a reference gene: forward: 5’-GGAGCATTCAGACTTGTCTT-3’, 
reverse: 5’-ATGCGGCATCTTCAAA-3’. t(4;11)+ infant ALL patient samples were 
screened for the presence of AF4-MLL expression using PCR analysis with the 
following primer sequences: forward: 5’-CTCCCCTCAAAAAGTGTTGC-3’ (AF4 exon 
3), reverse: 5’-CTTTGCCTGGAGTTGTGGAT-3’ (MLL exon 13). 
 
Western blot 
The MLL–AF4 fusion protein was detected using medium-sized 
5% polyacrylamide gels. Proteins are resolved at 60–80 volt for at least 10–12 
hours at room temperature. The blotting procedure was performed overnight at 
4°C on nitrocellulose membranes. Blots were incubated with mouse monoclonal 
anti-MLLN/HRX (clone N4.4) (Upstate Biotechnology, Temecula, CA, USA #05–
764) and anti-clathrin HC (clone TD.1) (Santa Cruz Biotechnology, Middlesex, 
UK #sc-12734) as a loading control. Visualization of the antibodies was done 
using standard procedures. Western blot procedure and quantification was 
performed twice. 
 
Gene expression data 
RNA was synthesized into biotinylated cRNA. Labeled cRNA was then 
fragmented and hybridized to HU133plus2.0 GeneChips (Affymetrix) according 
to the manufacturer’s guidelines. Differential gene expression analysis was 
performed using linear modeling for microarray data (LIMMA) (6) and was 
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performed in the statistical environment R using Bioconductor packages. 
Heatmaps were generated in Genepattern using Pearson correlation for 
hierarchical clustering. (7) The pediatric precursor B-ALL samples were deposited 
as GSE13351 (8) as part of recently published studies in the National Center for 
Biotechnology Information Gene Expression Omnibus. (9) Gene set enrichment 
analysis (GSEA) was performed using GSEA software (10). GSEA on gene sets 
which resulted from paired analyses were done on pre-ranked lists. Pathway 
analysis was done using DAVID bioinformatics (11) and Ingenuity Pathway 
Analysis  (IPA, QIAGEN Redwood City, www.qiagen.com/ingenuity). Gene sets 
that are used throughout the manuscript other than previously published gene 
sets are listed in the Supplemental data.  
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Table 1. Differentially expressed genes in response to the repression of MLL-
AF4 and MLL-ENL as compared to the siAGF1 control (n=101) or the pulse 
control (no siRNAs) (n=86) (Figure 2B)  
 
  101 probe sets:             86 probe sets:  
MLL fusion KD versus AGF1 control        MLL fusion KD versus pulse control                  
 
Probe set HGNC Gene 
Symbol 
logFC P.Value  Probe set HGNC 
Gene 
Symbol 
logFC P.Value 
225785_at REEP3 1.13 8.84E-11  225785_at REEP3 0.94 2,52E-08 
1552665_at LOC84989 0.95 8.30E-09  1552665_at LOC84989 0.94 5,30E-08 
202318_s_at SENP6 0.72 1.24E-08  202318_s_at SENP6 0.66 7,36E-08 
200918_s_at SRPR -0.51 2.36E-07  1568589_at NA 0.66 7,52E-08 
1568589_at NA -0.66 2.59E-07  200918_s_at SRPR 0.49 8,34E-08 
204897_at PTGER4 0.43 4.77E-07  202319_at SENP6 0.49 7,96E-07 
202319_at SENP6 0.54 5.91E-07  203408_s_at SATB1 -0.36 8,54E-07 
221045_s_at PER3 0.36 3.62E-06  228774_at CEP78 -0.35 2,48E-06 
203408_s_at SATB1 -0.38 3.69E-06  240016_at NA 0.26 2,54E-06 
226796_at ABHD15 -0.52 4.03E-06  212078_s_at MLL -0.38 2,64E-06 
235479_at CPEB2 -0.28 6.65E-06  226796_at ABHD15 -0.49 2,70E-06 
240016_at NA 0.23 9.69E-06  204304_s_at PROM1 -0.45 4,19E-06 
37384_at PPM1F -0.28 1.37E-05  235479_at CPEB2 -0.27 5,48E-06 
228774_at CEP78 -0.36 1.41E-05  1557985_s_at CEP78 -0.30 9,22E-06 
203753_at TCF4 -0.37 1.42E-05  201924_at AFF1 -0.42 9,71E-06 
219874_at SLC12A8 0.35 1.73E-05  214949_at NA -0.35 1,02E-05 
224862_at GNAQ 0.73 2.35E-05  204033_at TRIP13 -0.34 1,32E-05 
235016_at REEP3 0.35 3.01E-05  235016_at REEP3 0.38 1,33E-05 
213541_s_at ERG -0.40 3.52E-05  224862_at GNAQ 0.61 1,94E-05 
203216_s_at MYO6 -0.37 4.60E-05  219874_at SLC12A8 0.30 2,01E-05 
1557985_s_at CEP78 -0.32 4.86E-05  226939_at CPEB2 -0.47 2,06E-05 
207143_at CDK6 -0.37 5.14E-05  241926_s_at ERG -0.40 2,26E-05 
203063_at PPM1F -0.24 5.76E-05  213541_s_at ERG -0.36 2,36E-05 
214949_at NA -0.36 6.30E-05  225181_at ARID1B 0.37 4,15E-05 
235372_at FCRLA 0.33 6.49E-05  204897_at PTGER4 0.36 5,43E-05 
223750_s_at TLR10 0.24 6.68E-05  238767_at NA -0.24 7,14E-05 
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201924_at AFF1 -0.37 7.12E-05  216705_s_at ADA -0.40 7,27E-05 
208934_s_at LGALS8 0.25 7.47E-05  210571_s_at CMAHP 0.28 8,87E-05 
1564776_at NA -0.30 7.69E-05  219563_at LINC00341 -0.23 9,46E-05 
204639_at ADA -0.42 1.04E-04  235753_at HOXA7 -0.38 0,000105 
213413_at STON1 0.24 1.07E-04  37384_at PPM1F -0.25 0,00012 
201889_at FAM3C 0.34 1.16E-04  224861_at GNAQ 0.52 0,000129 
226939_at CPEB2 -0.46 1.19E-04  1561707_at LOC150185 0.24 0,000143 
200049_at KAT7 -0.31 1.24E-04  1567224_at HMGA2 -0.24 0,000145 
202615_at GNAQ 0.57 1.32E-04  207819_s_at ABCB4 0.20 0,000159 
207966_s_at GLG1 0.28 1.34E-04  230925_at APBB1IP -0.35 0,000165 
225181_at ARID1B 0.44 1.35E-04  207143_at CDK6 -0.35 0,000179 
235964_x_at SAMHD1 0.43 1.50E-04  203216_s_at MYO6 -0.33 0,000181 
224861_at GNAQ 0.57 1.59E-04  233931_at NA -0.30 0,00019 
226004_at CABLES2 -0.27 1.76E-04  212079_s_at MLL -0.32 0,000193 
203817_at GUCY1B3 -0.60 1.76E-04  204094_s_at TSC22D2 -0.30 0,000205 
230925_at APBB1IP -0.37 1.77E-04  226004_at CABLES2 -0.25 0,000231 
201859_at SRGN 0.40 1.82E-04  204639_at ADA -0.36 0,000232 
204304_s_at PROM1 -0.43 1.83E-04  224863_at GNAQ 0.43 0,00024 
225406_at TWSG1 0.30 1.91E-04  206847_s_at HOXA7 -0.41 0,000243 
214948_s_at TMF1 -0.35 2.31E-04  235122_at HIVEP3 0.32 0,000248 
204033_at TRIP13 -0.30 2.42E-04  218584_at TCTN1 0.34 0,000276 
201925_s_at CD55 0.27 2.49E-04  217853_at TNS3 0.42 0,000302 
243490_at NA -0.42 2.62E-04  214948_s_at TMF1 -0.33 0,000308 
235529_x_at SAMHD1 0.39 2.67E-04  235919_at NA -0.37 0,00031 
210480_s_at MYO6 -0.33 2.70E-04  202615_at GNAQ 0.48 0,00032 
211555_s_at GUCY1B3 -0.49 2.76E-04  204621_s_at NR4A2 0.16 0,000339 
AFFX-
M27830_M_at 
NA -0.31 2.80E-04  200629_at WARS 0.31 0,000378 
225355_at NEURL1B -0.25 2.91E-04  219497_s_at BCL11A 0.22 0,000417 
230281_at C16orf46 0.22 3.04E-04  210432_s_at SCN3A 0.36 0,00045 
216705_s_at ADA -0.41 3.15E-04  232544_at NA -0.24 0,000451 
218584_at TCTN1 0.38 3.17E-04  1553145_at FLJ39653 -0.32 0,000452 
221933_at NLGN4X 0.27 3.19E-04  224906_at ANO6 -0.21 0,000456 
235753_at HOXA7 -0.36 3.20E-04  213413_at STON1 0.24 0,000457 
200629_at WARS 0.30 3.37E-04  200049_at KAT7 -0.26 0,000473 
204836_at GLDC 0.28 3.49E-04  220459_at MCM3AP-
AS1 
-0.26 0,000491 
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202723_s_at FOXO1 -0.31 3.69E-04  223750_s_at TLR10 0.23 0,000527 
202656_s_at SERTAD2 -0.27 4.00E-04  205488_at GZMA 0.33 0,000529 
224882_at ACSS1 -0.28 4.01E-04  211965_at ZFP36L1 0.37 0,000553 
203860_at PCCA 0.20 4.27E-04  229838_at NUCB2 0.22 0,000574 
202388_at RGS2 0.44 4.37E-04  225639_at SKAP2 -0.34 0,000577 
212080_at MLL -0.20 4.40E-04  229498_at MBNL3 -0.32 0,000592 
209994_s_at NA 0.19 4.50E-04  225283_at ARRDC4 0.17 0,000613 
243001_at RBFA -0.34 4.60E-04  212045_at GLG1 0.20 0,000623 
213734_at NA 0.26 4.81E-04  202388_at RGS2 0.37 0,000624 
224863_at GNAQ 0.42 5.02E-04  203817_at GUCY1B3 -0.54 0,000626 
213704_at RABGGTB 0.23 5.19E-04  209994_s_at NA 0.19 0,000668 
235400_at FCRLA 0.30 5.38E-04  219498_s_at BCL11A -0.21 0,00067 
235401_s_at FCRLA 0.32 5.75E-04  211962_s_at ZFP36L1 0.38 0,000685 
230415_at NA -0.21 5.82E-04  206765_at KCNJ2 0.50 0,000729 
243879_at NA -0.25 5.90E-04  211991_s_at HLA-DPA1 -0.47 0,000791 
224567_x_at MALAT1 0.43 5.94E-04  204836_at GLDC 0.21 0,000796 
206765_at KCNJ2 0.47 5.95E-04  203063_at PPM1F -0.22 0,000801 
235122_at HIVEP3 0.35 5.97E-04  222862_s_at AK5 0.24 0,000817 
222862_s_at AK5 0.23 6.24E-04  243490_at NA -0.36 0,000817 
228496_s_at CRIM1 0.27 6.28E-04  228886_at LRRC27 0.16 0,000825 
205006_s_at NMT2 0.18 6.71E-04  235372_at FCRLA 0.27 0,000827 
236443_at NA -0.20 6.90E-04  235292_at FLJ32255 0.25 0,000923 
240236_at STXBP5L -0.22 7.00E-04  221933_at NLGN4X 0.27 0,000954 
231812_x_at PHAX 0.19 7.18E-04  221045_s_at PER3 0.25 0,000962 
243769_at NA 0.35 7.31E-04      
212078_s_at MLL -0.29 7.45E-04      
228377_at KLHL14 0.27 7.48E-04      
232096_x_at FOXP1-IT1 -0.23 7.78E-04      
224993_at MLLT1 -0.22 7.85E-04      
209447_at SYNE1 0.26 7.88E-04      
229594_at SPTY2D1 0.19 8.09E-04      
224793_s_at TGFBR1 0.34 8.53E-04      
237173_at NA -0.18 8.60E-04      
224699_s_at ESYT2 -0.22 8.91E-04      
234723_x_at NA 0.22 8.92E-04      
217853_at TNS3 0.38 9.05E-04      
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212079_s_at MLL -0.31 9.44E-04      
242911_at MED13L -0.21 9.47E-04      
226301_at C6orf192 0.23 9.56E-04      
228771_at ADRBK2 0.21 9.71E-04      
Supplemental material chapter 6       303             
 
 
Table 2. Differentially expressed genes in response to the repression of MLL-
AF4 and MLL-ENL as compared to the siAGF1 control and the pulse control (no 
siRNAs) combined (n=56) (Figure 2B)  
Probe set HGNC 
Gene 
Symbol 
1552665_at LOC84989 
1557985_s_at CEP78 
1568589_at NA 
200049_at KAT7 
200629_at WARS 
200918_s_at SRPR 
201924_at AFF1 
202318_s_at SENP6 
202319_at SENP6 
202388_at RGS2 
202615_at GNAQ 
203063_at PPM1F 
203216_s_at MYO6 
203408_s_at SATB1 
203817_at GUCY1B3 
204033_at TRIP13 
204094_s_at TSC22D2 
204639_at ADA 
204836_at GLDC 
204897_at PTGER4 
206765_at KCNJ2 
207143_at CDK6 
209994_s_at NA 
212078_s_at MLL 
212079_s_at MLL 
213413_at STON1 
213541_s_at ERG 
214948_s_at TMF1 
214949_at NA 
216705_s_at ADA 
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217853_at TNS3 
218584_at TCTN1 
219874_at SLC12A8 
221045_s_at PER3 
221933_at NLGN4X 
222862_s_at AK5 
223750_s_at TLR10 
224861_at GNAQ 
224862_at GNAQ 
224863_at GNAQ 
225181_at ARID1B 
225785_at REEP3 
226004_at CABLES2 
226796_at ABHD15 
226939_at CPEB2 
228774_at CEP78 
229498_at MBNL3 
230925_at APBB1IP 
235016_at REEP3 
235122_at HIVEP3 
235372_at FCRLA 
235479_at CPEB2 
235753_at HOXA7 
240016_at NA 
243490_at NA 
37384_at PPM1F 
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Table 3. Leading edge of GSEA comparing MLL-fusion knockdown samples 
versus control samples using MLL-AF4 target genes from Guenther et al (Figure 
3, upper panel) 
 
HGNC Gene 
Symbol 
ERG 
CDK6 
PROM1 
HOXA7 
PPP2R5C 
ZEB2 
GALNT2 
UBASH3B 
HOXA10 
TNRC18 
SUPT3H 
JMJD1C 
CPNE8 
ADAM10 
BCL7A 
MEIS1 
TWIST1 
SENP6 
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Table 4. Leading edge of GSEA comparing MLL-fusion knockdown samples 
versus control samples using MLL-AF4 target genes from Krivtsov et al (Figure 
3, lower panel) 
HGNC Gene 
Symbol 
PROM1 
HOXA7 
CLEC14A 
BCL2 
SOCS2 
RPL32 
MAP3K5 
HOXA10 
HOXA6 
CD93 
FOSL2 
ADCY9 
CEBPA 
ZNRF1 
FUT4 
MEIS1 
C3orf65 
HEXB 
KCNK12 
VLDLR 
MMP17 
MRM1 
LCN8 
GREM1 
HTRA3 
AKR7A2 
SERPINB1 
PCDHGC3 
RUNX2 
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CDKN1A 
NLRP3 
CTGF 
TMEM173 
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Table 5. Differentially lower expressed genes in response to the repression of 
MLL-AF4 and MLL-ENL as compared to the siAGF1 control and the pulse control 
(no siRNAs) combined (n=57)  (Figure 4B) 
Probe set HGNC Gene 
Symbol 
1553145_at FLJ39653 
1557985_s_at CEP78 
1564776_at NA 
1567224_at HMGA2 
1568589_at NA 
200049_at MYST2 
200918_s_at SRPR 
201924_at AFF1 
202656_s_at SERTAD2 
203063_at PPM1F 
203216_s_at MYO6 
203408_s_at SATB1 
203753_at TCF4 
203817_at GUCY1B3 
204033_at TRIP13 
204082_at PBX3 
204094_s_at TSC22D2 
204304_s_at PROM1 
204639_at ADA 
206847_s_at HOXA7 
207143_at CDK6 
210480_s_at MYO6 
211555_s_at GUCY1B3 
211991_s_at HLA-DPA1 
212078_s_at MLL 
212079_s_at MLL 
212080_at MLL 
213541_s_at ERG 
214948_s_at TMF1 
214949_at NA 
216705_s_at ADA 
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219498_s_at BCL11A 
219563_at C14orf139 
223840_s_at SPATA9 
224699_s_at ESYT2 
224882_at ACSS1 
224906_at ANO6 
225355_at NEURL1B 
226004_at CABLES2 
226796_at ABHD15 
226939_at CPEB2 
228774_at CEP78 
229498_at NA 
230415_at NA 
230925_at APBB1IP 
232544_at NA 
233931_at NA 
235479_at CPEB2 
235753_at HOXA7 
235919_at NA 
236443_at NA 
238767_at NA 
240236_at STXBP5L 
243001_at C18orf22 
243490_at NA 
243879_at NA 
37384_at PPM1F 
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Table 6. Differentially expressed genes in response to the repression of MLL-
AF4 and MLL-ENL as compared to the siAGF1 control and the pulse control (no 
siRNAs) combined (n=36) (Figure 5C) 
Probe set HGNC 
Gene 
Symbol 
1552726_at ADAMTS17 
204249_s_at LMO2 
208724_s_at RAB1A 
209789_at CORO2B 
211924_s_at PLAUR 
212080_at MLL 
212262_at QKI 
212636_at QKI 
212750_at PPP1R16B 
213708_s_at MLX 
214743_at CUX1 
214866_at PLAUR 
217910_x_at MLX 
219326_s_at B3GNT2 
222631_at PI4K2B 
222870_s_at B3GNT2 
222942_s_at NA 
222958_s_at DEPDC1 
223017_at TXNDC12 
223171_at DYM 
224967_at UGCG 
225935_at CUX1 
226297_at HIPK3 
226689_at CISD2 
226793_at LINC00294 
227069_at CUX1 
228008_at NA 
228094_at AMICA1 
228486_at SLC44A1 
232278_s_at DEPDC1 
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233727_at NA 
235545_at DEPDC1 
236513_at NA 
238041_at TCF12 
239400_at NA 
41577_at PPP1R16B 
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Table 7. Upstream regulators of the differentially lower expressed genes in 
response to the repression of MLL-AF4 and MLL-ENL. 
Upstream 
Regulator 
Molecule Type p-value of overlap 
miR-92a-3p mature microrna 9.39E-08 
mir-196 microrna 1.97E-06 
miR-344d-3p  mature microrna 2.65E-06 
miR-144-3p  mature microrna 6.57E-06 
miR-153-3p  mature microrna 1.07E-05 
miR-219a-5p  mature microrna 1.18E-05 
miR-17-5p  mature microrna 1.48E-05 
HOXA7 transcription regulator 1.76E-05 
miR-196a-5p  mature microrna 4.21E-05 
miR-137-3p  mature microrna 4.87E-05 
MIRLET7 group 5.61E-05 
mir-142 microrna 5.61E-05 
miR-142-3p  mature microrna 6.91E-05 
miR-148a-3p  mature microrna 7.82E-05 
miR-590-3p  mature microrna 8.92E-05 
LIN28B other 1.34E-04 
miR-3922-5p  mature microrna 1.63E-04 
miR-154-5p  mature microrna 1.72E-04 
miR-186-5p  mature microrna 1.90E-04 
UPF1 enzyme 2.89E-04 
miR-191-5p  mature microrna 3.79E-04 
miR-448-3p  mature microrna 3.79E-04 
miR-342-3p  mature microrna 4.49E-04 
miR-9-5p  mature microrna 4.87E-04 
miR-21-5p  mature microrna 5.42E-04 
miR-155-5p  mature microrna 7.12E-04 
EZH2 transcription regulator 8.23E-04 
miR-200b-3p  mature microrna 8.47E-04 
miR-128-3p  mature microrna 8.53E-04 
MBD1 transcription regulator 9.26E-04 
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Table 8. Leading edge of GSEA comparing MLL-rearranged patients versus wild-
type MLL patients using 57 MLL-AF4 target gene probe sets (Figure 4B) 
Probe set HGNC Gene 
Symbol 
204304_s_at PROM1 
232544_at IGFBP7 
212080_at MLL 
235753_at HOXA7 
206847_s_at HOXA7 
236443_at PAX5 
1553145_at FLJ39653 
233931_at ZFR 
203753_at TCF4 
1564776_at 1564776_at 
203216_s_at MYO6 
243001_at C18orf22 
1568589_at REEP3 
207143_at CDK6 
235479_at CPEB2 
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Table 9. Differentially expressed genes in response to the repression of MLL-
AF4 and MLL-ENL as compared to the siAGF1 control (n=80) or the pulse 
control (no siRNAs) (n=58) (Figure 5B)  
 
       80 probe sets:             58 probe sets: 
  
AF4-MLL KD versus AGF1 control             AF4-MLL KD versus pulse 
control                  
Probe set HGNC 
Gene 
Symbol 
logFC P.Value  Probe set HGNC 
Gene 
Symbol 
logFC P.Value 
222631_at PI4K2B -0.58 3.21E-07  212636_at QKI -0.89 1.14E-06 
212636_at QKI -0.87 5.29E-07  222631_at PI4K2B -0.64 2.31E-06 
209312_x_at NA 0.45 1.42E-06  226297_at HIPK3 -0.72 3.91E-06 
226297_at HIPK3 -0.72 1.57E-06  225935_at CUX1 -0.36 4.82E-06 
228486_at SLC44A1 -0.45 2.98E-06  204517_at PPIC 0.41 1.35E-05 
204670_x_at NA 0.40 3.23E-06  222870_s_at B3GNT2 -0.56 1.89E-05 
228008_at NA -0.33 5.30E-06  219326_s_at B3GNT2 -0.55 2.86E-05 
208306_x_at NA 0.39 6.16E-06  217910_x_at MLX -0.30 3.44E-05 
219326_s_at B3GNT2 -0.45 6.97E-06  212750_at PPP1R16B 0.40 3.98E-05 
213708_s_at MLX -0.36 8.64E-06  41577_at PPP1R16B 0.42 4.59E-05 
215193_x_at NA 0.42 1.06E-05  213708_s_at MLX -0.35 5.09E-05 
222870_s_at B3GNT2 -0.60 1.14E-05  201858_s_at SRGN 0.54 5.15E-05 
223343_at MS4A7 0.42 1.28E-05  223017_at TXNDC12 -0.46 7.93E-05 
222958_s_at DEPDC1 -0.56 1.93E-05  238041_at TCF12 -0.37 8.67E-05 
41577_at PPP1R16B 0.39 2.12E-05  205632_s_at PIP5K1B 0.29 1.36E-04 
208724_s_at RAB1A -0.35 2.60E-05  201859_at SRGN 0.42 1.45E-04 
226689_at CISD2 -0.42 3.66E-05  222958_s_at DEPDC1 -0.59 1.53E-04 
217910_x_at MLX -0.27 5.38E-05  236513_at NA -0.31 1.55E-04 
233727_at NA 0.35 5.85E-05  204518_s_at PPIC 0.32 1.60E-04 
236513_at NA -0.30 5.87E-05  208724_s_at RAB1A -0.29 1.62E-04 
204249_s_at LMO2 0.45 6.07E-05  228486_at SLC44A1 -0.51 1.95E-04 
227699_at C14orf149 -0.31 6.07E-05  229844_at FOXP1 -0.27 3.02E-04 
211990_at HLA-DPA1 0.29 7.34E-05  226793_at LINC00294 -0.25 3.30E-04 
225935_at CUX1 -0.29 7.47E-05  209789_at CORO2B -0.37 3.45E-04 
211924_s_at PLAUR 0.30 7.52E-05  214743_at CUX1 -0.31 3.59E-04 
212750_at PPP1R16B 0.35 1.00E-04  233727_at NA 0.30 3.74E-04 
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223047_at CMTM6 -0.35 1.13E-04  232278_s_at DEPDC1 -0.54 4.08E-04 
214866_at PLAUR 0.23 1.16E-04  209711_at SLC35D1 -0.26 4.51E-04 
217947_at CMTM6 -0.36 1.38E-04  223171_at DYM -0.57 4.52E-04 
229307_at ANKRD28 0.32 1.64E-04  1552726_at ADAMTS17 0.27 4.53E-04 
226793_at LINC00294 -0.27 1.65E-04  235545_at DEPDC1 -0.58 4.70E-04 
223171_at DYM -0.45 1.65E-04  203725_at GADD45A -0.29 4.83E-04 
235534_at NA -0.24 1.69E-04  204891_s_at LCK -0.30 4.89E-04 
223017_at TXNDC12 -0.43 1.72E-04  203320_at SH2B3 0.28 5.01E-04 
211654_x_at HLA-DQB1 0.32 1.82E-04  226689_at CISD2 -0.31 5.19E-04 
238759_at CCDC88A 0.26 1.94E-04  212262_at QKI -0.23 5.40E-04 
217974_at TM7SF3 -0.31 2.22E-04  225262_at FOSL2 0.23 5.47E-04 
235545_at DEPDC1 -0.54 2.24E-04  204249_s_at LMO2 0.40 5.50E-04 
211656_x_at HLA-DQB1 0.36 2.31E-04  228094_at AMICA1 0.27 5.59E-04 
1553601_a_at TMIE 0.25 2.35E-04  1554343_a_at STAP1 0.29 5.66E-04 
208894_at HLA-DRA 0.38 2.37E-04  222942_s_at NA 0.24 5.85E-04 
212262_at QKI -0.27 2.53E-04  221786_at C6orf120 0.24 5.97E-04 
232278_s_at DEPDC1 -0.48 2.75E-04  210845_s_at PLAUR 0.27 6.66E-04 
209789_at CORO2B -0.43 2.79E-04  214866_at PLAUR 0.22 6.75E-04 
211991_s_at HLA-DPA1 0.29 2.87E-04  221595_at C7orf64 -0.23 6.77E-04 
239400_at NA 0.27 2.94E-04  212080_at MLL -0.53 7.28E-04 
234915_s_at DENR -0.26 2.95E-04  209712_at SLC35D1 -0.29 7.34E-04 
210982_s_at HLA-DRA 0.40 3.00E-04  218446_s_at FAM18B1 0.30 7.41E-04 
242520_s_at C1orf228 0.41 3.33E-04  228008_at NA -0.34 7.59E-04 
222248_s_at SIRT4 -0.19 3.48E-04  204174_at ALOX5AP 0.33 8.10E-04 
226981_at MLL -0.61 3.73E-04  224967_at UGCG 0.39 8.13E-04 
213975_s_at LYZ 0.28 3.94E-04  218017_s_at HGSNAT -0.23 8.66E-04 
224391_s_at SIAE 0.32 4.07E-04  210752_s_at MLX -0.20 8.81E-04 
203416_at CD53 0.26 4.09E-04  210140_at CST7 0.40 9.15E-04 
222942_s_at NA 0.22 4.11E-04  239400_at NA 0.26 9.28E-04 
223060_at C14orf119 -0.27 4.25E-04  227069_at CUX1 -0.17 9.41E-04 
228094_at AMICA1 0.26 4.58E-04  238873_at NA -0.18 9.70E-04 
218865_at MOSC1 -0.25 4.66E-04  211924_s_at PLAUR 0.25 9.79E-04 
228135_at C1orf52 -0.51 5.01E-04      
207791_s_at RAB1A -0.32 5.14E-04      
226946_at NADKD1 0.27 5.36E-04      
228783_at BVES -0.30 5.39E-04      
202804_at ABCC1 0.36 5.55E-04      
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227069_at CUX1 -0.20 5.79E-04      
212080_at MLL -0.39 6.24E-04      
238041_at TCF12 -0.31 6.33E-04      
1554712_a_at GLYATL2 0.25 6.39E-04      
218668_s_at RAP2C -0.29 6.66E-04      
224967_at UGCG 0.32 6.79E-04      
227819_at LGR6 -0.31 7.29E-04      
201778_s_at KIAA0494 -0.34 7.33E-04      
214743_at CUX1 -0.29 7.54E-04      
224691_at UHMK1 -0.28 7.63E-04      
228345_at CHIC1 -0.34 8.10E-04      
227809_at ZC3H6 0.22 8.80E-04      
204635_at RPS6KA5 -0.18 8.92E-04      
225784_s_at ZC4H2 -0.20 9.03E-04      
212771_at FAM171A1 -0.19 9.42E-04      
224818_at SORT1 -0.29 9.63E-04      
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Table 10. Down-regulated genes in AF4-MLL signature (Figure 6B, upper panel) 
Probe set HGNC Gene Symbol 
1557192_at NA 
201776_s_at KIAA0494 
201778_s_at KIAA0494 
203725_at GADD45A 
204045_at TCEAL1 
205771_s_at AKAP7 
206498_at OCA2 
207791_s_at RAB1A 
208724_s_at RAB1A 
209711_at SLC35D1 
209789_at CORO2B 
210752_s_at MLX 
212080_at MLL 
212262_at QKI 
212636_at QKI 
213227_at PGRMC2 
213708_s_at MLX 
214743_at CUX1 
215001_s_at GLUL 
217910_x_at MLX 
217947_at CMTM6 
217974_at TM7SF3 
217982_s_at MORF4L1 
218865_at MOSC1 
219326_s_at B3GNT2 
222631_at PI4K2B 
222870_s_at B3GNT2 
222958_s_at DEPDC1 
223017_at TXNDC12 
223047_at CMTM6 
223060_at C14orf119 
223171_at DYM 
224818_at SORT1 
225784_s_at ZC4H2 
225935_at NA 
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226297_at NA 
226478_at TM7SF3 
226689_at CISD2 
226793_at LOC283267 
226868_at GLT8D3 
226980_at DEPDC1B 
226981_at MLL 
227069_at NA 
227699_at C14orf149 
228008_at NA 
228135_at C1orf52 
228345_at CHIC1 
228486_at SLC44A1 
228540_a]t QKI 
228783_at BVES 
229844_at NA 
231896_s_at DENR 
232278_s_at DEPDC1 
235545_at DEPDC1 
236513_at NA 
238041_at NA 
238756_at GAS2L3 
238873_at NA 
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Table 11. Down-regulated genes in MLL-AF4 signature (Figure 6B, lower panel) 
Probe set HGNC Gene Symbol 
1557192_at NA 
201776_s_at KIAA0494 
201778_s_at KIAA0494 
203725_at GADD45A 
204045_at TCEAL1 
205771_s_at AKAP7 
206498_at OCA2 
207791_s_at RAB1A 
208724_s_at RAB1A 
209711_at SLC35D1 
209789_at CORO2B 
210752_s_at MLX 
212080_at MLL 
212262_at QKI 
212636_at QKI 
213227_at PGRMC2 
213708_s_at MLX 
214743_at CUX1 
215001_s_at GLUL 
217910_x_at MLX 
217947_at CMTM6 
217974_at TM7SF3 
217982_s_at MORF4L1 
218865_at MOSC1 
219326_s_at B3GNT2 
222631_at PI4K2B 
222870_s_at B3GNT2 
222958_s_at DEPDC1 
223017_at TXNDC12 
223047_at CMTM6 
223060_at C14orf119 
223171_at DYM 
224818_at SORT1 
225784_s_at ZC4H2 
225935_at NA 
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226297_at NA 
226478_at TM7SF3 
226689_at CISD2 
226793_at LOC283267 
226868_at GLT8D3 
226980_at DEPDC1B 
226981_at MLL 
227069_at NA 
227699_at C14orf149 
228008_at NA 
228135_at C1orf52 
228345_at CHIC1 
228486_at SLC44A1 
228540_at QKI 
228783_at BVES 
229844_at NA 
231896_s_at DENR 
232278_s_at DEPDC1 
235545_at DEPDC1 
236513_at NA 
238041_at NA 
238756_at GAS2L3 
238873_at NA 
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Table 12. Leading edge of GSEA comparing AF4-MLL positive patients versus 
AF4-MLL negative t(4;11) patients using 58 AF4-MLL target gene probe sets 
(Figure 6B, upper panel) 
Probe set HGNC Gene 
Symbol 
226981_at MLL 
212080_at MLL 
206498_at OCA2 
217974_at TM7SF3 
222958_s_at DEPDC1 
228345_at CHIC1 
226868_at GXYLT1 
236513_at PRELID2 
238041_at TCF12 
222631_at PI4K2B 
226689_at CISD2 
210752_s_at MLX 
226980_at DEPDC1B 
227069_at CUX1 
223060_at C14orf119 
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Table 13. Leading edge of GSEA comparing MLL fusion knockdown versus 
control samples using dataset from Stumpel et al  (Figure 7) 
Probe set HGNC Gene 
Symbol 
1553264_a_at SYN1 
1554112_a_at ULK2 
1554980_a_at ATF3 
1570071_at MYO15A 
202388_at RGS2 
203898_at CRCP 
204739_at CENPC1 
204924_at TLR2 
206299_at FAM155B 
206906_at ICAM5 
206908_s_at CLDN11 
207373_at HOXD10 
207692_s_at ACAN 
208605_s_at NTRK1 
208942_s_at SEC62 
209119_x_at NR2F2 
210051_at RAPGEF3 
210673_x_at NKX2.1 
211170_s_at PDE10A 
216971_s_at PLEC 
219527_at MOSC2 
220487_at SNTG2 
221015_s_at CDADC1 
221608_at WNT6 
222200_s_at BSDC1 
226178_at SOCS4 
227062_at NEAT1 
233052_at DNAH8 
233287_at SLC6A17 
234721_s_at CYP26B1 
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SUPPLEMENTAL MATERIAL CHAPTER 8 
 
MATERIALS AND METHODS 
 
Gene expression profiling data 
The gene expression profiling data was generated according to the 
manufacturer’s guidelines, and deposited in the  National Center for 
Biotechnology Information Gene Expression Omnibus 1 and is accessible via GEO 
Series accession number GSE19475. 
 
Quantitative real-time PCR analysis 
Oligonucleotide primers used for PCR amplification were purchased from 
Eurogentec (Seraing, Belgium). Primer sequences were as follows: EID1 forward: 
5’-GGGCGAGGAATTTGA-‘3, reverse: 5’-CGGGTCTTCTCATAATG-3’; KAT2B 
forward: 5’-CTGCCAGCAAAAGAAG-3’, reverse: 5’-GTCGCCTCATAACAGTGAA-3’; 
EP300 forward: 5’-ACTTGGCACCTTTCTAGAGAATC-3’, reverse: 5’-
AGGACGGAAATGAACACTA-3’. B2M was used as a reference gene: forward: 5’-
GGAGCATTCAGACTTGTCTT-3’, reverse: 5’-ATGCGGCATCTTCAAA-3’. 
 
Cell line culturing and RNA interference 
SEM cells were maintained as a suspension culture in RPMI 1640 with glutamax 
(Invitrogen, Carlsbad, California) supplemented with 10% (v/v) FCS and 2% 
penicillin/streptomycin/fungizone (PSF; Invitrogen, Carlsbad, California) at 37°C 
in humidified air containing 5% CO2. 
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RNA interference was performed by means of lentiviral transduction using 
pLKO.1 vectors expressing specific shRNA target sequences obtained from the 
MISSION TRC library (Sigma-Aldrich, St. Louis, USA). Target shRNA sequences 
were as follows: EID1: 5’-GAAGAAGCCGACAAGATGTTT-3’, KAT2B: 5’-
GCAGATACCAAACAAGTTTAT-3’, and for EP300: 5’-CAATTCCGAGACATCTTGAGA-
3’. As a control we used vectors expressing validated non-silencing control 
sequences (RHS1707; Open Biosystems, Thermo Scientific, Waltham, 
Massachusets, USA). Virus was produced by transient transfection of 293T 
human kidney cells with a mixture of psPAX-2 and pMD2G-VSVG. 
 
Flow cytometry and cell cycle analysis 
Induction of apoptosis was assessed by an Annexin V/PI assay. For this, 0.2x106 
cells were incubated in annexin binding buffer (10 mM HEPES, pH 7.4; 0.14 M 
NaCl; 2.5 mM CaCl 2) and centrifuged at 1500 RPM at 4°C for 5’. Buffer was 
removed and a solution of Annexin V (1:1000) and PI (2 μg/ml) (BD Biosciences, 
San Jose, California, USA) was added to the cell culture, immediately followed by 
the measurement of Annexin V and PI positivity by flow cytometry using a FACS 
Calibur (Becton Dickinson, Franklin Lakes, New Jersey, USA).  
Cell cycle analysis was performed by BrdU labeling using the FITC BrdU Flow Kit 
(#559619, BD Pharmigen, Franklin Lakes, New Jersey, USA) according to 
manufacturer’s protocol. Briefly, 10 μM BrdU was added to 1x106/ml cells, and 
incubated for 30’ at 37◦C. Then, cells were fixated and permeabilized, refixated 
and treated with 300 μl of 300 μg/ml DNAse for 1 hr at 37◦C. Cells were 
incubated for 20’ with anti-BrdU and taken up in 20 μl7-AAD solution and 1 ml 
staining buffer to identify early apoptotic cells. BrdU and 7-AAD positivity was 
determined by flowcytometer.  
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Analysis of the flowcytometry data was performed using the FlowJo software 
version 7.6.5 (Tree Star, Ashland, Oregon, USA).  
 
Western blot analyses 
Cell pellets were snap-frozen in liquid nitrogen and stored at −80°C until further 
use. After thawing, cells were resuspended in 50 μL of lysis buffer containing: 5 
mM EDTA, 10% glycerol, 10 mM sodium pyrophosphate (Merck, Whitehouse 
Station, New Jersey, USA), 25 mM Tris, 150 mM NaCl, 1% Triton X-100, 1 mM 
sodium orthovanadate, 10 mM glycerolphosphate, 1 mM dithiothreitol, 1 mM 
phenylmethylsulfonyl fluoride, 1% aprotinin, 10 mM sodium fluoride  (Sigma-
Aldrich, St. Louis, USA) and 50 μM of freshly prepared sodium pervanadate. 
Next, cells lysis was allowed for 30’ on ice, following  centrifugation for 15’ at 
13.000 rpm and 4°C. Protein concentration was determined using the BCA 
protein assay (Pierce Biotechnology, Rockford, Illinois, USA) with varying 
concentrations of bovine serum alb umin as standards. Cell lysates containing 25 
μg of protein were separated on 10% polyacrylamide gels and transferred onto 
nitrocellulose membranes (Schleicher & Schuell, Dassel, Germany). Western 
Blots were probed with KAT2B rabbit monoclonal antibody (CellSignaling, 
Beverly, Massachusets, USA) and beta actin mouse monoclonal antibody (as a 
control for equal loading) (Abcam, Cambridge, UK) for 2 hours at room 
temperature. Next the western blots were incubated in fluorescently labeled 
secondary antibodies (LI-COR Biosciences, Lincoln, Nebraska, USA) for 1 hour 
and subsequently detected using the Oddyssey Infrared Imaging System (LI-COR 
Biosciences, Lincoln, Nebraska, USA). 
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Table 1. All EID1 probe sets significantly higher expressed in MLL-rearranged 
infant ALL patients. 
 
Table representing all probe sets of EID1 on the HGU133plus2.0 microarray with 
results from linear modeling for microarrays (LIMMA) searching for differential 
expression between MLL-rearranged infant ALL patients (n=68) and MLL wild-
type samples (consisting of MLL wild-type infant ALL patients (n=18), pediatric 
(non-infant) B-ALL patients (n=16) and healthy bone marrow samples n=13). ID = 
probe set; logFC = estimate of the log2-fold-change; T = moderated T-statistic; 
P.Value = raw p-value; adj.P.Val = FDR-adjusted p-value or q-value; B = log odds. 
 
 
  
ID logFC T P.Value adj.P.Val B 
211698_at 1.473499 15.25835 5.38E-28 5.88E-24 52.89395 
208669_s_at 1.001935 10.96376 6.63E-19 3.98E-16 32.49505 
208670_s_at 1.13307 7.80794 5.52E-12 3.57E-10 16.90912 
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Table 2. E2F-related gene set enrichment analysis in EID1 knockdown samples. 
Name Size ES NES 
FDR  
q-value 
Rank at 
max 
V$E2F1_Q6 191 -0.297 -1.77628 0.012848 3022 
V$E2F1DP1_01 195 -0.28545 -1.68798 0.012914 3022 
V$E2F_02 195 -0.28042 -1.75679 0.0134 3022 
V$E2F_Q6 192 -0.27967 -1.69279 0.013477 3022 
V$E2F1_Q6_01 202 -0.2783 -1.66796 0.013483 3040 
V$E2F1DP2_01 195 -0.28545 -1.71425 0.01448 3022 
V$E2F4DP1_01 200 -0.28027 -1.69323 0.014855 3108 
V$E2F4DP2_01 195 -0.28545 -1.71543 0.016372 3022 
V$E2F1DP1RB_01 191 -0.26611 -1.61549 0.016612 3040 
V$E2F_Q4 194 -0.27293 -1.623 0.017059 3022 
V$E2F_Q6_01 191 -0.26039 -1.55002 0.026141 2675 
V$E2F_03 194 -0.2425 -1.48024 0.039623 2675 
V$E2F_Q4_01 191 -0.24272 -1.45996 0.041936 2986 
V$E2F1_Q3 195 -0.22785 -1.34786 0.079357 2280 
V$E2F_Q3 180 -0.21263 -1.26453 0.127975 2675 
V$E2F1_Q4_01 184 -0.20863 -1.20229 0.188485 2986 
V$E2F1_Q4 199 -0.19949 -1.19508 0.189354 2977 
V$E2F_Q3_01 188 -0.19611 -1.1775 0.204105 2986 
V$E2F1_Q3_01 208 -0.16036 -1.00128 0.612541 3017 
Gene set enrichment analysis (GSEA) of gene expression in EID1 knockdown 
samples versus control samples using gene sets that contain genes that share a 
transcription factor binding site defined in the TRANSFAC database (C3: motif 
gene sets/TFT). Demonstrated is an enrichment of genes with promoter regions 
[-2kb,2kb] around transcription start site containing motifs matched with E2F(-
related) proteins. (N)ES = (normalized) enrichment score. FDR q-value = FDR-
adjusted p-value. 
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Figure 1. KAT2B and EP300 mRNA expression in infant ALL 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Graphical representation of VSN-normalized expression values of KAT2B mRNA 
(203845_at) and EP300 (202221_s_at) from gene-expression profiling data 
(Affymetrix HU133plus2 GeneChips) in patient material of MLL-rearranged infant 
ALL patients (MLL-r infant ALL, n=68), MLL wild-type infant ALL patients (MLL wt 
infant ALL, n=18), healthy bone marrow (healthy bone marrow, n=13) and 
pediatric (non-infant) precursor B-ALL patients (pediatric B-ALL, n=16). Error bars 
represent the mean ± standard error of the mean. 
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